Identification of mammalian proteins inhibiting apoptosis downstream of cytochrome c release in a yeast survival screen by Brezniceanu-Mehedinti, Marie-Luise Ligia
  1
 
 
IDENTIFICATION OF MAMMALIAN PROTEINS 
INHIBITING APOPTOSIS DOWNSTREAM OF 
CYTOCHROME C RELEASE 
IN A YEAST SURVIVAL SCREEN 
 
 
 
 
 
 
 
 
 
Dissertation 
zur Erlangung des Doktorgrades 
der Naturwissenschaften 
 
 
Vorgelegt beim Fachbereich 15-Biologie und Informatik- 
der Johann Wolfgang Goethe-Universit￿t 
in Frankfurt am Main 
 
 
 
 
 
 
 
by 
Marie-Luise Ligia Brezniceanu-Mehedinti 
from Paris (France) 
 
 
 
 
 
Frankfurt am Main 2003 
(DF1) 
 
 
   2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vom Fachbereich Biologie und Informatik der Johann Wolfgang Goethe-Universit￿t 
als Dissertation angenommen. 
 
 
 
 
 
 
 
 
 
Dekan: 
............................................................................................................................... 
 
Gutachter: 
.......................................................................................................................... 
 
Datum der Disputation: 
..................................................................................................... 
 
 
 
 
 
 
 
 
 
 
   3
 
 
 
Eidestattliche Erkl￿rung 
 
 
Ich erkl￿re hiermit an Eides statt, dass ich die vorliegende Dissertation selbst￿ndig 
und nur mit den angegebenen Hilfsmitteln angefertigt habe. 
 
 
 
Frankfurt am Main, den 19. Mai 2003 
 
 
 
 
 
 
 
(Marie-Luise Ligia Brezniceanu-Mehedinti) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   4
Abstract 
 
One of the known apoptotic pathways in mammalian cells involves release of 
mitochondrial Cytochrome c into the cytosol. Cyt c then together with ATP or dATP 
induces a conformational change in the adaptator protein Apaf-1 (a homologue of the 
C. elegans CED4 protein) (Zou, Henzel et al. 1997), leading to its oligomerization 
and the recruitment of several pro-Casp-9 molecules. This protein complex assembly 
called "apoptosome" leads to the activation of Casp-9 which then initiates or 
amplifies the caspase cascade. 
The cell death program can be stalled at several points and we were interested 
in identifying new proteins inhibiting cell death downstream of Cyt c release. This 
thesis describes how I have screened a cDNA library derived from a pool of human 
breast carcinomas in a yeast-based survival screen, using the S. pombe yeast strain 
HC4 containing an inducible CED4 construct(James, Gschmeissner et al. 1997). The 
screen resulted in the identification of six proteins displaying cell death-inhibiting 
activity in S. pombe as well as anti-apoptotic potential in mammalian cells. Those six 
molecules were RoRet (Ruddy, Kronmal et al. 1997), Aven (Chau, Cheng et al. 
2000), Fte-1/S3a (Kho, Wang et al. 1996), PGC2 (Padilla, Kaur et al. 2000; Goetze, 
Eilers et al. 2002), SAA1-2β  (Moriguchi, Terai et al. 2001) and FBP (Brockstedt, 
Rickers et al. 1998) of which I selected RoRet, Aven and Fte-1/S3a for further 
analysis. 
RoRet is a new anti-apoptotic molecule that can inhibit the mitochondrial 
pathway via its PRY-SPRY domain. RoRet does not seem to bind to Apaf-1, and does 
not co-localize with the activated Apaf-1/Caspase-9 complex.  
Aven was published to act as an anti-apoptotic protein and suggested to 
function via the recruitment of Bcl-XL to Apaf-1. This work shows that its C-terminal 
domain can bind to Apaf-1 and has a strong anti-apoptotic activity by itself. 
Moreover, Aven co-localizes with the activated Apaf-1/Caspase-9 complex 
suggesting that it is a component of the apoptosome. Furthermore, the expression of 
Aven is regulated in mammary glands during the pregnancy cycle. 
Fte-1/S3a has been already implicated in increased transformation capacity of 
v-Fos in fibroblasts (Kho and Zarbl 1992; Kho, Wang et al. 1996). This work shows 
that it has anti-apoptotic activity and can protect against Bak- and Apaf-1-induced 
apoptosis. It can bind directly to activated Apaf-1 at the linker domain between the 
WD40 repeats and the CED4-like domain, suggesting that it may protect by 
sequestering the activated Apaf-1 to some organelles whose nature remains to be 
determined. Moreover, expression studies on mRNA and protein level showed 
upregulation of Fte-1/S3a in colon, lung and kidney carcinoma.  
Hmgb1 (Flohr, Rogalla et al. 2001; Pasheva, Ugrinova et al. 2002; Stros, 
Ozaki et al. 2002) was identified during a survival screen performed with a NIH 3T3 
mouse fibroblast cDNA library in a Bak-expressing yeast S. pombe strain. HMGB1 
can protect against Bak-, UV-, FasL- and TRAIL-induced apoptosis. Significant 
overexpression of HMGB1 was found in breast and colon carcinoma, and elevated 
mRNA amounts were detected in uterus, colon and stomach carcinoma, suggesting 
that it may be a tumour marker (Brezniceanu et al., 2003). 
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I-Introduction 
A-Apoptosis-a special form of PCD 
 
Apoptosis is a genetically regulated process of cell suicide that is capital to the 
development, homeostasis and integrity of multicellular organisms. Its importance is 
such that the disregulation of mechanisms controlling cell suicide plays a role in the 
pathogenesis of a wide range of diseases. Different from autophagy and necrosis 
which have lately also been defined as orchestrated by a genetically programmed 
mechanism, apoptosis can be defined by specific morphological changes: membrane 
blebbing, chromatin condensation and fragmentation, and exposure of markers on the 
outer cytoplasmatic cellular membrane like phosphatidyl-serine that will mark the cell 
for phagocytosis by macrophages. By contrast, autophagy targets a population of cells 
or entire tissues that will die by the presence of ￿autophagic vacuoles￿ in their 
cytoplasm containing the machinery needed to degrade the dying cell. An early loss of 
membrane integrity leading to the leakage of cellular componants is the hallmark of 
necrosis. While great progress has been achieved in unveiling of the molecular 
mechanisms of programmed cell deaths, a new level of complexity, with important 
therapeutic implications, has begun to emerge, suggesting (i) that several different 
self-destruction pathways may exist and operate in parallel in cells, and (ii) that 
molecular effectors of cell suicide may also perform other functions unrelated to cell 
death induction and crucial to cell survival. 
 
1-Apoptosis-general considerations 
 
Initial questions about the possible existence, mechanisms, and role of 
physiological cell death emerged during the second half of the 19th century, from the 
study of animal development, (Clarke and Clarke 1996), (Lockshin and Zakeri 2001), 
but it is only during the second half of the 20th century that a series of conceptual and 
experimental advances progressively led to the idea that cells from multicellular 
animals may have the capacity to activate a program of self-destruction, and that this 
self-destruction program may be regulated by signals provided by other cells. (Clarke 
and Clarke 1996), (Lockshin and Zakeri 2001), (Saunders 1966), (Kerr, Wyllie et al. 
1972), (Umansky 1982), (Cowan, Fawcett et al. 1984), (Ellis and Horvitz 1986), 
(Clarke 1990), (Ellis, Yuan et al. 1991). The identification of a genetic regulation of 
physiological cell death, of the features of its most frequent phenotype,  apoptosis, 
and of its central role, not only in development, but also in adult tissue homeostasis, 
has led to the idea that all cells all multicellular  animals may be intrinsically 
programmed to self-destruct, and that cell survival continuously depends on the 
repression of this self-destruction program by other cells, in other words that cells 
may survive only as long as they are signalled to suppress the induction of a ’default’ 
pathway leading to cell suicide (Kerr, Wyllie et al. 1972), (Vaux 1993),(Hengartner 
2000), (Raff 1992). 
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2-Apoptosis in development and morphogenesis. 
 
The coupling of the fate of each cell to the nature of the interactions with other 
cells has led to the concept of ’social control’ of cell survival and cell death, allowing a 
stringent regulation of cell numbers, of their tissue localization, and a constant 
adjustment of the different cell types that constitute our organs and tissues (Raff 
1992). This interdependence generated between cells, is one of the bases of life 
perennity and species plasticity, allowing bodies to build themselves, to constantly 
reconstruct, and to adapt to ever changing environments. Programmed cell death 
participates in particular in morphogenesis (the sculpting of the form of embryos like 
the fingers and toes of hands and feet), in sexual differentiation (in male embryo the 
M￿ller channel is deleted by apoptosis), and in the epigenetic self-organization 
processes (where the cells are selected more by environmental criteria than genetic 
predestination) that allow the emergence of the  two most complex regulatory organs 
of our body, the immune system and the nervous system (Oppenheim 1991), 
(Flanagan 1999), (Goldrath and Bevan 1999), (Yuan and Yankner 2000). Indeed 
during development, an excess of cells is generated in these tissues which are 
subsequently deleted by apoptosis. For example, in the Thymus where a repertoire of 
T cells is selected whose receptors have the potential to recognize foreign antigenic 
peptides, but not auto-antigenic peptides (those cells are cleared by apoptosis) bound 
to the individual￿s own MHC molecules (Ashton-Rickardt, Van Kaer et al. 1993; 
Kishimoto and Sprent 1997; Suzuki, Guinter et al. 1998). 
 
3-Apoptosis and genetic integrity 
 
Specific organ or tissue cell-cell interaction, represents only one dimension of 
the ’social control’ of cell survival and cell death. At another level, each individual cell 
may be considered as a complex entity, a ’society’ by itself, a mingling of 
heterogeneous organelles and components that behaves as a whole. Thus, self-
destruction can occur not only as a response to signals originating from the outside 
environment of the cell, but also from its inside environment. Accordingly, genetic 
damage causes the activation of the p53 protein family, that induces either DNA 
repair and cell cycle arrest, or programmed cell death, a radical and extreme means 
preventing the emergence of genetic heterogeneity, and the progression towards 
cancer.(Rich, Allen et al. 2000) Similarly, alterations in endoplasmic reticulum 
integrity, induced, for example, by abnormal protein folding, (Mehmet 2000) or 
alterations in mitochondrial activity, such as respiratory chain dysfunction (Wang, 
Silva et al. 2001) can induce signalling leading to programmed cell death. Thus, cell 
suicide plays an essential role in the maintenance of the genetic identity and the 
integrity of the body, by inducing the rapid elimination of altered cells.  
 
4-Apoptosis and diseases 
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Programmed cell death is also crucial in the adult, by controlling tissue 
homeostasis, elimination of damaged or abnormal cells, and defense against infections 
(Cohen 1993),(Ameisen 1994),(Vaux, Haecker et al. 1994),(Williams 1994).   
Conversely, programmed cell death dysregulation has been proposed to participate in 
the pathogenesis of many diseases, ranging from cancer and autoimmunity to 
infectious diseases and neurodegenerative disorders, (Umansky 1982), (Ameisen, 
Estaquier et al. 1994), (Nagata and Golstein 1995), (Teodoro and Branton 
1997),(Evan and Littlewood 1998), (Krammer 2000) leading to the emergence of new 
concepts of therapeutic intervention, aimed at the selective modulation of the 
mechanisms involved in the regulation of cell death and cell survival (Yuan and 
Yankner 2000), (Williams 1991), (Kerbel 1997), (Nicholson 2000). Finally, 
programmed cell death may also participate in the physiologically regulated process 
of aging (Umansky 1982), (Migliaccio, Giorgio et al. 1999).(See Clinical 
implications) 
 
5-Apoptosis and evolution 
 
Programmed cell death has been found to operate in all multicellular animals 
studied so far, including nematodes, insects, amphibians, birds and mammals (Ellis, 
Yuan et al. 1991), (Meier, Finch et al. 2000), (Vaux and Korsmeyer 1999), (Steller 
1995), (Cikala, Wilm et al. 1999). Lately PCD has also been identified in unicellular 
organisms like bacteria, yeast, Thetrahymena thermophila or Dictyostelium discoidum 
(Lewis 2000; Arnoult, Tatischeff et al. 2001; Madeo, Engelhardt et al. 2002), 
(Christensen, Chemnitz et al. 1998). The evolutionary conservation of  this 
programmed cell death in the animal kingdom points toward some central  aspects of 
its genetic control, and to important aspects of its most frequent phenotype, apoptosis 
(Saunders 1966), (Ellis, Yuan et al. 1991), (Vaux and Korsmeyer 1999), (Steller 
1995), (Cikala, Wilm et al. 1999). In most cases that have been studied to date, 
programmed cell death is regulated by signals provided by other cells, either  in the 
form of cell-lineage information, of soluble mediators, or of cell-to-cell contacts. 
Programmed cell death induction may depend on cell-lineage information, such as in 
the nematode Caenorhabditis elegans, on the activation of gene transcription, or, in a 
more stochastic way, on a combination of cell-lineage information, intercellular 
signaling, transcription factor activation and cytoplasmic second messengers, such as 
in mammals (see rev. (Meier, Finch et al. 2000). During the last nine years, 
homologues of genes involved in the regulation of programmed cell death in 
Caenorhabditis elegans have been identified in sponge (Wiens, Diehl-Seifert et al. 
2001), in Hydra vulgaris (Cikala, Wilm et al. 1999), in the fruitfly Drosophila 
melanogaster (White, Grether et al. 1994), in zebrafish (Inohara and Nunez 2000) and 
in mammals (Yuan, Shaham et al. 1993), (Hengartner and Horvitz 1994) (Fig.3). As 
frequently occurs during evolution, however, this striking conservation in both 
sequences (Vaux and Korsmeyer 1999), (Horvitz 1999) and functional properties 
(Vaux, Weissman et al. 1992) has been associated with a great level of diversification 
(Hengartner 2000), (Vaux and Korsmeyer 1999) mostly due to gene duplication. In 
humans and mice, around twenty gene products that are homologues of the cell death   16
repressor Ced-9 and its antagonist Egl-1 (the Bcl-2 family) have been identified, as  
well as more than ten homologues of the executioner protease Ced-3 (the caspase 
family) and at least three variant of Apaf-1(apoptotic protease-activating factor 1) the 
homologue of Ced-4(Fu, Kelsey et al. 2001).  
 
6- Key players of the apoptotic process 
 
Two apoptotic pathways have been described recently: the extrinsic and the 
intrinsic pathway. Both of them act through the activation of the cascade of cysteine 
proteases (caspases). The extrinsic pathway which acts through the activation of 
initiator caspases can be directly coupled to cell surface receptor signalling, such as 
Caspase-8 activation induced by the recruitment of the FADD adaptor protein, 
consecutive to the engagement of ’death’  receptors of the CD95/tumor necrosis factor 
receptor (TNFR) family by their ligands. The intrinsic pathway involves another 
initiator caspase, Caspase-9, that is activated downstream of the mitochondria outer 
membrane permeabilization induced by members of the Bax family in response to 
various pro-apoptotic stimuli, through the release of Cytochrome c that activates the 
Apaf-1 adaptor protein (Fig.1). There are two types of cells described for the death-
receptor apoptosis induction: type I cells can activate enough Caspase-8 to activate 
Caspase-3 and proceed to apoptosis of the cell, the type II cells need to induce the 
release of pro-apoptotic molecules from the mitochondria (Cytochrome c, Smac,￿) to 
activate Caspase-3 through the formation of the apoptosome (Scaffidi, Fulda et al. 
1998). In type II cells the intrinsic and extrinsic pathways can cross-talk through the 
induction of the mitochondria. The initiator caspases are autocatalytically cleaved and 
activated through recruitment by adaptor proteins that share death-effector domains 
(DED) or caspase activation and recruitment domains (CARD) with these initiator 
caspases (Hengartner 2000), (Krammer 2000), (Green 2000), (Thornberry and 
Lazebnik 1998).  
  Downstream in the cascade, caspases are termed effector or executionary 
caspases, such as  Caspase-3, -6 and  -7, which cleave numerous nuclear and 
cytoplasmic proteins, thereby inducing several of the typical features of apoptosis 
(Hengartner 2000), (Nagata 2000) (Fig.6). The activation of these effector caspases 
requires their initial cleavage by other upstream caspases (initiator caspases) such as 
Caspase-8 and ￿9 (Fig.6).  
The death  repressors (Bcl-2/Bcl-XL) and their antagonists  (Bax/Bak) share 
the capacity to homodimerize or oligomerize, and to neutralize each other through 
heterodimerization, and, for some of them, to insert through a carboxyterminal 
hydrophobic transmembrane domain into the outer membrane of intracellular 
organelles such as the nucleus, endoplasmic reticulum and mitochondria. While there 
are alternative views (Finkel 2001), it is generally believed that it is through their 
control of mitochondrial outer membrane permeability that the Bcl-2/Bax family 
members exert an important part of their antagonistic effect on cell death and survival, 
by repressing (Bcl-2) or  inducing (Bax) the release of mitochondrial intermembrane 
space proteins into the cytosol that will favor the induction of cell death (Gross,   17
McDonnell et al. 1999), (Vander Heiden and Thompson 1999), (Green 2000), 
(Kroemer and Reed 2000), (Martinou and Green 2001) (Fig.1). Some of these 
intermembrane space proteins, such as Cytochrome c, Smac/Diablo, and Omi/HtrA2 
will induce caspase activation (Green 2000), (Martinou and Green 2001), (Suzuki, 
Imai et al. 2001), while others, such as AIF (apoptosis inducing factor), (Susin, 
Lorenzo et al. 1999), or endonuclease G may favor the induction of caspase-
independent executionary pathways. 
  Importantly these multiple pathways of activation, that can amplify each 
other, can also be repressed at the level of the effector caspases, for example by IAPs 
(inhibitors of apoptosis proteins) that block the activity of already processed caspases 
(Goyal 2001). The IAPs themselves can be inhibited by the Smac/Diablo protein, 
which is released by mitochondria and binds to IAPs, thereby releasing the caspases 
molecules (Goyal 2001) (Fig.7 and 10). 
 
Fig.1: The cell death machinery.  
Illustration of the death receptor induced apoptosis, the DISC formation (the circle 
containing FasL/Fas/FADD/FLICE complex) induced by ligand binding. Then takes 
place the proteolytic activation of Caspase-8, -9, -6, -7 and ￿3. The mitochondria is 
induced by Bak/Bax translocation after Bid cleavage, and release Cytochrome c. The 
apoptosome formation follows (the circle containing APAF-1/Cytochrome c/Pro-
caspase-9/ATP or dATP) tht can activate Caspase-9 and lead to activation of Caspase-
3. IAPs, Bcl-2 and Bcl-XL can inhibit a different levels.   18
 
 A series of knock-out experiments in mice, including the deletion of genes 
encoding either members of the Bcl-2/Bax family, the Apaf-1 and FADD adaptor 
proteins, members of the caspase family, or, more recently, cytochrome c or AIF have 
indicated that each of these proteins controls some, but not all, suicide pathways, in  
some, but not all, cell types.  
Thus, in contrast to the simple paradigm of Caenorhabditis elegans, in 
mammalian cells, programmed cell death can proceed along multiple intracellular 
molecular pathways, and the pathways followed will not be the same in different cell 
types, in response to a given death signal, nor in the same cell type, in response to 
different death signals. In some instances, the molecular pathway leading to self-
destruction will even be different in a given cell type, in response to the same death 
signal, depending on the particular differentiation stage of the cell. Moreover, the 
complexity of the molecular control of cell survival and cell death also involves 
various epigenetic mechanisms such as alternative splicing and post-translational 
modifications (phosphorylation, dephosphorylation, or proteolytic cleavage) that can 
transform the product of a given gene into either a pro-apoptotic or an anti-apoptotic 
protein (Yuan and Yankner 2000), (Gross, McDonnell et al. 1999), (Xiang, Chao et 
al. 1996). These modifications include or example the activation of Bad through 
dephosphorylation or the cleavage of procaspases in active caspases during the so 
called ￿caspase cascade￿ (Cohen 1997; Thornberry and Lazebnik 1998; Wolf, Witte 
et al. 2001). 
 
B-General pathways 
1-Programmed Cell Death in unicellular organisms 
 
Until very recently, studies on programmed death of free-living unicellular 
eukaryotes were at a preliminary stage. But as several reports describing apparent 
programmed cell death in unicellular eukaryotes like Thetrahymena thermophila 
(Christensen, Chemnitz et al. 1998), Dictyostelium discoidum  (Arnoult, Tatischeff et 
al. 2001) or even prokaryotes like bacteria, the idea that unicellulars may commit 
suicide for the advantage of the colony becomes accepted easier. A theory has 
emerged that a unicellular organism undergoing PCD in a colony preserving genetic 
integrity would act the same way a single cell in a multicellular organism would 
commit suicide to preserve the genetic integrity of a whole body or tissue, or even to 
allow an evolutive advantage to spread in the species. Staurosporine (a non-specific 
protein kinase inhibitor inducing apoptosis in cells of higher organisms) was shown to 
stimulate reactive oxygen species (ROS) production and to kill Tetrahymena 
(Christensen, Chemnitz et al. 1998). Petit and his colleagues (Arnoult, Tatischeff et al. 
2001) identified in the slime mold Dictyostelium discoideum an apoptosis-inducing 
factor (DdAIF) structurally and functionally similar to the mammalian AIF (Susin, 
Lorenzo et al. 1999). It was found that DdAIF is involved in cell death caused by 
adding protoporphyrin IX or differentiation-inducing factor-1 (DIF-1). However, one   19
should keep in mind that D. discoideum at some stage of its life cycle is a 
multicellular organism (for some other indications of the programmed death of 
constantly unicellular eukaryotes, see reviews (Ameisen 1996),  (Lewis 2000)).  
During the last decade, programmed cell death was intensively studied in 
yeast. The majority of these studies dealt with expression of mammalian pro- and 
anti-apoptotic proteins in these microorganisms. Kane et al. (Kane, Sarafian et al. 
1993) reported that the anti-apoptotic mammalian protein Bcl-2 partially rescued a S. 
cerevisiae yeast mutant lacking superoxide dismutase. Manon and co-workers 
(Manon, Chaudhuri et al. 1997) found that the pro-apoptotic mammalian protein Bax 
caused growth arrest of yeast S. cerevisiae cells, which was accompanied by 
Cytochrome  c release from mitochondria into the cytosol. Coexpression of anti-
apoptotic Bcl-xL prevented the effects of Bax. Ink and al. (Ink, Zornig et al. 1997) 
studied Bak induced Cell Death in Schizosaccharomyces pombe, and found that not 
only Bak was able to induce yeast cell lethality, but that this lethality could be 
antagonized by the mammalian anti-apoptotic protein Bcl-xL. Moreover, in this case 
cell death was accompanied by morphological feature resembling apoptosis like loss 
of nuclear membrane integrity, vacuolisation and chromatin condensation and 
fragmentation (Ink, Zornig et al. 1997). The possibility that cell death may be caused 
by simple overexpression of a foreign protein was excluded by overexpressing Bcl-xL 
(which had phenotype) and by overexpression of a deletion mutant of Bak lacking the 
BH3 domain necessary to induce apoptosis in mammals (Ink, Zornig et al. 1997). 
Since this mutant did not kill yeast cells either, it was speculated that some conserved 
pathways in evolution must be involved in programmed Cell Death in Yeast.  
The possibility of using  Schizosaccharomyces pombe  as a model system to 
study the activity of proteins involved in apoptosis of multicellular organisms, allows 
the precise functional analysis of theses proteins, often in the absence of further, 
potentially redundant family members. For example James and al. discovered a death-
inducing function of CED4 in yeast (James, Gschmeissner et al. 1997). Indeed the 
authors could show that CED4 could induce active cell death in S. pombe, and that 
this cell death was accompanied by the translocation of CED4 from the ER and 
mitochondria to the nucleus. In dying yeast cells CED4 was co-localizing with the 
condensed chromatin. Moreover, the authors could show that yeast killing by CED4 
could be inhibited by CED9 co-expression, but not by CED9L (an inactive mutant in 
C. elegans) or p35 co-expression (James, Gschmeissner et al. 1997). CED4 directly 
interacts with CED9 as shown by the authors using S. cerevisiae for yeast-two-hybrid 
studies. The observed effects strongly suggest that some evolutionary programmed 
cell death pathway has been conserved from unicellular organisms to mammals.   
Later Manon and co-workers (Manon, Chaudhuri et al. 1997; Priault, 
Camougrand et al. 1999) found that neither cytochrome c nor ATP/ADP antiporter are 
required for the Bax-induced death of yeast S. cerevisiae, moreover yeast Cytochrome 
c injection was not able to induce yeast cell death . Thus, Cytochrome c release might 
be a side effect of Bax. For example, it is known that Bax, if added together with 
mitochondrial porin, induces permeabilization of an artificial phospholipid membrane 
for Cytochrome c (Shimizu, Ide et al. 2000). It was found that porin is required for the 
killing of yeast by Bax (Shimizu, Shinohara et al. 2000). The Bax-induced death of 
yeast seemed to be a consequence of an oxidative stress since co-expression of some   20
plant proteins preventing Bax-induced ROS burst rescued the Bax-expressing yeast 
(Levine, Belenghi et al. 2001),  (Moon, Baek et al. 2002).  
Some other studies have  demonstrated that certain mutations in the yeast 
genome result in death showing features of apoptosis like chromatin condensation, 
cytoplasmatic vacuolisation, and loss of nuclear and organelles membrane integrity 
(Madeo, Frohlich et al. 1997). A Saccharomyces cerevisiae mutant in cell division 
cycle gene CDC48 shows typical markers of apoptosis: membrane staining with 
annexin V, indicating an exposure of phosphatidylserine at the outer layer of the 
cytoplasmic membrane, DNA fragmentation and chromatin condensation and 
fragmentation (Madeo, Frohlich et al. 1997).   
Other cases were described which point to programmed death  for example of 
yeast treated by a lethal dose of some toxic compounds. Madeo et al. (Madeo, 
Frohlich et al. 1999) and Corte-Real et al. (Ludovico, Sousa et al. 2001) reported that 
H2O2 or acetate kill yeast S. cerevisiae, the death being accompanied by some typical 
apoptotic features. The discovery of a yeast caspase YCA1 in 2002 by Madeo ans Al. 
(Madeo, Engelhardt et al. 2002) who succeeded in finding in S. cerevisiae a meta-
caspase, a key enzyme of the animal apoptotic cascade (this discovery was, in fact, 
predicted by Koonin, Dixit and their bioinformatic colleagues analyzing the yeast 
genome (Uren, O’Rourke et al. 2000)). Madeo et al. (Madeo, Engelhardt et al. 2002) 
studied a 52 kDa protein, the amino acids sequence of which resembled that of 
mammalian caspases. It was found that overexpression of the enzyme resulted in 
removal of a 12 kDa fragment of this protein and appearance of the caspase-like 
proteolytic activity. When the potentially catalytic cysteine 297 of the protein was 
mutated, no formation of the 12 kDa product could be observed. Moreover, 
overexpression of the 52 kDa protein reduced viability of the prolonged yeast culture. 
Addition of H2O2 to the yeast overexpressing p52 cell extract hydrolyzation of typical 
caspase substrates. Deletion of the corresponding gene increased the lethal dose of 
H2O2 by a factor of 3 and entailed appearance of 6￿8% ‘immortal· cells surviving 
more than 28 days under nutrient-depleted conditions whereas all the wild-type cells 
died within 10 days. The authors called the 52 kDa protein yeast caspase 1 (YCA1). 
Madeo et al. (Madeo, Engelhardt et al. 2002) identified one more component of the 
YCA1-mediated yeast programmed death. It was shown that the absence of a protein 
encoded by the Ygl129c gene completely prevented the death caused by the YCA1 
overexpression. As indicated by Berger et al. (Berger, Brigl et al. 2000), this protein is 
an ortholog of the animal mitochondrial protein DAP-3, which is involved in 
apoptosis induced by some cytokines (Kissil, Cohen et al. 1999). 
 
 
2- Caenorhabditis elegans 
 
   The first evidence for the existence of genetic information  specific for the 
control of cell death was provided by pioneering experiments in the nematode 
Caenorhabditis elegans, (Ellis and Horvitz 1986), (Ellis, Yuan et al. 1991), (Horvitz, 
Shaham et al. 1994; Horvitz 1999) a metazoan whose phylogenic divergence predates 
ours by several hundred million years and whose body is constituted of exactly 959   21
somatic  cells. During the development of C.  elegans, 131 of the somatic cells die by 
apoptosis, and are rapidly ingested by neighboring cells. The investigation of genetic 
mutants revealed that the survival or death of most, if not all, cells during 
development depends on the presence, and expression, of only four genes, ced-3, ced-
4, ced-9, and egl-1 (Hengartner 2000), (Horvitz 1999) (Fig.2). In addition to these 
four gene products involved in the control of self-destruction and survival, there are at 
least seven gene products that allow the rapid ingestion of the dying cells by its 
neighbours, (Savill and Fadok 2000), (Horvitz 1999). Ced-3, a key protein in the 
induction of cell death is an  aspartate-directed cystein protease (a caspase) that, like 
most proteases, is synthesized as an inactive pro-enzyme precursor, and requires 
cleavage to become active. Ced-4 is an adaptor protein that, by oligomerizing and 
binding the Ced-3 pro-enzyme, induces Ced-3 autocatalytic cleavage and  activation. 
Ced-9 is a repressor of cell death that, by binding Ced-4, prevents it from activating 
Ced-3. Finally,  Egl-1, which is transcriptionally upregulated is an antagonist of Ced-
9, that by binding Ced-9 prevents its protective effect, releasing Ced-4 from Ced-9, 
and allowing Ced-4 to activate Ced-3 and to trigger self-destruction.  
 
 
 
Fig.2: The genetic pathway of apoptosis in C. elegans and their mammalian 
homologues. Egl-1 inhibits CED-9 inhibition of CED-3 activation by CED-9. CED-3 
activation results in morphological changes, expression of phagocytosis-signal 
proteins and DNA degradation. 
 
These findings provided a new paradigm: a simple genetic module suffices to 
control the fate of all somatic cells in response to the various cell-lineage and cell-
type specific signals involved in cell differentiation and embryonic development. At 
the same time, these findings also illustrate the ambiguity intrinsic to the concept of a 
’death program’. Indeed, Ced-3 is an executioner of cell death, but only if Ced-4 is 
present and available; Ced-4 is an activator of the executioner, but only if Ced-9 is 
lacking or not available; and Ced-9 is a repressor of cell death, but only if Egl-1 is   22
lacking, or not available. In other words, the completion of the ’death program’ will 
depend, in each cell, on the interactions between each of these four proteins, that 
depend, at least in part, on their respective expression level, regulated by cell 
signalling during development (Fig.2). Very recent findings  have also suggested that 
the activation of the Ced-3 protease may not obligatorily represent a ’point of no 
return’ beyond which cells are condemned to die, and that an unexpected form of 
social control may be involved in the process of cell death. Indeed, while Ced-3 
activation seems required for the  initiation of self-destruction, the execution of cell 
death also requires the expression of the proteins involved in the ingestion of dying 
cells, in the neighbouring surviving cells (Hoeppner, Hengartner et al. 
2001),(Reddien, Cameron et al. 2001). 
 
3-Drosophila melanogaster 
 
  Regulation of cell death has also been extensively studied in Drosophila. Flies 
with mutations in the caspase dcp-1 (drosophila caspase-1) die as larvae with tumours 
or are infertile because of defects associated with oogenesis (Song, McCall et al. 
1997; McCall and Steller 1998). Furthermore, flies with a strong null mutations in 
dark gene (the drosophila homologue of Apaf-1) die during metamorphosis, have 
defects in nervous system cell death and often develop  tumours (Rodriguez, Oliver et 
al. 1999).  Furthermore, Kumar and colleagues have recently reported that DARK 
may form an apoptosome complex which is built by Apaf-1 and Caspase-9 or 
homologues in mammalian cells and which results in the activation of Caspase-9) by 
recruitment of the fly Caspase-9 homologue DRONC (Dorstyn, Colussi et al. 1999; 
Dorstyn, Read et al. 2002). Mutations in the inhibitor of apoptosis (IAP) gene diap 
result in massive ectopic cell death and embryonic lethality owing to the activity of 
caspases (Wang, Hawkins et al. 1999; Goyal, McCall et al. 2000) (Fig.3). Recent 
studies have shown that deletion of dark suppresses this dramatic diap
-/- phenotype, 
indicating that caspase-activated cell death requires input from dark (Rodriguez, Chen 
et al. 2002). Although initial experiments indicated that DARK interacted with 
Cytochrome c (Rodriguez, Oliver et al. 1999), two recent studies suggest that fly 
apoptosomes do not require this protein as a cofactor for their assembly. In addition, 
the Drosophila Reaper protein has been found to promote mitochondrial Cytochrome 
c release upon addition to a Xenopus cell-free system (Evans, Kuwana et al. 1997). 
Thus, although the recent data suggest that the Drosophila apoptosome may be 
regulated in a Cytochrome c-independent manner, it remains possible that 
Cytochrome c may participate in Drosophila PCD in some ways.  
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Fig.3: Conserved genes and pathways throughout evolution. (Molecular Cell biology, 
2002, (Baehrecke 2002)). 
 
  A unique feature of Drosophila is that the products of three closely linked 
genes, reaper (rpr), head involution defective (Hid), and grim, control essentially all 
developmental-related PCD in this organism (White, Grether et al. 1994). Rpr, Hid 
and Grim share a short region of homology at their N-termini, known as the RHG 
(Rpr, Hid, Grim) motif, and this region is both necessary and sufficient for binding to 
the Drosophila IAPs, DIAP1 and DIAP2. While the RHG (for Rpr, Hid and Grim) 
proteins were initially thought to contain pro-apoptotic activities that could be 
repressed by the fly IAPs, recent studies suggest that the RHG proteins act by 
repressing the caspase-inhibitory function of DIAP1 and DIAP2 (Wang, Hawkins et 
al. 1999; Goyal, McCall et al. 2000). Drosophila embryos that lack rpr, hid and grim 
expression due to deletion of the H99 interval, are essentially devoid of all PCD 
(White, Grether et al. 1994) (Fig.4). Studies from several laboratories have also 
shown that apoptosis due to DIAP1 loss is both DARK- and DRONC-dependent. This 
suggests that the loss of DIAP1 is sufficient to activate the apoptosome (Rodriguez, 
Chen et al. 2002; Zimmermann, Ricci et al. 2002). Taken together with the 
observation that Cytochrome c may not be a required cofactor for apoptosome 
assembly in the fly, these data suggest that caspase activation in Drosophila may be 
regulated primarily through neutralization of DIAP1-mediated repression of DARK-
dependent caspase activation. Two possibilities have been proposed: either 
DARK/DRONC apoptosomes may have a propensity to assemble spontaneously, 
which is normally prevented through DIAP1-mediated inhibition of DRONC activity. 
It is also possible that in addition to neutralization of DIAP1 function, a second signal 
provided by neighbouring cells is required to promote DARK-dependent activation of 
DRONC (Zimmermann, Ricci et al. 2002).   24
Using an in vitro ubiquitination assay, Ryoo et al. provide convincing 
evidence that the binding of Rpr to DIAP1 activates the intrinsic E3 ubiquitin-ligase 
activities of this protein towards itself (Ryoo, Bergmann et al. 2002). Thus, Rpr-
induced DIAP1 downregulation in vivo is almost certainly due to proteasome-
mediated destruction of this protein as a consequence of polyubiquitination. Steller 
and colleagues identified a Drosophila mutant, ubcD1/effete (which encodes an E2 
ubiquitin-conjugating enzyme) (White, Grether et al. 1994), that dominantly 
suppressed Rpr-induced cell death. UBCD1 was found to interact physically with 
DIAP1 and to promote Rpr-induced DIAP1 polyubiquitination in vitro. Morgue, 
another protein belonging to a class of enzymes known as ubiquitin conjugating 
enzyme variants (UEVs), can also interact with DIAP1 and probably acts in concert 
with UBCD1 to polyubiquitinate DIAP1 (Hays, Wickline et al. 2002) (Fig.4). 
Evidence that DIAP1 promotes the ubiquitination of DRONC have been provided by 
Meier and colleagues, however, it is not clear whether this targets DRONC for 
proteasome-mediated destruction (Wilson, Goyal et al. 2002). 
 
 
 
Fig.4: Regulation of DIAP1 stability by Reaper in the fly D. melanogaster. 
Autoubiquitination of DIAP1 is stimulated by the binding of Reaper (and possibly by 
Hid) in a reaction catalysed by an E2 conjugase (UBCD1), assisted by Morgue (E2-
like). DIAP1 degradation results from the assembly of the DARK/DRONC 
apoptosome. When DARK is absent, the DIAP1/DRONK complex allows 
ubiquitination and degradation of DRONK.  
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4-Mammals 
4.1-Extrinsic and intrinsic apoptosis pathways 
 
  Many more gene members have been described for the mammals Bcl-2 
family, Caspase-family and BH3-only family, resulting in an increased complexity in 
the different interacting and cross-talking apoptotic pathways. Two general apoptosis 
pathways have been identified in mammalian cells: the extrinsic and the intrinsic 
apoptosis pathway. The extrinsic pathway is also called death receptor pathway. Upon 
ligation, death receptors such as CD95 and TNF-R1 bind to and oligomerize adaptor 
proteins and procaspases (Fig.1). FADD, which contains a DD (death domain, protein 
interaction domain), is recruited directly to CD95 and indirectly (through TRADD) to 
TNF-R1, resulting in the recruitment (through the DEDs: death effector domain, 
interaction) and autoactivation of Caspase-8 (Fig.7). The complex formed by CD95, 
FADD and Caspase-8 is called DISC (death inducing signal complex) and has been 
characterized biochemically in P. Krammer￿s group (Muzio, Chinnaiyan et al. 1996; 
Scaffidi, Fulda et al. 1998; Scaffidi, Krammer et al. 1999; Scaffidi, Schmitz et al. 
1999). In an analogous manner, the adaptor protein RAIDD/CRADD, which contains 
a CARD (Caspase recruitment domain), can associate with TNF-R1 and promote 
activation of pro-Caspase-2 ((Ahmad, Srinivasula et al. 1997); (Duan and Dixit 1997), 
(Li, Bergeron et al. 1997)).  
Based on their structure and role in cell death pathways, caspases can be 
divided into initiator and effector caspases. Effector caspases generally contain only a 
short prodomain and cleave diverse cellular substrates, whereas initiator caspases 
have a long prodomain and exert regulatory roles by cleaving and activating 
downstream effector caspases (Fig.6). Activation of initiator caspases is mediated by 
recruitment of these proteases to protein complexes, thereby increasing the local 
concentration of caspases. Two general types of interaction have been identified 
((Martin, Siegel et al. 1998); (Muzio, Stockwell et al. 1998); (Srinivasula, Ahmad et 
al. 1998)). Pro-Caspase-8 and -10 each contain two tandem death effector domains 
(DEDs), while pro-Caspase-1, -2, -4, and -9 contain a caspase-recruitment domain 
(CARD). In each case, the procaspases bind to adaptor molecules containing similar 
domains, and they either directly aggregate or interact with other molecules. Although 
not related, CARDs and DEDs have a similar structure composed of amphipathic, 
antiparallel  α -helices, which are also present in the death domain DD of death 
receptors, and in adaptor proteins like FADD (Fig.5). 
  Besides death receptor￿mediated apoptosis, a related but different way of 
caspase activation exists that is triggered for instance by cytotoxic drugs or p53 and 
essentially controlled by mitochondria. This is the so-called intrinsic or mitochondrial 
pathway. In early phases of apoptosis, mitochondria release cytochrome c which, 
together with dATP or ATP, activates the adaptor protein Apaf1 ((Li, Nijhawan et al. 
1997)). Apaf1 binds to the prodomain of pro-Caspase-9 via CARD￿CARD 
interaction, while a different region of Apaf1 self-associates resulting in Caspase-9 
activation (for more details see: Proapoptotic proteins released from the 
mitochondria).  
   26
 
 
 
Fig.5: Role of the recruitment domains in the two principal signalling pathways of 
Apoptosis (Immunity, 1999 (Los, Wesselborg et al. 1999)). 
One pathway (left) involves ligation of death receptors, resulting in the recruitment of 
the adaptor protein FADD through interaction between the death domains (DD) of 
both molecules. The death effector domain (DED) of  FADD in turn recruits pro-
Caspase-8, which is cleaved and activated at the receptor complex. Another pathway 
(right), which is triggered by many apoptotic stimuli, is initiated at the mitochondrion.  
 
 
4.3- p53 
 
  One of the central molecule in the apoptotic pathways is p53. Various stress 
stimuli such as cytotoxic drugs, γ -irradiation, heat shock, hypoxia, osmotic shock, and 
DNA-damaging agents
 stabilize the tumor suppressor protein p53, which promotes 
cell-cycle
 arrest to enable DNA repair or apoptosis to eliminate defective
 cells (Levine 
1997), (Herr and Debatin 2001). However, it is still largely unknown how
 p53 selects 
the pathways of G1 arrest or apoptosis. One hypothesis is that
 the proline-rich domain 
(residues 64-92) (Venot, Maratrat et al. 1998), (Walker and Levine 1996) and a 
recently
 identified transcriptional activation domain (residues 43-63) (Zhu, Zhou et al. 
1998) are necessary for mediation of apoptosis
 because deletion of either of these   27
2  domains abolishes this activity.
  On the other hand, it has been shown that 
phosphorylation and
  acetylation play important roles for regulating biological 
activities
 of p53 (Giaccia and Kastan 1998), (Prives 1998). Although the functions of 
these modifications are
 not fully characterized, they are likely to regulate
 the binding 
of p53 with its negative regulator, Mdm2. Other negative
  regulatory mechanisms 
involve binding of JNK to p53, which mediates
 ubiquitination and proteolytic removal 
of p53 (Fuchs, Adler et al. 1998), and the retinoblastoma
 gene product (Rb), which 
prevents the apoptotic function of p53 (Haupt, Rowan et al. 1995), (Morgenbesser, 
Williams et al. 1994).
 Both p53 inhibitors, Rb and Mdm2, are cleaved by caspases 
during
  apoptosis (An and Dou 1996), (Erhardt, Tomaselli et al. 1997), (Janicke, 
Walker et al. 1996), suggesting a positive self-regulation of programmed
 cell death 
and close connection to key cell-cycle regulators. The transcriptional activating
 
function of p53 is a major component of its biological effects.
 Many p53 target genes 
have been identified, and those functions
 have been characterized. Cell-cycle arrest 
that is dependent on
 p53 requires transactivation of p21
Waf1, GADD45, and cyclin 
G. Pro-apoptotic p53 target proteins include
 Bax, PIG genes, CD95, DR5 (a receptor 
for the death ligand TRAIL),
  IGF-BP3, Rpr (in Drosophila), Cdc42 (a Ras-like 
GTPase), Noxa
  (a Bcl-2 family protein), and p53AIP1 (Oda, Ohki et al. 2000), 
(Levine 1997), (Brodsky, Nordstrom et al. 2000), (Muller, Wilder et al. 1998), (Oda, 
Arakawa et al. 2000), (Owen-Schaub, Zhang et al. 1995), (Sheikh, Burns et al. 1998), 
(Thomas, Giesler et al. 2000), (Wu, Burns et al. 1999).  
The mechanism by which p53-induces apoptosis is described involving the 
translocation of p53 to the mitochondria, thus activating the Apaf-1/caspase-9
 
pathway (Soengas, Alarcon et al. 1999; Sansome, Zaika et al. 2001; Mihara, Erster et 
al. 2003), death receptor signalling (Muller, Strand et al. 1997), (Bennett, Macdonald 
et al. 1998), (Munsch, Watanabe-Fukunaga et al. 2000), and cleavage
 of downstream 
caspases (Li, Dietz et al. 1999). For example, cells expressing mutant
  p53 fail to 
induce CD95 and are less sensitive to drug-induced
 apoptosis (Muller, Strand et al. 
1997), (Newton and Strasser 2000). Independently of transcription, p53 may facilitate
 
the transport of CD95 from Golgi stores to the membrane, leading
 to death receptor 
aggregation (Bennett, Macdonald et al. 1998). However, in some cases CD95
 is not 
essential for p53-mediated apoptosis, and p53-dependent
 up-regulation of CD95 does 
not obligatory induce apoptosis (O’Connor, Harris et al. 2000). An
 additional route by 
which p53 may signal apoptosis is through
 the production of ROS, which influence 
the mitochondrial membrane
 potential without involving Cytochrome c release (Li, 
Dietz et al. 1999), (Johnson, Yu et al. 1996). In particular,
 the p53-inducible gene 
PIG3 shares homology with an NADPH-quinone
  oxidoreductase, which generates 
ROS. When overexpressed alone,
 PIG3 failes to initiate apoptosis, implying that other 
signals
 must be activated in parallel (Polyak, Xia et al. 1997). Recently, p53 itself was 
shown
 to cause caspase activation in cell-free extracts from E1A/ras-transformed,
 but 
not normal, fibroblasts by a mechanism independent of transcription
 or presence of 
Bax or Cytochrome c (Ding, McGill et al. 1998). Activation
 of caspases by p53 is 
mediated by the c-Myc oncogene (Ravi, Bedi et al. 2001). Apparently, p53 can 
transduce
 apoptotic signals through protein-protein interactions, thereby
 modulating 
p53-dependent caspase activation. Another mechanism
  by which p53 promotes 
apoptosis is through activation of the Ras-like
 GTPase Cdc42, which results in the   28
JNK1-induced phosphorylation
  of Bcl-2 (Thomas, Giesler et al. 2000). All theses 
pathways and their componants are explained in detail in the following chapters. 
4.2- Caspases  
 
Mammalian caspases comprise a group of at least fourteen members that can 
promote apoptosis ((Cohen 1997), (Nicholson and Thornberry 1997), (Cryns and 
Yuan 1998), (Schulze-Osthoff, Ferrari et al. 1998)).  
 
 
 
Fig.6: Schematic diagram of the mammalian caspases (Molecular Cell, 2002 (Shi 
2002)). 
Except Caspase-11 (mouse), -12 (mouse) and ￿13 (bovine), all listed caspases are of 
human origin. Their phylogenetic relationship (left) appears to correlate with their 
function in apoptosis or inflammation. Initialy expressed as zymogens, pro-caspases 
are activated either by auto-catalytical cleavage induced by the forced proximity 
created in complexes like the DISC or the apoptosome (Caspase-8 or ￿9), either by 
cleavage by an other upstream active caspase (Caspase-3, -6 and ￿7). The initiator and 
effector caspases are labelled in purple and red, respectively. The position of the first 
activation cleavage (between the large and small subunits) is highlighted with a large 
arrow while additional sites of cleavage are represented by medium and small arrows. 
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Some caspases, like Caspase-1, generate mature proinflammatory cytokines 
and thereby regulate immune responses. Based on phylogenetic analysis and 
positional scanning studies of their peptide substrates, caspases are divided into three 
subfamilies: The ICE-like protease family includes Caspase-1, -4, -5, -13, and -14 as 
well as murine Caspase-11 and -12. The CED-3 subfamily includes Caspase-3, -6, -7, 
-8, -9, and -10, whereas the third subfamily consists of only one member, Caspase-2 
(Fig.6). Within each subfamily, the peptide sequence preferences in the substrates are 
similar ((Thornberry, Rano et al. 1997); (Garcia-Calvo, Peterson et al. 1998)). 
Because at least in some cases different caspases can cleave the same substrates, this 
illustrates some degree of functional redundancy within the caspase family. Caspases 
exist as latent zymogens that contain an N-terminal prodomain followed by the region 
that forms two subunits with the catalytic domain. The core of the catalytic center is 
formed by the conserved pentapeptide sequence QACXG (the central cystein has 
given its name to the caspase family). The proforms of caspases are activated by 
proteolytic cleavage at specific aspartate residues. Generally, an initial cleavage event 
separates the C-terminal short subunit from the rest of the molecule, allowing 
assembly of an active protease that autocatalytically cleaves off its prodomain. As 
deduced from the crystal structure of Caspase-1 and Caspase-3, the mature enzyme of 
all caspases is a heterotetrameric complex composed of two large subunits and two 
small subunits ((Walker, Talanian et al. 1994); (Wilson, Black et al. 1994); (Rotonda, 
Nicholson et al. 1996); (Mittl, Di Marco et al. 1997)). Once activated, some caspases 
can propagate activation of other family members and thus initiate a proteolytic 
cascade (Fig.1). 
Although caspases are the essential components of many, if not all apoptotic 
pathways, their precise physiological role remains controversial. Indeed, Caspase-8 
has been shown for example to be important for T-cell proliferation (Newton, Harris 
et al. 1998; Strasser and Newton 1999), (Hueber, Zornig et al. 2000), (Salmena, 
Lemmers et al. 2003) and caspases activation was shown to be crucial in monocytic 
differentiation of myeloid leukaemia cells (Pandey, Nakazawa et al. 2000). Very 
recent studies using gene targeting and transgene technologies have provided some 
answers to questions like ￿are caspases simply redundant or do they play specific 
roles in specific apoptotic pathways?￿ or ￿are the molecular components of apoptosis 
only implicated in apoptosis or are they important also for other pathways like 
proliferation and differentiation?￿. These studies have shed new light on the 
distinctive role of individual caspases in cell death as well as in other unexpected 
biological processes. Caspase-1 was originally identified as interleukin 1b￿converting 
enzyme (ICE), the protease that cleaves the precursor of IL-1b into the active cytokine 
((Cerretti, Kozlosky et al. 1992)). More recently, Caspase-1 has been shown to further 
process the cytokine precursors of IL-16 and IL-18. Furthermore studies from 
knockout (KO) mice indicated that Caspase-1 mediates partially apoptosis induced by 
IFN-γ . In this scenario, a positive amplification loop between IFN-γ  and Caspase-1 
seems to exist. IFN-γ  is able to induce Caspase-1 expression through activation of the 
STAT (signal transducer and activator of transcription) signaling pathway (Chin, 
Kitagawa et al. 1997).  
Homozygous disruption of the mouse caspase-8 gene was found to be lethal in 
utero ((Varfolomeev, Schuchmann et al. 1998)). However, whereas Caspase-3
-/- mice   30
exhibited profound brain defects, Caspase-8
-/- embryos presumably died from cardiac 
failure. Two salient features of Caspase-8 null mice were impaired heart muscle 
development and abdominal hemorrhage. Extensive erythrocytosis was present also in 
other organs such as liver and lung. The fact that the heart was hypotrophic rather 
than enlarged strongly suggests that Caspase-8 may be involved in the transmission of 
survival rather than death signals. This is supported by the fact that hematopoietic 
precursor cells from KO mice revealed a strongly impaired colony-forming activity. 
Disruption of Caspase-8 thus appears to result in a primary or secondary depletion of 
the hematopoietic precursor pool ((Varfolomeev, Schuchmann et al. 1998)). 
Embryonic fibroblasts deficient in Caspase-8 were completely resistant to apoptosis 
mediated by death receptors, such as CD95, TNF-R1 and DR3, whereas they retained 
sensitivity to a wide range of apoptotic stimuli including UV irradiation, ceramide, 
chemotherapeutic drugs, and infection with the cytopathic vesicular stomatitis virus. 
A Jurkat T cell line deficient in Caspase-8 is not only completely resistant to death 
receptor￿induced apoptosis, but also partially resistant to cell death induced by UV 
irradiation, adriamycin, and etoposide ((Juo, Kuo et al. 1998)). Complementation of 
these cells with Caspase-8 restores apoptosis sensitivity. In addition, adenoviral E1A 
induces pro-Caspase-8 processing and apoptosis in cells deleted of FADD, indicating 
the existence of alternative activation pathways ((Nguyen, Branton et al. 1998)). 
Thus, these findings indicate that Caspase-8 plays a necessary and non-redundant role 
in apoptosis induction by death receptors.  
FADD KO mice brought further insights to this rather complicated death-
induction/proliferation mechanisms. Like Caspase-8 KO mice, gene targeting of the 
adaptor protein FADD results in a lethal phenotype with profound signs of cardiac 
failure and haemorrhage ((Yeh, Pompa et al. 1998)). Since FADD
-/- mice die in utero, 
T cell maturation has been analyzed in chimeric mice deficient for the recombination 
activating gene product RAG1, which activates rearrangement of immunoglobulin 
and T cell receptor genes ((Zhang, Cado et al. 1998)). T lymphocytes from FADD
-/- 
chimera were completely resistant to CD95-induced apoptosis. Thymocyte 
populations were apparently normal in newborn chimeras. As these mice age, their 
thymocytes, however, decreased to undetectable levels, although peripheral T cells 
were present. Thus, FADD
-/- mice seem to be inefficient in maintaining thymic 
cellularity possibly due to an intrinsic survival defect. Activation-induced 
proliferation was impaired in FADD
-/- T cells, despite normal production of IL-2. 
Thus, this suggests a rather unexpected connection between cell proliferation and 
apoptosis ((Zhang, Cado et al. 1998)). A growth-promoting activity of FADD is 
supported by the phenotype of transgenic mice expressing a dominant-negative 
FADD mutant (FADD-DN) under control of a T cell￿specific promoter ((Newton, 
Harris et al. 1998), (Zornig, Hueber et al. 1998), (Walsh, Wen et al. 1998)). 
Expression of FADD-DN enhanced negative selection of self-reactive thymic 
lymphocytes. FADD-DN mice displayed increased apoptosis and reduced 
proliferation and clonogenic growth of mitogen-activated T cells. Interestingly, this 
impaired T cell proliferation was not observed in CD95-deficient mice or animals 
overexpressing the viral caspase inhibitor CrmA ((Smith, Strasser et al. 1996)). Thus, 
signaling through FADD does not lead exclusively to cell death, but under certain 
circumstances can promote cell survival and proliferation.   31
 
 
 
 
 
4.3- The central role of mitochondria 
 
An early step in apoptosis is the mitochondrial release of Cytochrome c into 
the cytosol which, together with dATP or ATP, binds to the CED-4 homolog Apaf1. 
This event leads to a conformational change which induces oligomerization of the 
molecule in a heptamer resembling a wheel with seven spokes and a hub. In each of 
the seven Apaf-1 monomers, the CARD and part of the NBD (nucleotide binding 
domain) contribute to the hub, whereas the remainder of the Apaf-1 molecule (its 
carboxy-terminal moiety) forms a Y-shaped spoke (Acehan, Jiang et al. 2002), 
(Adams and Cory 2002). Subsequently, procaspase-9 binds to the complex through 
CARD/CARD interactions (Fig.5). This oligomerization of Apaf-1 and pro-caspase-9 
forms the mega-complex called apoptosome. The mitochondrial (but not the death 
receptor) pathway is inhibited by Bcl-2. Antiapoptotic members of the Bcl-2 family 
may interfere with the relocalization of cytochrome c or with the binding of 
Cytochrome c to Apaf-1 (see: How cells are protected from apoptosis).  
A comparison of the so far established KO mice allows the separation of 
distinct  in vivo apoptotic pathways that are strikingly cell type￿specific and 
differentially utilized in response to certain stimuli (Scaffidi, Fulda et al. 1998). First, 
the classical death receptor pathway that is Caspase-3- dependent but can be 
independent of Caspase-9 (in the so-called type I cells). The existence of this pathway 
is exemplified in activated T cells. Caspase-3 deficiency protects activated T cells 
from apoptosis induced by anti-CD95, TRAIL, and anti-CD3, whereas Caspase-9 
deficiency has no obvious effect. Secondly, the classical mitochondrial pathway 
(intrinsic pathway or death receptor pathway in type II cells) that is dependent on 
Apaf-1 and Caspase-9. For example, embryonic stem cells from both Apaf1
-/- and 
Caspase-9
-/-  mice are resistant to several apoptotic signals including UV and γ -
irradiation or chemotherapeutic drugs (Fig.1).  
Following activation of the initiator caspases Caspase-8 or Caspase-9, the two 
pathways, extrinsic and intrinsic, converge on the activation of the effector Caspase-3, 
-6, and -7, which finally cleave various ￿death￿ substrates. Because Caspase-8 cleaves 
Bid and generates a truncated, proapoptotic BH3-containing fragment (tBid) that 
induces cytochrome c release, both pathways (intrinsic and death receptor pathway in 
type II cells) cross-communicate. Caspase-8, in turn, can be also activated by 
Caspase-6 following Caspase-9 cleavage, thereby amplifying the apoptotic signal 
(Ghayur, Banerjee et al. 1997), (Gu, Kuida et al. 1997), (Fantuzzi, Puren et al. 1998). 
Here again, the generation of KO mice helped to unravel the role of Caspase-3 in 
apoptosis. Indeed, gene targeting of Caspase-3 generated mice with profound defects 
in apoptosis ((Kuida, Zheng et al. 1996); (Woo, Hakem et al. 1998)). The most 
pronounced effect is seen in the central nervous system, while no discernible 
abnormalities are found in embryonic heart, lung, liver, or kidney. Caspase-3 deficient   32
animals show massive hyperplasia and ectopic cell masses of the brain with a variety 
of disorganized cellular structures. Hence, Caspase-3 plays a critical role during 
morphogenetic cell death in the mouse brain. The central role of Caspase-3 for 
induction of apoptosis has been shown also in hepatocytes and thymocytes derived 
from KO mice ((Zheng, Schlosser et al. 1998)).  
Although caspase-3
-/- hepatocytes or thymocytes were killed at a similar rate 
as control cells when cocultured with CD95 ligand-expressing 3T3 cells, wild-type 
cells displayed typical apoptotic features such as cytoplasmic blebbing and nuclear 
fragmentation within 6 hr, while none of these events was observed for Casp3
-/- cells. 
The cleavage of various caspase substrates implicated in apoptotic events, including 
gelsolin, fodrin, lamin B, and DFF/ICAD, an endonuclease inhibitor, was delayed or 
absent in the Caspase-3
-/- cells. Thus, the altered cleavage of these key substrates is 
likely to be responsible for the aberrant apoptotic phenotype in Caspase-3-deficient 
cells. Although Caspase-3 is highly expressed in cells of hematopoietic origin, lack of 
Caspase-3 did not affect immature T and B cell development ((Kuida, Zheng et al. 
1996)). Gene-targeted mice contained fewer thymocytes, related to their overall 
smaller size. Surprisingly, thymocytes from Caspase-3
-/- and wild-type mice were 
equally sensitive to induction of apoptosis by anti-CD95, dexamethasone, ceramide, 
staurosporin, and γ -irradiation. Using Caspase-3
-/- lymphocytes from RAG1
-/- mice, it 
was shown that peripheral T cells were resistant to activation-induced cell death and 
apoptosis triggered by anti-CD3 and anti-CD95 ((Woo, Hakem et al. 1998)). The 
requirement for intact Caspase-3 appeared to dependent on the apoptotic stimulus. In 
embryonic stem cells, Caspase-3 was necessary for efficient apoptosis following UV 
irradiation, but not γ -irradiation or cytotoxic killing of target cells. Conversely, the 
same stimulus can show tissue specific consequences: TNF-α  treatment induced 
normal levels of apoptosis in Caspase-3
-/- thymocytes, but defective apoptosis in 
oncogene-transformed fibroblasts ((Woo, Hakem et al. 1998)). Hence, the 
consequences of Caspase-3 deficiency appear to be remarkably context-dependent 
with apoptotic defects being both cell type and stimulus-specific.  
 
 
C-Mitochondria and the apoptosome 
 
  The complex role of mitochondria in mammalian cell apoptosis came into 
focus when biochemical studies identified several mithochondral proteins that are able 
to activate cellular apoptotic programs directly (Liu, Kim et al. 1996; Susin, Lorenzo 
et al. 1999; Du, Fang et al. 2000; Li, Luo et al. 2001). Normally, these proteins reside 
in the intermembrane space of mitochondria. In response to a variety of apoptotic 
stimuli, they are released to the cytosol and/or the nucleus. They promote apoptosis 
either by activating caspases and nucleases, or by neutralizing cytosolic inhibitors of 
this process (Fig.7). 
 
1- The apoptosome pathway studied through knockout mice. 
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  The two major components of the apoptosome are Apaf-1 and 
Caspase-9. Recently both Caspase-9 and Apaf-1deficient mice have been generated 
(Cecconi et al., 1998; Hakem et al., 1998; Kuida et al., 1998; Yoshida et al., 1998). 
The phenotypes of these mice resembled Caspase-3 deficient animals in that they 
primarily developed brain malformations and overgrowth with excess cells in the 
central nervous system. The ectopic cell masses consisted of differentiated postmitotic 
cells that had escaped apoptosis. A nearly 10-fold reduction of TUNEL-positive cells 
was found in the brain of Caspase-9
-/- mice at E12.5. In situ immunostaining showed 
the absence of Caspase-3 activation in vivo. Both Caspase-9- and Apaf-1 deficient 
mice died at about day 16.5 of development. Unlike the brain, other non-neural organs 
such as heart, lung, and liver or spinal cord were unaffected and appeared remarkably 
normal. The similar phenotypes of Caspase-3, Caspase-9, and Apaf-1 deficient mice 
therefore indicate that the molecules act in line in a common apoptotic pathway. It is 
interesting to note that the phenotypes of the three KO mice are similar, but do not 
accurately mimic each other. Although disruption of either Caspase-9 or Caspase-3 
caused brain malformations, the abnormalities were more severe in mice lacking 
Caspase-9. Caspase-3-deficient cells rarely exhibited an overt exencephaly 
abnormality. One possibility to account for this difference in severity of the 
malformation is that Caspase-9 may also activate other effector caspases such as 
Caspase-6 or Caspase-7. While Caspase-9
-/-  mice exhibited a more pronounced 
phenotype than mice with a Caspase-3 null mutation, the most severe morphogenetic 
distortions were found in Apaf-1 KO mice (Cecconi et al., 1998; Yoshida et al., 
1998). Apaf-1
-/- mice showed strong craniofacial abnormalities such as ossification 
defects, deficient midline fusion of the palatal shelves, as well as dramatic alterations 
of the lens and retina. Also cauliflower-like masses on the face present in Apaf-1
-/- 
mice were not observed in either Caspase-3 or Caspase-9 gene￿targeted mice.  
It has been suggested that Caspase-8 can physically interact with Apaf-1 in 
overexpression systems. A more detailed analysis, however, showed that Caspase-9 is 
the only Apaf-1 interacting protease in living cells (Slee et al., 1999). Thus, the idea 
that another caspase may substitute Caspase-9 is appealing, but currently none of the 
other known caspases appears to be activated by Apaf-1. Despite a normal 
development of the thymus, thymocytes from Caspase-9- and Apaf-1-deficient mice 
were resistant to a number of apoptotic stimuli. Nevertheless, both mouse models 
contained a comparable number to wild type mice of double-positive thymocytes, 
indicating that Apaf-1 and Caspase-9 are not involved in negative selection. In 
thymocytes and embryonic stem cells from KO mice, Cytochrome c was translocated 
into the cytosol, confirming that Apaf-1 and Caspase-9 act downstream of 
Cytochrome  c. Thymocytes from Apaf-1
-/-  mice were also resistant to a loss of 
mitochondrial transmembrane potential (Yoshida et al., 1998). It has been suggested 
that opening of the mitochondrial permeability pore and loss of transmembrane 
potential may be an initial event for Cytochrome c release and subsequent caspase 
activation (Kroemer, 1997). The results observed in KO mice, however, strongly 
suggest that the decrease of the transmembrane potential is downstream of Apaf-1-
mediated caspase activation. This assumption is supported by the fact that in several 
apoptotic systems Cytochrome c release preceded mitochondrial membrane 
depolarization by many hours.    34
 
 
 
 
 
 
 
2-Proapototic proteins released from the mitochondria 
2.1-Cytochrome c 
 
 Cytochrome  c, a component of the mitochondrial electron transfer chain, 
initiates caspase activation when released from the mitochondria during apoptosis 
(Liu, Kim et al. 1996). Cytosolic Cytchrome c binds to Apaf-1, a protein containing a 
caspase recruitment domain (CARD), a nucleotide binding domain, and multiple WD-
40 repeats(Zou, Henzel et al. 1997). The binding of Cytchrome c increases Apaf-1 
affinity for dATP/ATP about 10 fold (X). The binding of nucleotide to the Apaf-
1/Cytochrome c complex triggers its oligomerization to form the apoptosome, which 
subsequently recruits multiple Procaspase-9 molecules to the complex and facilitates 
their autoactivation. Only the caspase-9 bound to the apoptosome is able to efficiently 
cleave and activate downstream executioner caspases such as Casase-3(Rodriguez and 
Lazebnik 1999). Murine embryos devoid of Cytochrome c die in utero by 
midgestation, but cell lines established from early cytochrome c null embryos are 
viable under conditions that compensate for defective oxidative phosphorylation. As 
compared to cell lines established from wild-type embryos, cells lacking Cytochrome 
c show reduced Caspase-3 activation and are resistant to the proapoptotic effects of 
UV irradiation, serum withdrawal, or staurosporine. In contrast, cells lacking 
Cytochrome  c demonstrate increased sensitivity to cell death signals triggered by 
TNFalpha (Li, Li et al. 2000). 
 
 
2.2-Smac/Diablo and Omi/HtrA2 
 
Concurrent with Cytochrome c, smac/Diablo, a 25-kD mitochondrial protein, 
is released from mitochondria into cytosol during apoptosis(Du, Fang et al. 2000). 
Smac is a nuclear-encoded mitochondrial protein containing a 55-amino-acid 
mitochondrial targeting sequence at its N-teminus. This sequence is removed upon 
import into the mitochondria (Du, Fang et al. 2000). The four extra amino acids (at 
the N-terminus) of the mature Smac, Ala-Val-Pro-Ile (AVPI), bind to the BIR 
(baculovirus IAP (inhibitor of apoptosis protein) repeat) domain of IAPs  (for details 
about IAPs see chapter 3.2) (Chai, Du et al. 2000) (Fig.7). The exposed N-terminal 
alanine of mature Smac is absolutely required for the binding of IAPs (Chai, Du et al. 
2000; Liu, Sun et al. 2000; Wu, Chai et al. 2000). Because this alanine becomes 
exposed only when the signal peptide is cleaved after mitochondrial entry,   35
mitochondrial targeting becomes a critical step for Smac function. smac 
-/- mice are 
viable, grow, and mature normally and they do not show any histological 
abnormalities (Okada, Suh et al. 2002). Although the cleavage in vitro of Procaspase-
3 was inhibited in lysates of smac 
-/- cells, all types of cultured smac 
-/- cells tested 
responded normally to all apoptotic stimuli applied. There were also no detectable 
differences in Fas-mediated apoptosis in the liver in vivo. These results suggeste that 
there may be a redundant molecule or molecules capable of compensating for a loss of 
Smac function (Okada, Suh et al. 2002). Such a molecule is Omi/HtrA2, a 
mammalian serine protease with high homology to bacterial HtrA chaperones. 
Omi/HtrA2 is localized in mitochondria and is released to the cytoplasm in response 
to apoptotic stimuli. Omi/HtrA2 induces cell death in a caspase-dependent manner by 
interacting with the inhibitor of apoptosis protein as well as in a caspase-independent 
manner that relies on its protease activity (Suzuki, Imai et al. 2001; Hegde, 
Srinivasula et al. 2002; Cilenti, Lee et al. 2003). 
 
 
 
Fig.7: Smac inhibitory function (Cell, 2000 (Green 2000)). 
A. Cytochrome c release and apoptosome formation. B. XIAP inhibits Caspase-9 
activation by the apoptosome. C. Smac binds to XIAP and blocks its inhibitory 
activity, thereby promoting apoptosis. 
 
  In addition to the BIR3 domain of XIAP, Smac/Diablo has also been shown to 
form a stable complex with the BIR2 domain of XIAP (Chai, Shiozaki et al. 2001). 
The linker sequence immediately preceding the BIR2 domain is involved in XIAP-
mediated binding and inhibition of Caspase-3 and Caspase-7 (Chai, Shiozaki et al. 
2001) (Sun, Cai et al. 1999; Huang, Park et al. 2001; Riedl, Renatus et al. 2001). 
Smac/Diablo binds to the BIR2 domain and presumably disrupts its inhibition of   36
Caspase-3 and Caspase-7 by steric hindrance  (Chai, Shiozaki et al. 2001). The ability 
of Smac/Diablo to counter the inhibition of apoptosis by IAPs at multiple levels 
provides a powerful way for mitochondria to ensure rapid execution of apoptosis. The 
direct competition and mutual exclusion between Smac and activated caspases 
suggest an interesting feedback system in cells (Fig.7 and 10).  
In this regard, Omi
 resembles Smac/DIABLO. It also binds IAPs and as a 
result activates
 caspase-9 (Suzuki, Imai et al. 2001; Cilenti, Lee et al. 2003). Omi 
protein is synthesized as a precursor
 that is processed in the mitochondria to produce 
the mature protein.
 This processing exposes an internal tetrapeptide motif, AVPS,
 at 
the amino terminus (Martins 2002). Processing of the precursor Omi polypeptide is an 
intramolecular
 reaction and requires an intact protease domain. Omi can also induce 
apoptosis in a caspase-independent pathway
  that relies entirely on its ability to 
function as a serine protease (Hegde, Srinivasula et al. 2002)
 . 
 
 
 
2.3-Apoptosis-inducing factor (AIF) 
 
  Apoptosis-inducing factor (AIF) is a 57-kD flavoprotein that resembles 
bacterial oxidoreductase and resides in the mitochondrial intermembrane space 
(Susin, Lorenzo et al. 1999). Upon induction of apoptosis, AIF translocates from the 
mitochondria to the nucleus and causes chromatin condensation and large-scale DNA 
fragmentation (Susin, Lorenzo et al. 1999). These effects are independent of caspases 
and the oxidoreductase activity of AIF (Miramar, Costantini et al. 2001). The 
mechanism by which AIF induces chromatin condensation and large-scale DNA 
fragmentation is not yet understood. Moreover AIF has not measurable DNase   
activity by itself, resulting in the possibility that AIF may work with another protein 
to cause such an effect(Susin, Lorenzo et al. 1999). 
 
2.4-Endonuclease G 
 
  Endonuclease G (EndoG), a known 30-kD nuclease in the mitochondria, was 
purified recently from the supernatant of mouse mitochondria that was treated with 
Caspase-8-activated Bid (tBid), a condition that mimicked the initiation of cell death 
after activation of the cell surface death receptor CD95 (Li, Luo et al. 2001). EndoG is 
encoded by a nuclear gene, translated in the cytosol ,  and imported subsequently into 
the mitochondria. It has been described that Ca2+-induces mitochondrial permeability 
transition and causes complete release of rat liver EndoG activity from its exclusive 
location within the mitochondrial intermembrane space (Davies, Hershman et al. 
2003).  Once released, EndoG is able to induce nucleosomal DNA fragmentation. 
EndoG activity is independent of caspase activation (Liu, Zou et al. 1997; Enari, 
Sakahira et al. 1998; Liu, Li et al. 1998; Li, Luo et al. 2001). 
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3-Induction of the mitochondria 
 
  The induction of the mitochondria usually takes place upon translocation of 
Bcl-2 family members to the mitochondria. Among them, the BH3-only family shares 
sequence homology with Bcl-2 only in the BH3 domain, an amphipathic helix 
required to interact with other Bcl-2 family members (Huang, Tschopp et al. 2000). 
At the mitochondria, they cause mitochondrial damage and release of apoptogenic 
proteins either by interacting with other members of the Bcl-2 family, or by relieving 
the inhibition exerted by anti-apoptotic Bcl-2 family members. In mammals, Bcl-2 
has at least 20 relatives, all of which share at least one conserved Bcl-2 homology 
(BH) domain (Korsmeyer 1999) (Fig.8). The family includes four anti-apoptotic 
proteins: Bcl-xL, Bcl-w, A1(Wang, Guttridge et al. 1999) and Mcl1(Leuenroth, 
Grutkoski et al. 2000), and two groups of proteins that promote cell death: Bax and 
Bak, and the BH3-only family.  
 
 
 
Fig.8: The three subfamilies of Bcl-2-related mammalian proteins (Cancer Rev., 2002 
(Cory and Adams 2002)) 
 
  Moreover, the BH3-only family members are differently regulated. Some need 
proteolytic cleavage to be activated (Bid) (Li, Zhu et al. 1998), some are regulated 
through phosphorylation (Bad) (Wolf, Witte et al. 2001) or release from different 
cellular compartments (Bim, Bmf) (O’Connor, Strasser et al. 1998; Puthalakath, 
Huang et al. 1999) (Puthalakath, Villunger et al. 2001) (Fig.9), and some are 
transcriptionaly regulated (Noxa, Puma) (Oda, Ohki et al. 2000; Nakano and Vousden 
2001; Schuler, Maurer et al. 2003).  
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3.1-Cleavage of Bid 
 
  Bid is exclusively cytosolic in living cells. Upon activation of cell surface 
receptors like Fas/APO-1/CD95, TNFR1, DR-3, DR-4/TRAIL-R1 and DR-5/TRAIL-
R2, Bid is cleaved by Caspase-8. The truncated Bid (tBid) translocates from cytosol 
to mitochondria and induces Cytochrome c release (Li, Zhu et al. 1998; Luo, 
Budihardjo et al. 1998). tBid targets mitochondria through its helices 4-6, the 
targeting specificity is provided by the binding to the mitochondria-specific lipid 
cardiolipin (Lutter, Fang et al. 2000). The targeting efficiency is dramatically 
enhanced by myristoylation at the N-terminal glycine residue of tBid that becomes 
exposed after Caspase-8 cleavage (Zha, Weiler et al. 2000) (Fig.1).  
The ability to cleave and activate Bid may not be limited to Caspase-8. Other 
caspases, such as Caspase-3, as well as other proteases, like granzyme B and 
lysosomal proteases, have been shown to cleave and activate Bid (Li, Zhu et al. 1998; 
Heibein, Goping et al. 2000; Sutton, Davis et al. 2000; Alimonti, Shi et al. 2001; 
Stoka, Turk et al. 2001). Bid may therefore serve as a general integrator and amplifier 
for many apoptotic signals. Bid
-/- mice injected with an antibody directed against Fas 
that can activate the receptor, nearly all survive, whereas wild-type mice die from 
massive hepatocyte apoptosis and haemorrhagic necrosis. About half of the Bid-
deficient animals have no apparent liver injury and show no evidence of activation of 
the effector Caspase-3 and -7, although the initiator Caspase-8 was activated. Other 
Bid-deficient mice survive with only moderate damage: all three caspases (-8, ￿3 and 
-7) are activated but their cell nuclei are intact and no mitochondrial Cytochrome c is 
released. In bid
-/- cultured cells treated with anti-Fas antibody (hepatocytes and 
thymocytes) or with TNFα  (fibroblasts), mitochondrial dysfunction is delayed, 
Cytochrome c is not released, effector caspase activity is reduced and the cleavage of 
apoptosis substrates is altered. This loss-of-function model supports evidence that Bid 
is a critical substrate in vivo for signalling by death-receptor agonists, which mediates 
a mitochondrial amplification loop that is essential for apoptosis of certain cell types 
(Yin, Wang et al. 1999). 
 
 
3.2-Phosphorylation of Bad 
 
  Bad, another BH3-only protein, is regulated primarily by phophorylation and 
dephosphorylation. In the absence of survival signals, Bad is dephosphorylated. The 
BH3 domain of Bad binds to and inactivates the antiapoptotic members of the Bcl-2 
family at the outer mitochondrial membrane, thereby promoting cell death. Conversly, 
in the presence of trophic factors, Akt a mitochondria-anchored protein kinase (del 
Peso, Gonzalez-Garcia et al. 1997) phosphorylate Bad, resulting in its binding to 14-
3-3 proteins in the cytosol (Wolf, Witte et al. 2001). Several phosphatases, including 
calcineurin, protein phosphatase 1α , and protein phosphatase 2A, have been shown to 
dephosphorylate Bad in vitro and to activate its pro-apoptotic activity (del Peso, 
Gonzalez-Garcia et al. 1997; Zundel and Giaccia 1998; Hinton and Welham 1999;   39
Scheid, Schubert et al. 1999; Datta, Katsov et al. 2000; Kuwahara, Saito et al. 2000; 
Springer, Azbill et al. 2000). 
 
 
3.3-Dissociation of Bim and Bmf from the cytoskeleton 
 
  Bim and Bmf are further BH3-only proteins, which have been found to 
associate with cellular microtubule complexes by binding to dynein light chains 
(Fig.9). Early during apoptosis, Bim/LC8 dissociates from the microtubule complex 
(Puthalakath, Huang et al. 1999) and Bmf/LC2 dissociates from the actin cytoskeleton 
(Puthalakath, Villunger et al. 2001), and both translocate to the mitochondria. This 
dissociation seems to represent an independent starting point for apoptosis. 
Recombinant Bim alone is as efficient as tBid in releasing Cytochrome c and EndoG 
when incubated with mitochondria in vitro.  
Mice lacking Bim show apoptosis defects in their immune system (Bouillet, 
Cory et al. 2001). Moreover, the abundance of Bim also seems to be critically 
regulated at the level of transcription during apoptosis (Biswas and Greene 2002). In 
healthy cells,
 Bmf is sequestered to myosin V motors by association with dynein
 light 
chain 2. Certain damage signals, such as loss of cell attachment
 (anoikis), unleash 
Bmf, allowing it to translocate and bind prosurvival
  Bcl-2 proteins (Puthalakath, 
Villunger et al. 2001). 
 
 
 
Fig.9: Diverse modes of post-translational regulation of BH3-only proteins (Cancer 
Rev., 2002 (Cory and Adams 2002)). 
In healthy cells, BH3-only proteins are held in check by a variety of strategies. Bim 
and Bmf are sequestered to the microtubules or cytoskeleton, respectively, via 
interaction with a dynein light chain (DLC). Phosphorylated Bad is bound by 14-3-3 
scaffold proteins. Bid is synthetized as precursor, which requires proteolytic cleavage 
to be fully active. 
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3.4-The role of Bax and Bak 
 
  Once the BH3-only proteins reach the mitochondria, they need to cooperate 
with other mitochondrial proteins to induce the release of apoptogenic proteins. The 
proapoptotic members of the Bcl-2 family that contain BH1-BH3 but not BH4, such 
as Bax and Bak, are the likely mediators for the BH3-only proteins(Korsmeyer, Wei 
et al. 2000) (Fig.8). The important role of these proteins in apoptosis has been 
demonstrated dramatically in bax and bak double KO mice. MEF cells lacking both 
bax and bak are resistant to multiple apoptotic stimuli, including overexpression of 
the BH3-only proteins tBid, Bim and Bad (Wei, Zong et al. 2001). Concurrent with 
the translocation of the BH3-only proteins to the mitochondria, Bax and Bak undergo 
conformational changes and oligmerization, presumably induced by transient 
interaction with the BH3-only protein tBid (Korsmeyer, Wei et al. 2000; Nechushtan, 
Smith et al. 2001). The oligomerized Bax and Bak may form a pore big enough for 
the apoptogenic proteins to pass through or else destabilize the mitochondrial outer 
membrane through an unknown mechanism. So the common mechanism usually 
involves the inhibition of the Bcl-2/Bcl-XL  heterodimer by an activated BH3-only 
member, heterodimer that can inhibit Bax/Bak activity at the mitochondria (Hsu, 
Wolter et al. 1997; Lutter, Fang et al. 2000; Murphy, Ranganathan et al. 2000; 
Shimizu and Tsujimoto 2000; Wei, Zong et al. 2001; Thomenius, Wang et al. 2003).  
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Fig.10: Bcl-2 family member activity and function during apoptosis (Cell, 2000 
(Green 2000)) 
 
 
4-Apoptosis-inhibiting mechanisms 
4.1-The Bcl-2 anti-apoptotic members 
.  
Bcl-2 and its closest homologues, Bcl-xL and Bcl-w, inhibit apoptosis in 
response to many, but not all, cytotoxic insults (Chiou, Rao et al. 1994; Zha, Aime-
Sempe et al. 1996; Furukawa, Estus et al. 1997; Badrichani, Stroka et al. 1999; 
Huang, Tschopp et al. 2000). Their hydrophobic carboxy-terminal domain helps to 
target them to the cytoplasmatic face of three intracellular membranes: the outer 
mitochondrial membrane, the endoplasmic reticulum (ER) and the nuclear envelope 
(Akao, Otsuki et al. 1994; Thomenius, Wang et al. 2003). Bcl-2 is an intergral 
membrane protein, even in healthy cells (Janiak, Leber et al. 1994; Lee, Hoeflich et 
al. 1999), wheras Bcl-w and Bcl-xL only become tightly associated with the 
membrane after a cytotoxic signal (Hsu, Wolter et al. 1997). This indicates an induced 
conformational change of these proteins. In bcl-2 deficient mice, extensive apoptosis 
occurs during abnormal nephrogenesis, and renal failure is found very quickly after 
birth (Gassler, Elger et al. 1998).  
The less well studied proteins A1 and Mcl1 have a weaker survival activity 
and are more divergent in sequence, perhaps indicative of additional functions (Fujise, 
Zhang et al. 2000). The mechanism of their antiapoptotic activity is not yet absolutely 
clear, but it is  generally acknowledged that they can form hetero-dimers with the 
proapoptotic members of Bcl-2 family and the BH3-only proteins, sequestering those 
and preventing their targeting to the mitochondria [Murphy, 2000 #199; Zha, 1996 
#202; Priault, 1999 #200; Thomenius, 2003 #201].  
Posttranslational modifications of Bcl-2 have also been proposed as regulatory 
mechanism of apoptosis. Phosphorylation of Bcl-2 has been reported, although it is 
still unclear whether phosphorylation is activating or inactivating the inhibitory 
function of this protein (May, Tyler et al. 1994; Haldar, Jena et al. 1995; Ito, Deng et 
al. 1997) and whether this is a general phenomenon since it appears to occur 
prominently in M-phase arrested cells (Ling, Tornos et al. 1998; Scatena, Stewart et 
al. 1998). More recently, Bcl-2 was reported to be a cleavage substrate for activated 
Caspase-3 with the carboxyl-terminal Bcl-2 cleavage product triggering apoptosis 
(Cheng, Kirsch et al. 1997).  
Moreover, Bcl-XL was found to indirectly bind to Apaf-1 through a new 
protein called Aven, and disrupt the apoptosome formation (Chau, Cheng et al. 2000). 
 
 
4.2-The IAPs 
  
Another family of related proteins, the inhibitor of apoptosis proteins (IAPs), 
have been identified and described as caspases inhibitors (e.g. Caspase-9 and ￿3   42
(Deveraux, Takahashi et al. 1997; Roy, Deveraux et al. 1997)). IAPs contain at least 
one, but usually three, BIR (baculovirus IAP repeat) motifs that are capable of 
interacting with caspases and occluding their catalytic pockets (Hozak, Manji et al. 
2000). Certain IAPs also possess C-terminal RING domains (Fig.11). 
 
 
 
Fig.11: Mammalian IAPs/BIRPs.  
Alternative designations are shown in brackets. The X-linked IAP (XIAP) is the best 
characterized member of this family. BIR, baculovirus IAP repeat; CARD, caspase-
recruitment domain; ILP, IAP-like protein; MIHA, mammalian IAP homologue A; 
NAIP, neuronal apoptosis inhibitory protein. 
 
 Many proteins that contain the latter motif act as E3 ubiquitin ligases and can 
participate in reactions that culminate in the transfer of polyubiquitin chains to their 
target proteins (Hozak, Manji et al. 2000). Polyubiquitinated proteins are typically 
rapidly bound and destroyed by the proteasome. IAPs preferentially interact with 
active caspases, although evidence that they can promote polyubiquitination of the 
proteases in vivo has been lacking. However, numerous studies have shown that IAPs 
can impede caspase activity and delay the onset of apoptosis (Tran, Rak et al. 1999). 
Anti-apoptotic activity of IAPs can be releaved by competitive binding of 
Smac/Diablo when released from the mitochondria [Wu, 2000 #213] (see 
Smac/Diablo and Omi/HtrA2) (Fig.7 and 10). 
 
 
4.3-Receptor-mediated  survival pathway 
 
  Apoptosis can also be blocked by activation of survival receptors upon binding 
of the appropriate ligand. The best understood survival pathway is governed by the 
insulin-like growth factor 1 receptor (IGF-1R). Binding of IGF-1 to the receptor 
stimulates its tyrosine kinase activity, resulting in activation of the phosphatidyl   43
inositol 3￿ kinase (PI3 kinase) that in turn phosphorylates and activates protein kinase 
B (Pkb/Akt) (Kandel and Hay 1999). Pkb/Akt can inhibit the apoptotic pathway by its 
ability to phosphorylate the proapoptotic Bcl-2 family member Bad, thereby 
preventing the release of Cytochrome c and the activation of caspases (Lawlor and 
Alessi 2001) (see Phosphorylation of Bad).  
 
 
 
D-Clinical implications of apoptotic pathways disruption 
 
In the past years more and more diseases have be correlated to apoptotic 
dysfunction, like: cancer, AIDS, neurodegenerative disorders, meningitis, diabetes, 
transplant-rejection, etc￿. Some model are developed in the following chapters as 
examples. 
 
1-Cancer 
 
  Cancer is a widespread disease, causing about 20% of death in the developed 
world. Since decades, intense biomedical research has focused on the elucidation of 
the cause and etiology of this disease in pursuit of the development of more effective 
therapies. Due to mutations of certain genes, all cancer cells have escaped normal 
control mechanisms that restrain cell proliferation, and statistical analysis of 
epidemiological surveys suggest the necessity of 3 to 7 independent mutations for the 
formation of a malignant cancer cell (Hanahan and Weinberg 2000).  
Mutations within several hundred of different genes have been linked to 
human cancer, indicating that possibly every cancer might carry its individual set of 
mutated genes. Most often, mutation that result in unrestrained proliferation affect 
either proto-oncogenes or tumour suppressor genes. Proto-oncogenes often act at 
many points along the pathway that stimulate cell proliferation, whereas the task of 
tumour suppressors are mainly confined to negatively regulating cell growth. 
Analyses of human cancer specimens revealed that mutations of tumour suppressors 
genes involved in apoptotic pathways are found in almost any kind of cancer, 
indicating that loss of the apoptotic function is a prerequisite for the development of 
cancer (Fig.12). Hence the therapeutic approaches that aim to re-establish the 
apoptotic pathway in cancer cells have gained immense interest, particularly because 
those therapies might achieve the complete elimination of cancer cells (Ehlert and 
Kubbutat 2001). Moreover, it is important to notice that until now, every cancer 
derived cell line studied is still able to undergo apoptosis by some kind of stimulus, 
even when some apoptotic pathways are blocked. 
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Fig.12: The integrated apoptotic pathways (Cell, 2002 (Johnstone, Ruefli et al. 2002)) 
A schematic diagram showing some of the known components of the intrinsic and 
death receptor apoptotic programs that may modulate tumour development and 
therapy. 
 
The cellular targets for different cytotoxic agents are diverse. Thus, anticancer 
drugs are classified as DNA-damaging agents (cyclophosphamide, cisplatin, 
doxorubicin), antimetabolites (methotrexate, 5-fluorouracil), mitotic inhibitors 
(vincristine), nucleotide analogues (6-mercaptopurine), or inhibitors of topoisomerase 
(etoposide). The common underlying mechanisms for chemotherapy-induced 
apoptosis might be damage to DNA, lipid components of cell membranes, and cellular 
proteins causing an imbalance of the cellular homeostasis commonly designated as 
cellular stress. The type and dose of stress within the cellular context appears to 
dictate the outcome of the cellular response, which is intimately converted to complex 
pathways mediating cell cycle control or cell death. Apoptosis seems to be induced if 
damage exceeds the capacity of repair mechanisms (Herr and Debatin 2001). 
Mutation of many genes involved in the regulation of apoptosis have been identified 
in human cancer, resulting in the development of novel therapeutic approaches such 
as activations of death receptors using recombinant ligand, inhibition of Bcl-2 
expression by antisense reagents (Nicholson 2000) or induction of apoptosis through 
peptides derived from pro-apoptotic proteins like Smac or TRAIL (Yang, Mashima et 
al. 2003), (Fulda, Wick et al. 2002). Although based on different targets and delivery 
methods,  all these approaches have the common goal to eliminate tumour cells by 
restoration of the apoptotic function (Ehlert and Kubbutat 2001). 
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2-AIDS 
 
  In vivo infection of lymphatic tissue with HIV is accompanied by enhanced 
apoptosis, which affects mainly bystander cells. Indeed, apoptosis is suspected (but it 
is not yet clear exactly how) to play an important role in the clinical development of 
the disease. It has been observed that 1/10
5 cells dying by apoptosis are infected by 
HIV. This effect might result, at least in part, from the Nef-induced upregulation of 
expression of Fas-ligand on the surface of the infected cells, a phenomenon for which 
the mechanism remains unclear but seems to involve the T-cell receptor (TCR) 
pathway (Mueller, De Rosa et al. 2001) (Fig.13). FasL on the surface of HIV-infected 
cells could interact with Fas molecules displayed on the neighbouring cells, including 
virus-specific CTLs, thereby triggering their apoptosis. Furthermore, recent analyses 
of HIV-infected patients have shown that HIV-specific CTLs are more prone to Fas-
mediated apoptosis than the HCMV-specific CTLs from the same individuals 
(Peterlin and Trono 2003).  
 
 
 
Fig.13: HIV and Apotosis (Nature Immunology, 2003 (Peterlin and Trono 2003)). 
Nef protein can protect HIV-infected cells against HIV-specific CTLs killing. 
 
  Other Fas-related events contribute to HIV-induced cell death of bystander 
lymphocytes. For example, crosslinking of CD4 by the HIV envelope in the presence 
of the soluble Tat can induce the expression of FasL and the apoptosis of uninfected   46
cells. HIV can also protect its host cell from apoptosis through the Nef protein. Nef 
inactivates the proapoptotic Bad, thereby blocking the mitochondrial-induced 
apoptotic pathway (Wolf, Witte et al. 2001). 
 
 
 
3-Neurodegenerative disorders 
 
  Neuronal cell death underlies the symptoms of many human neurological 
disorders, including Alzheimer￿s, Parkinson￿s and Huntington￿s diseases, stroke and 
amyotrophic lateral sclerosis (Mattson 2000). The identification of specific genetic 
and environmental factors responsible for these diseases has bolstered evidence for a 
shared pathway of neuronal death and neuronal apoptosis involving oxidative stress, 
perturbed calcium homeostasis, mitochondrial dysfunction and activation of caspases 
(Tab.1). For each of the disorders described below, analysis of post-mortem tissue 
from patients and studies of experimental animal and cell-culture models have 
implicated neuronal apoptosis. Studies of the pathogenic mechanisms of genetic 
mutations that cause early-onset autosomal dominant forms of Alzheimer￿s (Guenette 
and Tanzi 1999) and Huntington￿s (Sathasivam, Hobbs et al. 1999) diseases and 
amyotrophic lateral sclerosis (Borchelt, Wong et al. 1998) have been particularly 
valuable in implicating apoptosis in age-related neurological disorders. 
 
Table 1: Proteins implicated in neurodegenerative disorders. 
 
 
In most of the neurodegenerative disorders considered here, the disease 
process lasts for years or even decades. It is therefore likely that, although individual 
neurons may be dysfunctional for extended periods in these disorders, they may die   47
rapidly once the apoptotic cascade is fully activated. In this view, the progressive 
deficits that occur in chronic neurodegenerative disorders are the result of progressive 
attrition of the individual neurons (Mattson 2000).  
 
 
4-Autoimmune disease 
 
 The  in vivo function of CD95/Fas was originally defined by the observation 
that the recessive mouse lpr mutation associated with systemic autoimmunity and 
lymphoproliferation is due to a transposable element insertion that inactivates Fas 
transcription. A similar mouse syndrome is caused by the recessive gld allele of the 
FasL gene (Watanabe-Fukunaga, Brannan et al. 1992). In humans, the autoimmune 
lymphofroliferative syndrome (ALPS), which has many similarities to lpr-associated 
disease in mice, is associated with dominant mutations in Fas, FasL or other genes in 
the Fas pathway (Siegel, Chan et al. 2000) (Fig.14).  
 
 
  
Fig. 14: Fas-FasL control of immune cell homeostasis (Nature Immunology, 2000 
(Siegel, Chan et al. 2000)) 
 
Analysis of mutations from a large number of ALPS patients show that all 
dominantly interfering Fas mutants harbor mutations within the PLAD domain 
(preligand assembly domain), whereas not all encode the ligand-binding CRD2 
region. Thus, preassociation is critical for the dominant-interfering effect of these 
mutations (Fisher, Rosenberg et al. 1995). Moreover, this paper suggests that CD95 
might be ￿preassembled￿ in trimers and that the CD95L induces a conformational 
change rather than oligomerization.   48
 
  
 
E-The goal of the project 
 
  The previous chapter has made it clear that most of human diseases and 
disorders are related to the apoptotic pathway dysfunction. Unrevealing and 
understanding the complex crosstalks that take place during this process, as well as 
determining all the players involved in these multiple pathways leading to program 
cell death, has become an urgency, since it was clear that this could lead to more 
specific, more potent and less toxic clinical applications. The aim of this work was to 
identify new anti-apoptotic proteins and to understand their mechanistic function. 
Moreover, it is clear that the mitochondria play a central role in initiating, activating 
and amplifying nearly all apoptotic pathways. It therefore seems relevant to 
investigate all the blocking check-points of apoptosis downstream of mitochondria 
induction.  
Because yeast systems are generally used and intensively optimised 
(Jurgensmeier, Krajewski et al. 1997; Xu and Reed 1998), I decided to perform a 
yeast survival screen to look for ￿anti-apoptotic proteins inhibiting downstream of 
Cytochrome c release￿. Therefore, I used a cDNA library constructed from a pool of 
breast tumours (in order to increase the possible expression of anti-apoptotic 
proteins), to transforme an HC4 S. pombe strain constructed by myself. This HC4 
strain expresses the CED4 (C. elegans homologue of Apaf-1) under the control of the 
inducible promoter nmt-1. As CED4 (but not Apaf-1) can efficiently kill yeast S. 
pombe cells (James, Gschmeissner et al. 1997), I reasoned that this HC4 strain would 
be a good model to find new anti-apoptotic proteins capable of inhibiting CED4 and 
subsequently Apaf-1 induced apoptosis in yeast cells as well as in mammalian cells. 
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II-Material and methods 
A-The yeast survival screen 
1-cDNA libraries used for the yeast survival screen 
1.1- 1 Human mammary carcinoma cDNA-library cloned into the yeast 
expression vector pART1b, without start codon provided by a linker. 
 
The library was repared in collaboration with PROMEGA and cloned into the pART 
1b vector (pART 1 with an additional XhoI-site in the SmaI-site) 
 
 
                                                 Pst I        Sal I           Bam HI        Xho I              
Multiple cloning site: gaa ttg ctg cag gtc gac tct aga gga tcc ccc ctc gag gcc tcg  
 
The pART1 vector was kindly provided by Dr. Paul Nurse (ICRF, London) and 
modified further by PROMEGA. 
 
 
5￿ : PstI-Adapter:  
5￿-         g ggg cac gag-3￿ 
3￿-  ac gtc ccc  gtg ctc-5￿ 
 
3￿ : poly(dT)-XhoI-linker: 
 5￿-gag aga gag aga gag aga gaa cta gtc tcg agt ttt ttt ttt ttt ttt tt-3￿ 
 
cDNA Size Fractionation: >0.5 kB   50
Recombination frequency (representing the percentage of plamids containing a cDNA 
insert) : >50%. 
Average Insert Size : 0.8 kB  
Purified plasmid DNA containing the cDNA cloned into pART1b: 85µ g/ml . 
 
 
 
1.2- Human mammary carcinoma cDNA-library 2 cloned into the yeast 
expression vector pART1b, with a start codon provided by a linker. 
 
The library was repared in collaboration with PROMEGA and cloned into the pART 
1b vector (pART 1 with an additional XhoI-site in the SmaI-site) 
 
5￿ : PstI-ATG-HA-Adapter:  
5￿-          g aaa atg gcc tac ccc tac gac gtg ccc gac tac gcc  tcc  ctc gga tcc-3￿ 
3￿-   ac gtc ttt tac cgg atg ggg atg ctg cac ggg ctg atg cgg agg gag cct agg-5￿ 
 
3￿ : poly(dT)-XhoI-linker: 
5￿-gag aga gag aga gag aga gaa cta gtc tcg agt ttt ttt ttt ttt ttt tt-3￿ 
 
cDNA Size Fractionation: >0.5 kB 
Recombination frequency (representing the percentage of plamids containing a cDNA 
insert) : >40%. 
Average Insert Size : 0.75 kB 
Purified plasmid DNA containing the cDNA cloned into pART1b: 400µ g/ml . 
 
 
2-Yeast transformation  
 
150 ml of yeast culture in EMM medium (Bio 101) plus appropriate 
supplements (leucine, uracil, adenine (all Bio 101), thiamine (Sigma)) were grown to 
a density of 1x10
7 cells/ml (O.D.600 = 0.5). Yeast cells were washed twice with water 
(centrifugation at 1,000 g for 5 min) and resuspended in 1.5 ml fresh 1xTE/1xLiAc 
(0.1 M) yielding competent cells. 100 ng plasmid DNA (yeast expression construct 
with appropriate selection marker) were mixed with 0.1 mg denaturated herring sperm 
DNA (Bio 101) and 100 ￿l competent yeast cell suspension. 600 ￿l 40% PEG 8000 
(Sigma)/LiAc (0.1 M) were added and the mixture was vortexed for 10 seconds. The 
cells were incubated at 30
0C for 30 minutes with mild shaking, then after adding 70 ￿l 
DMSO the suspension was heat shocked for 15 minutes at 42
0C. Afterwards, yeast 
cells were chilled for 2 minutes on ice, washed, resuspended in 100 ￿l TE and plated 
on EMMA agar plates (Bio 101) containing appropriate supplements. 
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3-Buffers and solutions 
 
0.1M Lithium acetate: 10.2 g in 1 L, pH 4.9 
 
Tris/EDTA (TE): 200 mM Tris-base, 20 mM EDTA, ddH2O. 
 
 
B-Basic molecular biology 
1-Mini-Prep. 
1.1-QIAGEN column  (according to manufacturer’s protocol) 
 
1.2-Alkaline Lysis Method. 
 
1.5 ml of saturated overnight bacteria culture in a 1.5 ml Eppendorf reaction 
tube (￿Eppi￿) was centrifuged 20sec at maximal speed in bevel centrifuge at 13,000 
rpm. The supernatant was removed, and the pellet was resuspended in 100 µ l GTE 
and incubated at room temperature for 5min. Then 200 µ l of freshly prepared 0.2M 
NaOH/1% SDS were added and the mixture was shaked by inverting the tube. Then  
the mixture was incubate on ice for 5min. Add 150 µ l of Potassium Acetate, vortex 
and incubated on ice 5min, spin 3min at maximal speed and the supernatant transfered 
to a fresh tube. 800 µ l of 95% Ethanol were added and the mixture was incubated 2 
min at room temperature. Then the mixture was spin 1min to pellet the plasmids and 
RNA, the supernatant was remove and the pellet washed with 600 µ l of 70% Ethanol. 
Then the pellet was air-dried and resuspended it in 30-50 µ l of water (or TE buffer) 
with 3 µ l RNAse (10 mg/ml). 
 
 
1.3-Buffers and solutions 
Glucose/Tris/EDTA pH 8.0 (GTE): 50 mM glucose, 25 mM Tris-Cl pH 8.0, 10 mM 
EDTA pH 8.0. Autoclave and store at 4￿C. 
Potassium acetate, 5 M, pH 4.8: 29.5 ml glacial acetic acid, KOH pellets to pH 4.8, 
H20 to 100 ml. 
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2-Maxi-Prep. 
2.1-QIAGEN column (according to manufacturer’s protocol). 
 
2.2-Lithium Chloride Method. 
 
250 ml of saturated overnight bacteria culture were centrifuged at 5,000 rpm 
and 4￿C for 20 min in sterile polypropylene 500 ml Beckman bottle in a J2-21 
centrifuge (Beckman) equipped with an JA-10 rotor (Beckman) . The pellet was 
resuspended in 10 ml GTE (0￿C), add Lysosyme (Roth) and left 10 min on ice. 20 ml 
of freshly prepared 0.2 N NaOH/1%SDS were added, the tubes were gently inverted 
3-6 times and left 10 min on ice. Then 15 ml of 5 M KO Ac, pH 4.8 was added, and 
the mixture was shaked gently and left 10 min on ice. It was then centrifuged 15 min 
at 5,000 rpm, 4￿C and the supernatant was filtered through a tissue (or ￿Falten filter￿) 
in a 50 ml Falcon. 20 ml Isopropanol were added and the mixture was left 15 min at 
room temperature. It was then spin 10 min at 5,000 rpm. The pellet was resuspended 
in 4-ml water and 4 ml of 5 M LiCl were added to the mixture that was then left on 
ice 30 min at least. Then the mixture was spin 5 min at 5,000 rpm, at 4￿C and the 
supernatant was transfered into a fresh 50 ml falcon. 18 ml 95% ethanol were added 
and the mixture was left 1 hour at ￿20￿C. Then it was spin 15 min at 5,000 rpm, at 
4￿C, the pellet was resuspend in 0.5 ml TE pH 8.0 and transfered to a 1.5 ml   
Eppendorf reaction tube. 10 µ l (10 mg/ml) RNAse were added and the mixture was 
incubated at 56￿C for 30 min, then 10 µ l (10 mg/ml) proteinase K were added and the 
mixture was incubate at 37￿C for 30 min. The DNA was extracted with an equal 
volume of 1: 1 Phenol-Chloroform and a centrifugation step of 2 min at 13,000g. The 
supernatant was transferred to a fresh tube and the procedure was repeated  2 times 
(until the protein interface has disappeared). 1.0 ml 95% Ethanol was added, the 
mixture was shaked and spin 10 min at maximal speed. Finally, the pellet was washed 
with 70% ethanol and resuspended in 200 µ l TE pH8.0. 
 
 
3-Mega-Prep for cDNA Library amplification (QIAGEN column). 
 
4-DNA digestions, and DNA ligations 
4.1- DNA digestion 
 
In 20 µ l total volume 1 µ g DNA,  2 µ l restriction enzyme (40 units), 2 µ l  
reaction buffer 10x and if necessary 2 µ l  BSA  10x (New England BioLabs) were 
added. The mixture was incubated 1-2 hours at 37￿C (overnight when a PCR insert 
was prepared for ligation). 
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4.2- DNA Phenol-extraction and DNA precipitation 
 
To the DNA sample the same volume phenol/chlorophorm (1:1) was added. It 
was then vortexed and spin down 2 minutes at 13,000 rpm in microfuge. The water 
upper phase was transfered into a fresh 1.5 ml Eppendorf tube and 2x volume of 
100% ethanol and 2 µ l 5M NaCl (end concentration is about 30 µ M) was added. The 
mixture was vortexed and keeped 30 minutes at ￿20￿C before spinning 20 minutes at 
13,000 rpm in microfuge. The pellet was washed with 70% ethanol and air-dried. 
Then it was resuspended in an appropriate volume of H2O. If the DNA sample was a 
cloning vector that needed dephosphorylation, it was resuspended in 88 µ l H2O. 
 
 
4.3- 3’-OH DNA dephosphorylation 
 
To the 88 µ l DNA sample, 10 µ l 10x phosphatase buffer and 2 µ l Phosphatase 
Alkalin (CIP) were added. It was then incubated 1h at 37￿C. 
 
 
4.4- Gel extraction 
 
DNA samples were loaded  on 1% agarose gel and after migration, DNA 
samples were  cut out of the gel with a scalpel (minimal amount of agarose) and the 
extraction was performed conforming to QIAGEN-gel extraction kit (QIAGEN), 
according to the manufacturer￿s protocol. 
 
 
4.5- DNA ligation 
 
In 10 µ l of total volume the cloning vector with digested DNA insert (ratio 
1:3), 1 µ l 10x ligation buffer and 1 µ l ligase (400 unit) (New England BioLabs) were 
mixed, digested and dephosphorylated. The mixture was incubated overnight at 16￿C 
and 2-4 µ l of the ligation mix were used for transformation of competent bacteria. 
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5-Bacterial transformation 
5.1-Calcium chloride transformation 
 
5.1.1-Preparation of calcium chloride competent cells. 
One vial of frozen glycerol stock of the appropriate strain of E. coli (e.g 
DH5α  *) was thawn and added to an Erlenmeyer flask containing 50 ml of pre-
warmed LB medium, and incubated at 37￿C with shaking at 250 rpm overnight. Then 
bacterial cells were diluted in LB medium to O.D600 0.2 and grown to O.D600 0.5-0.6 
(about 1/2 hour). Then cells were transferred to a sterile polypropylene 500 ml 
Beckman bottle in a J2-21 centrifuge (Beckman) equipped with an JA-10 rotor 
(Beckman), and collected  the cells by centrifugation at 3,000 rpm (1,600 g) for 8 
minutes at 4￿ C in a J2-21 centrifuge (Beckman) equipped with an JA-10 rotor. After 
centrifugation,  the supernatant was decanted and resuspended the cell pellet in one-
half volume (250 ml) of cold, sterile 50 mM calcium chloride, incubated in an ice-
water bath for 20 minutes, and centrifuged as before. The supernatant was decanted 
and the cell pellet was gently resuspended in one-tenth volume (25 ml) of cold, sterile 
50 mM calcium chloride to yield the final competent cell suspension.  
For stocks, 1 ml of the competent cell suspension was transfered  to sterile 
Eppendorf 1.5 ml tubes. 300 µ l of sterile glycerol were added to the 1 ml aliquots of 
the final competent cell suspension prepared above, giving a final concentration of 
23% glycerol. The competent cells were stored at ￿80￿C indefinitely.  
*DH5a: F· 80dlacZ(lacZYA-argF)U169 deoR recA1 endA1 hsdR17(rK-, mK+) phoA 
supE44 - thi-1 gyrA96 r (Biocompar). 
 
5.1.3-Transformation of competent bacteria with plasmid DNA. 
To use competent cells for transformation, one stock vial was thawn on ice. 
Plasmid DNA was added and the mixture was incubated for 1/2 hour. Then it was 
heat shocked at 42￿C for 90 seconds, 500 µ l of LB were added and the mix was 
incubated for 1 hour at 37￿C  with gentle shaking before spreading on plates with 
adequate selective LB-agarose medium.  
 
5.2-Bacteria transformation by electroporation. 
 
5.2.1- Preparation of electrocompetent Cells. 
KC8* or BL21** cells were grown overnight at 37 ￿C while shaking with 250 
rpm in LB-medium. Bacteria were diluted to O.D600 0.2 and grown to an O.D600 of 0.5   55
(which typically required 1 hour of shaking at 250 rpm at 37 ￿C). The 1 litre of cells 
was distributed into four sterile polypropylene 500 ml Beckman bottle in a J2-21 
centrifuge (Beckman) equipped with an JA-10 rotor (Beckman) and centrifuged at 
5,000 rpm (4,500 g) at 4 ￿C for 10 minutes. Each pellet was resuspended in 100 ml of 
ice cold sterile double distilled water and combined into two Sorval centrifuge bottles 
(i.e each bottle then will contain 200 ml of resuspended pellet). The mixture was 
centrifuged at 5,000 rpm at 4 ￿C for 10 minutes in the JA-10 (Beckman) rotor and the 
pellets resuspended each in 100 ml of ice cold sterile double distilled water and then 
combined pellets into one Beckman centrifuge bottle and centrifuged at 5,000 rpm at 
4 ￿C for 10 minutes in the JA-10 (Beckman) rotor once more. (Note: The purpose of 
all these centrifugation/resuspension/centrifugation steps is to insure that the cells are 
essentially "salt-free" as salt causes arching during the electroporation step). The 
pellet was resuspended in 100 ml of 10% ice cold sterile glycerol, centrifuged as 
above, and finally the pellet was resuspended in about the same volume of 10% ice 
cold sterile glycerol to give salt-free, concentrated electrocompetent cells. 40 µ l of 
these electrocompetent cells were aliquoted into small snap cap tubes and 
immediately frozen by placing in crushed dry ice and then store at -80￿C until needed.  
* KC8 genotype: hsdR, leuB600, trpC9830, pyrF::Tn5, hisB463, lacDX74, strA, 
galU,K . Due to the Tn5 transposon, KC8 is kanamycin resistant; in addition, it does 
not provide alpha-complementation of the beta-galactosidase gene (Clontech).  
** BL21 : hsdR, leuB600, trpC9830, pyr::Tn5, hisB463, lacDeltaX74, strA, galU, 
galK Note: Tn5 confers kanr Carries the trpC, leuB, and hisB mutations for 
complementation to yeast TRP1, LEU2, and HIS3 wild-type genes, respectively. For 
selectively rescuing either the AD or DNA-BD vector from yeast after a GAL4 or 
LexA two-hybrid library screening.  (Amersham). 
 
5.2.2-Electroporation Protocol  
The electrocompetent bacteria were thawn on ice for about one minute. 50-100 
ng of the plasmid or 1-2  µ l of the DNA ligation mix was added to the bacterial cells. 
40 µ l of the mix was transfered into Bio-Rad electroporation cuvettes (0.2 cm wide). 
The Bio-Rad  Gene Pulser
TM was turned on and the voltage set on 1.5 kV and 
capacity on 25 µ F. After electroporation, the cells were immediately resuspended in 1 
ml of SOC and transfered into an Eppendorf 1.5 ml tube. The cells were then 
incubated at 37 ￿C for 30 minutes with 250 rpm in a Thermomixer compact 
(Eppendorf). Finally cells were spin in a microfuge at 13,000 rpm for 20 seconds, 
resuspended in 200 µ l fresh LB and plated on appropriate LB-agarose selective 
medium. 
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5.2.3-Buffers and solutions 
SOC medium: 0.5% yeast extract, 2% tryptone (Roth), 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2, 10 mM MgSO4, 20 mM glucose. 
 
6-Southern Blot analysis. 
6.1- Yeast genomic DNA extraction 
 
Yeast genomic DNA was obtained by vortexing yeast cells in 
Phenol:Chlorophorm (volume 1:1) with glass beads (425-600 µ m) from Sigma (1 
volume beads per 1 volume yeast cell suspension). The mixture was centrifuged at 
13,000 g and 4
0C for 5 min. The supernatant was transferred into a fresh tube. DNA 
was precipitated by adding 2x the volume of 100% ethanol and spinning the mixed 
solution at 13,000 g for 20 min. The pellet was washed with 70% ethanol and 
resuspended in ddH2O. 
 
 
6.2- Protocol for the DNA transfer on the membrane, the insert radioactive 
labelling and the insert hybridization.  
 
Genomic DNA samples were digested overnight with appropriate restriction 
enzymes and loaded on a 1% agarose  gel. After electrophoresis (160 V), the gel was 
soaked in 0.2 M HCl solution and shacked gently for about 15 minutes until the 
marker colours change. The gel was then transferred to a 0.4 M NaOH solution and 
shacked gently until the colours return to their original shade. Hybond-N+   
(Amersham) membrane is soaked in a 0.4 M NaOH solution and transfer  was 
prepared as follows: 
 
 
 
Weight 
Glass 
Tissue paper 
3x whatman 3mm 
Hybond-N+ membrane 
Gel (smooth side on top) 
whatman 3mm                                                                                      
Glass                           
0.4 M NaOH solution   57
The DNA transfered overnight. 
 
The DNA was then UV cross-linked on the membrane in a Stratalinker
R UV 
Crosslinker (Stratagene) with the ￿crosslink￿ mode. The membrane was rolled in a 
glass tube of appropriate size and incubated 1 hour in Church buffer at 65￿C. 
 
Radioactive labelling of DNA probes: 
50 ng DNA in 21 µ l H2O was denaturated at 100￿C for 5 minutes and then put 
on ice.  From a DNA labelling kit (Amersham), 4 µ l dATP, 4 µ l dTTP, 4 µ l dGTP, 5 
µ l primer solution, 5 µ l reaction buffer, 2 µ l polymerase (klenow) and in the 
radioactive laboratory 5 µ l [
32P]dCTP (Amersham) with 10 mCi/ml were added to 
the mixture. The mixture was incubate 1h at 37￿C. A Nick column (Sephadex
TM G-
50, Amersham)  was equilibrated with TE buffer, and the radioactive sample was 
dropped on the filter of the Nick column. Then 400 µ l TE were added, and the 
eliminated liquid was collected in an Eppendorf tube and discarded in appropriate 
trash. 400 µ l TE were added and the radioactive sample was collected in a fresh 
Eppendorf tube. 1µ l was kept to quantify radioactivity in the sample by scintilisation 
counter. The sample was denaturated at 100￿C before being carefully pipetted it in the 
glass tube with the membrane. The membrane was then incubated with the 
radioactively labelled DNA probe on roller overnight at appropriate temperature (e.g 
65￿C). The membrane was washed with the high stringency 2x SSC/1% SDS buffer 
and the low stringency 20x SSC/1% SDS buffer, 20 minutes each at 65￿C, check 
radioactivity levels and then washed last time with 0.2x SSC/1% SDS at room 
temperature. The membrane was exposed to a Hyperfilm MP (Amersham)  overnight 
at ￿80￿C. 
 
 
6.3- Buffers and solutions 
 
SSC 20x 3M NaCl, 0.3 M Na3citrate•2H2O adjust to pH 7.0 with 1 M HCl 
CHURCH buffer: 1% BSA, 1mM EDTA, 0.5M Na2HPO4 pH 7.2, 7% SDS 
1M Na2HPO4 pH 7.2 (500 ml): 134 g Na2HPO4•7H2O or 71g anhydrous Na2HPO4, 4 
mL 85% H3PO4 
 
 
7-Northern Blot analysis 
7.1- RNA extraction 
 
Yeast RNA was obtained by vortexing yeast cells in Trizol reagent (Life 
Technologies) with glass beads (1 volume beads per 1 volume yeast cell suspension)   58
according to the Trizol reagent manufacturer·s protocol (Life Technologies). The 
mixture was centrifuged at 13,000 g and 4
0C. The supernatant (clear phase) was 
transferred into a fresh tube. RNA was precipitated by adding 2x the volume of 100% 
ethanol and spinning the mixed solution at 13,000 g. The pellet was washed with 70% 
ethanol and resuspended in ddH2O. 
 
 
7.2-Protocol for the RNA transfer on the membrane, the insert radioactive 
labelling and the insert hybridization. 
 
RNA samples were loaded on a formaldehyde-containing agarose gel. After 
electrophoresis, RNA was transfered onto a Hybond N
+ membrane (Amersham) and 
hybridized with 100 ng of a 
32[P]-labelled full length cDNA probe/250 µ l Herring 
DNA* according to standard protocols (see: southern-blot). The membrane 
hybridization is done in STARK buffer or in Hybridization solution (Clontech) 
between 42￿C and room temperature due to the weaker affinity of DNA/RNA.  
 
 
7.3- Buffers and solutions 
 
STARK solution: 5xSSC, 25 mM Sodium phosphate buffer, 1x Denhardts solution, 
50% v/v formamid, 0.5% w/v non fat dried milk, 4% w/v SDS 
 
Sodium Phosphate buffer 25 mM in 100ml: 14.2 g Na2HPO4, 15.6 g NaH2PO4•2H2O 
 
*250 µ g/ml Herring sperm DNA (250 µ l/10ml STARK) 
 
Denhardt 100x: 500ml, 10 g Ficoll 400, 10 g polyvinylpyrrolidone, 10 g bovine serum 
albumin, H2O to 500 ml  
 
Gel 1% :150 ml, 126 ml H2O, 1.5 g agarose (boil), 9 ml formaldehyde, 15 ml 10x 
MOPS (dry under a hoot)  
 
10x MOPS: 2 M MOPS pH 7.0, 5 M NaOH, 1 M EDTA pH 8.0 (Store in the dark). 
 
 
8-Western Blot analysis 
8-1-Protein extract 
 
Yeast cell lysates were prepared by vortexing yeast cells for 5 min. in lysis 
buffer (TE buffer/1 mM PMSF, 1 tablet Complete-Mini protease inhibitor cocktail 
(Roche) per 10 ml buffer) and glass beads (425-600 µ m) from Sigma (1 volume beads   59
per 1 volume yeast suspension). The mixture was centrifuged at 13,000 g, 4
￿C for 5 
min. The supernatant was used for quantification of protein concentration and 
Western blot analysis. 
 
 
8.2-Protocol 
 
5-10 µ g protein samples are loaded on 12% PAGE gel. Proteins are submitted 
to vertical electrophoresis for about 2 h in PAGE buffer, with 120 V. 
 
                                         4x Whatman 3mm 
                                         gel  
            membrane 
                                         4x Whatman 3mm 
 
Semidry transfer is set for 2 hours, with appriate milli-Ampers (e.g. 40 cm
2 
membrane with 40 mA). 
Protein transfer was checked by incubating the membrane 2 minutes in Ponceau and 
washing the membrane with PBS/0.05% Tween. All subsequent steps were   
performed with constant shaking. The membrane was blocked in 5% low fat 
milk/PBS/0.05% Tween for minimum 1 hour. The primary antibody was incubated 
with the membrane in 5% low fat milk/PBS/0.05% Tween diluted in a suitable 
manner (usually 1/500 to 1/3,000) overnight at 4￿C or 1-2 hours at room temperature. 
The membrane was then washed in PBS/0.05% Tween for 30 minutes with buffer 
changes every 10 minutes. The secondary antibody coupled to the HRP enzyme was 
incubated with the membrane 1-2 hours at room temperature diluted in 5% low fat 
milk/PBS/0.05% Tween (usually 1/2000 to 1/10 000 following instructions). Then the 
membrane was washed again for 30 minutes with buffer changes. ECL solution 
(Amersham) substrate to HRP was used to reveal the experiment result. 
 
 
8.4-Stripping membrane for subsequent hybridizations. 
 
1 µ l β -mercapto-ethanol per 1ml stripping buffer was added to the stripping 
buffer, and the membrane was incubated in 10 ml stripping buffer at 56￿C for 30 
minutes. The membrane was washed with H2O until the smell was not detectable any 
longer, then washed for 15 minutes in PBS/0.05% Tween. 
 
8.4-Buffers and solutions 
 
10 ml  Migration gel (12%): 4.2 ml 30% Acrylamide, 2.5 ml Tris-HCl pH 8.8 (1.5 M), 
3.2 ml H2O, 100 µ l 10% SDS, 7 µ l TEMED, 70 µ l 10% APS 
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5 ml Stacking gel (2,4%): 830 µ l 30% Acrylamide, 1.2 ml Tris-HCl pH 6.8 (0,5 M), 
2.8 ml H2O, 50 µ l 10% SDS, 3.3 µ l TEMED, 70 µ l 10% APS. 
 
SDS-PAGE 10x, 5 l : 1% SDS (375 ml  20% stock solution), 300 g Tris, 750 g 
Glycin, H2O to  5 l. 
 
Stripping buffer 500 ml : 2% SDS (5 ml 20% stock solution), 62.5 mM Tris-HCl pH 
6.0 (62.5 ml 0.5 M Tris), H2O to 500 ml. 
 
PBS 10x  137mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4•7H2O, 1.4 mM KH2PO4, pH 
7.4 
 
SDS/glycerol stock solution: 7.3% w/v SDS, 29.1% v/v glycerol, 83.3 mM Tris-base, 
tip of a small spatula of Bromophenol blue, dd H2O. 
 
9-GST-pulldowns 
 
BL21* bacteria were were grown as an overnight culture in 3ml selective LB 
medium. The next day, 2ml of the saturated culture were transferred  in a 10ml 
selective (usually ampicilin) LB-culture and grown up to O.D600. 0.5 at 37￿C (1 or 2 
h). The bacteria were induced with 1mM IPTG for 3h (30 or 37￿C) and  centrifuged at 
4,500 g, 4￿C for 10 min then resupended in 1ml Lys-S buffer (with PMSF and anti-
proteinase cocktail tablets) into an Eppendorf 1.5 ml tube. Bacteria were sonicated 3x 
30 sec with a Branson SONIFIER 250 from G.HEINEMANN (90% duty cycle, output 
control 4) and left on ice for 30 min, they were inverted every 5 min. Centrifuge 30 
min at 4￿C with 13,000 rpm and supernatant was transfered into a fresh Eppendorf 
1.5ml tube. 50µ l Gluthation-agarose were added to the lysate and the mixture was put 
on a spinning wheel for 30 min at 4￿C. Mixture was centrifuged 2 min at 5,000 rpm at 
4￿C, then washed 3 times with 1ml 0.5xLys-S and beads were resuspended in 50 µ l 
0.5xLys-S. The yield of GST fusion protein was estimated by running an aliquot on 
SDS PAGE gel. 
 
* E. coli BL21: E. coli B F
-, ompT, hsdS (rB
-, mB
-), gal, dcm. (Amersham) 
 
Lys-S buffer 1x: 50 mM Tris pH 7.8, 0.4 M NaCl, 0.5 M EDTA, 10% Glycerol, 
0.1NP40. 
 
 
10-Immunoprecipitation 
10.1-Protocol 
 
Cells were lysed in 500 µ l 1% Triton-buffer with 1 M PMSF and cocktail 
inhibitor (1 tablet/10 ml lysis buffer, Roche), then incubated on ice 10 minutes and   61
sonicated 3x 10 seconds with a Branson SONIFIER 250 from G.HEINEMANN (90% 
duty cycle, output control 4). The lysate was centrifuged at 13,000 rpm, 4￿C for 30 
minutes and the supernatant was transfered into a fresh eppendorf tube (50 µ l were 
kept in a separate tube for the 10% input). All subsequent steps were performed at 
4￿C. 500 µ l HNTG, 30 µ l protein A/G coupled to agarose beads (Santa Cruz 
Biotechnology) and 5-10 µ l antibody suitable for immunoprecipitation were added to 
the lysate. The mixture was shaken on a spinning wheel in eppendorf tubes at 4￿C, 4 
hours (or overnight)  and then spin 2 minutes at 5,000 rpm, 4￿C. Supernatant was 
discarded and beads washed by resuspending them in 1 ml HNTG. Washing steps 
were repeated twice and finally the mixture was centrifuged 2 minutes at 13,000 rpm, 
4￿C. 20 µ l protein loading buffer were added and the mixture was boiled at 95￿C for 5 
minutes. After centrifuging 1 minute in a microfuge at 13,000 rpm, the supernatant 
was loaded on polyacrylamid/SDS gel. 
 
 
10.2-Buffers and solutions 
 
1% Triton: 1% triton-100, 0.1% SDS, 150 mM NaCl, 5 mM EDTA and 50 mM Tris-
HCl pH 7.5 (keep at 4￿C). 
 
HNTG: 20 mM HEPES pH 7.5, 150 mM NaCl, 0.1% triton-100 and 10% glycerin 
(keep at 4￿C). 
 
11-PCR and RT-PCR 
11.1- PCR 
 
In a 1.5 ml eppendorf tube to 25 µ l of total volume were added: 100 ng 
template DNA, 2.5 µ l of 10x reaction buffer, 1 µ l of MnSO4 (50 nM stock solution), 3 
µ l of dNTP mix (2.5 mM stock solution), 2.5 µ l of primer 1 (3 µ M stock solution), 
2.5 µ l of primer 2 (3  µ M stock solution), 0.5 µ l (10 units) platinum polymerase 
(Invitrogen) and H20 to total reaction volume. Then one drop of mineral oil was added 
on top to avoid evaporation. Samples were set in a PCR machine programmed as 
follow: 
 
 1x     94￿C     5 minutes,  
 35x   -    94￿C    30 seconds  
 -    X￿C    1min 30 sec 
 -   68￿C    1 min/kbp of insert to be amplified,  
1x      68￿C    10 min.  
X￿C = appropriate annealing temperature for the primers   62
11.2- RT-PCR 
 
0.5 to 5 µ g of total RNA and the RT-PCR kit from Amersham were used. 
In a PCR tube, 2 µ g RNA in 11 µ l H2O were mixed with 0.2 µ g hexanucleotides (1 
µ l). The mixture was incubated 5 min at 70￿C, then laid on ice. 4 µ l 5x RT-buffer, 2 
µ l 10 mM dNTPmix (dATP, dCTP, dTTP and dGTP), 0.5 µ l RNAsin (20u) and 1.5 µ l 
H2O were added. Mixture was incubated 5 min at 25￿C, then 1 µ l RTCMulv Reverst 
Aid MBI/Zugatase (the reverse transcriptase) was added and the mixture was 
incubated 10 min at 25￿C, 60 min at 42￿C and 5 min at 70￿C. 2-10 µ l of the final 
mixture were used as a PCR template. 
 
 
 
13-Plasmids maps and cloning strategies 
13.1- pcDNA3.1+/-  (Invitrogen) 
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The following genes were cloned into pcDNA3.1+ 
 
∆ aven-pcDNA3.1+ (BamHI/XhoI) 
Primer 1: Habam  
5’-aca gga tcc aaa atg gcc tac ccc tac gac gtg ccc gac tac gcc-3￿ 
Primer 2: pArt1 3￿, 5￿-ttg gaa ttc gag ctc ggt ac-3￿ 
A PCR reaction was set up with the above primers and clone B2 or ∆ aven (in part-1 S. 
pombe expression vector) as the template. 
 
∆ roret-pcDNA3.1+ (PstI/XhoI) 
Primer 1: part 1 5￿-ata gtg ggt ggt gga cag gt-3￿ 
Primer 2: pArt1 3￿, 5￿-ttg gaa ttc gag ctc ggt ac-3￿ 
A PCR reaction was set up with the above primers and clone B1 or ∆ roret (in part-1 
S. pombe expression vector) as the template. 
 
13.2- In pEGFP-N1 (Clontech) 
 
 
 
The following genes were cloned into pEGFP-N1: 
 
∆ aven-pEGFP-N1(XhoI/XhoI) 
Primer 1: ∆ Aven 5￿-aca ctc gag atg agt gag tta ttg gtt cga gcc ctt caa gag-3￿ 
Primer 2: AvenX 3￿-Stop, 5￿-aca ctc gag gga aat cat gct gtc caa cca gtc ttc-3￿ 
A PCR reaction was set up with the above primers and Aven-pSG5 as the template. 
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∆ roret- pEGFP-N1(XhoI/XhoI) 
Primer 1: ∆ RoretX 5￿-aca ctc gag atg tcc aag ctt tac ttc gat gtg aag aaa atg-3￿ 
Primer 2: RoRetX 3￿-Stop,  
5￿-aca ctc gag gtc acc tgg ggg agg cag aaa caa agg-3￿ 
A PCR reaction was set up with the above primers and ∆ roret-pcDNA3.1+ as the 
template. 
 
roret(celera cDNA collection) (XhoI/XhoI) 
Primer 1 : RoRetX 5￿-aca ctc gag atg gcc tca acc acc agc acc aag aag atg-3￿ 
Primer 2 : RoRetX 3￿-Stop,  
5￿-aca ctc gag gtc acc tgg ggg agg cag aaa caa agg-3￿ 
A PCR reaction was set up with the above primers and RoRet-pCMV.SPORT6 as the 
template. 
 
roret(genestorm cDNA collection) (XhoI/XhoI) 
Primer 1: RoRetX 5￿-aca ctc gag atg gcc tca acc acc agc acc aag aag atg-3￿ 
Primer 2: RoRetX 3￿-Stop,  
5￿-aca ctc gag gtc acc tgg ggg agg cag aaa caa agg-3￿ 
A PCR reaction was set up with the above primers and RoRet-pcDNA3.1/GS as the 
template. 
 
fte-1- pEGFP-N1(XhoI/XhoI) 
Primer 1: Fte-1X 5￿-aca ctc gag atg gcg gtt ggc aag aac aag cgc ctt acg-3￿ 
Primer 2: Fte-1X 3￿-Stop, 5￿-aca ctc gag aac aga ttc ttg gac tgg tgg ttc ata-3￿ 
A PCR reaction was set up with the above primers and fte-1-pMEXneo as the 
template. 
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13.3- In pCR3.3-Gaytway-compatible modified. (parental vector is pCR3.1 from 
Invitrogen) 
 
The pCR3.3 vector was modified in a Gateway (Invitrogen) compatible system by Dr. 
Vladimir Kirchin (Georg-Speyer-Haus, Frankfurt). 
 
 
 
 
 
The following genes were cloned in the Gatway compatible pCR3.3 vector: 
 
Flag-∆ roret (EcoRI/EcoRV) 
Primer 1: dRoRet-EcoRI 5￿-cag gaa ttc tcc aag ctt tac ttc gat gtg aag aaa atg-3￿ 
Primer 2: RoRetEcRV 3￿, 5￿-cag gat atc tta gtc acc tgg ggg agg cag-3￿ 
A PCR reaction was set up with the above primers and RoRet-pcDNA3.1/GS as the 
template. 
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Flag-roret(genestorm) (EcoRI/EcoRV) 
Primer 1: RoRetEcoRI-ATG 5￿-cag gaa ttc gcc tca acc acc agc acc aag-3￿ 
Primer 2. RoRetEcRV 3￿, 5￿-cag gat atc tta gtc acc tgg ggg agg cag-3￿ 
A PCR reaction was set up with the above primers and RoRet-pcDNA3.1/GS as the 
template. 
 
 
13.4- In pGADT7 (Clontech) 
 
This vector is a two-hybrid vector for the prey (fusing the cDNA to the GAL4 
activation domain). 
 
 
 
 
 
The following genes were cloned in pGADT7: 
 
∆ aven-pGADT7 (BamHI/XhoI) 
Primer 1: dAven-ATGBH 
 5￿-acg gga tcc tgc agg cgg agc gag gag ctc ggg gag gcc-3￿ 
Primer 2: AvenX 3￿, 5￿-aca ctc gag tta gga aat cat gct gtc caa cca gtc ttc-3￿   67
A PCR reaction was set up with the above primers and Aven-pSG5 as the template. 
 
 
∆ roret-pGADT7 (EcoRI/XhoI) 
Primer 1: dRo-ATGEc 5￿-agt gaa ttc tcc aag ctt tac ttc gat gtg aag aaa atg-3￿ 
Primer 2: RoRetX 3￿, 5￿-aca ctc gag tta gtc acc tgg ggg agg cag aaa caa agg-3￿ 
A PCR reaction was set up with the above primers and ∆ RoRet-pcDNA3.1+ as the 
template. 
 
 
Fte-1-pGADT7 (BamHI/XhoI) 
Primer 1: Fte-ATGBH 5￿-acg gga tcc tgg cgg ttg gca aga aca agc gcc tta cga-3￿ 
Primer 2: Fte-1X 3￿, 5￿-aca ctc gag tta aac aga ttc ttg gac tgg tgg ttc ata-3￿ 
A PCR reaction was set up with the above primers and fte-1-pMEXneo 
as the template. 
 
 
13.5- In pArt1 (expression vector for S. pombe kindly provided by Dr. Paul 
Nurse, NCBR, London). 
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The following genes were cloned in pArt1: 
 
 
HA-BclXL-pArt1(pstI/BamHI) 
Primer 1: BclXLpArt1 5￿-aca ctg cag aaa atg gcc tac ccc tac gac gtg ccc gac tac gcc 
tcc ctc gga tcc tct cag agc aac cgg gag ctg gtg gtt gac-3￿ 
Primer 2: BclXLpArt1 3￿,  
5￿-aca gga tcc tca ttt ccg act gaa gag tga gcc cag cag-3￿ 
A PCR reaction was set up with the above primers and BclXL-pcDNA3.1 as 
the template. 
 
 
13.6- In pRIP 45 (expression vector for S. pombe kindly provided by Dr. Paul 
Nurse, NCBR, London). 
 
 
The following genes were cloned in pRIP45: 
 
HA-CED4-pRIP45 (SmaI/SmaI) 
Primer 1: HA-ced4-Sma-5￿- aca ccc ggg aaa atg gcc tac ccc tac gac gtg ccc gac tac 
gcc tcc ctc gga tcc ctc tgc gaa atc gaa tgc cgc gct ttg agc-3￿ 
Primer 2: HA-ced4-3￿,  
5￿-aca ccc ggg tta aca gca tgc aaa att ttt gag gga gtc ata-3￿ 
A PCR reaction was set up with the above primers and Rep 45-CED4   69
as the template. 
 
 
13.7- In pGEX-AHK (expression vector for GST-fusion proteins in BL21 E. coli, 
fusing gene to GST.  
 
The parental vector is pGEX-2T from Clontech  and the pGEX-AHK was 
kindly provided by Dr. Thorsten Heinzel, Georg-Speyer-Haus, Frankfurt) 
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The following genes were cloned in pGEX-AHK: 
 
∆ aven- pGEX-AHK (XhoI/XhoI) 
Primer 1: dAvenX-ATG 5￿-aca ctc gag agt gag tta ttg gtt cga gcc ctt caa gag-3￿ 
Primer 2: AvenX 3￿, 5￿-aca ctc gag tta gga aat cat gct gtc caa cca gtc ttc-3￿ 
A PCR reaction was set up with the above primers and Aven-pSG5 as the template. 
 
 
∆ roret- pGEX-AHK (XhoI/XhoI) 
Primer 1: dRoRetX-ATG 5￿-aca ctc gag tcc aag ctt tac ttc gat gtg aag aaa atg-3￿ 
Primer 2: RoRetX 3￿, 5￿-aca ctc gag tta gtc acc tgg ggg agg cag aaa caa agg-3￿ 
A PCR reaction was set up with the above primers and ∆ RoRet-pcDNA3.1+ 
as the template. 
 
 
Fte-1- pGEX-AHK (XhoI/XhoI) 
Primer 1: Fte1X-ATG 5￿-aca ctc gag gcg gtt ggc aag aac aag cgc ctt acg-3￿ 
Primer 2: Fte-1X 3￿, 5￿-aca ctc gag tta aac aga ttc ttg gac tgg tgg ttc ata-3￿ 
A PCR reaction was set up with the above primers and fte-1-pMEXneo as the 
template. 
 
 
13.8- Constructs provided by other research groups 
 
 
fte-1-pMEXneo (from Dr. Helmut Zarbl, Fred Hutchinson cancer research 
centre, Seattle, WA, USA) 
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hSAA1.1-pBR322 (from Dr. Barbara Kluve-Beckerman, Dep. Path. And lab. 
Medicine, Indianapolis, US) 
 
 
 
 
Aven-pSG5 (from Dr. Marie Harwick, Johns Hopkins University, Baltimore, US) 
 
 
 
 
   72
 
RoRetpcDNA3.1/GS genestorm cDNA collection (Resgen, Invitrogen) 
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RoRetpCMV.SPORT6 celera cDNA collection (Resgen, Invitrogen) 
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14-Yeast Two-Hybrid (Y2H)assay. 
14.1-ββββ -galactosidase assay. 
 
AH109 or CG-1945* yeast cells are co-transformed with the GAL4 DNA-
binding domain fused to the prey gene and the GAL4 activation domain fused to the 
bait gene. They were plated on selective medium (DOBA, -uracil, -tryptophane and -
leucine). When colonies were large enough, a Whatman filter (90 mm Dia, No.5) was 
pressed on the plate until humidity diffuses into the filter. Then the filter was gently 
removed with the yeast colonies now attached to it and thrown in liquid nitrogen for 
10 sec to break membrane wall. Then filter was allowed to thaw and placed on a filter 
paper soaked in Z buffer/X-gal solution. The yeast colonies hosting interacting 
partners turned blue within the next 8 hours. 
 
*AH109 and CG-1945. (can be purchased fom Clontech).    
 
 
 
 
 
 
 
                           
 
 
14.2-Buffers and solutions. 
 
Z buffer: 16.1 g/l Na2HPO4•7H2O/5.5 g/L NaH2PO4•H2O/0.75 g/l KCl/0.246 g/l 
MgSO4•H2O adjust to pH 7.0 and autoclave. 
 
Z buffer/X-gal solution: 100 ml Z buffer/0.27 ml β -mercaptoethanol/1.67 ml X-gal 
stock solution. 
 
X-gal stock solution: dissolve 5-bromo-4-chloro-3-indolyl-β -D-galacto-pyranoside 
(X-gal; #8060-1) in N,N-dimethylformamide (DMF) at a concentration of 20 mg/ml. 
Store in the dark at ￿20￿C. 
 
 
C-Cell culture 
1-Basic handling 
 
Cells were trypsinized and resuspended in DMEM (LIFE TECH) complete 
medium and passaged one to eight them just before confluency is reached. Normal   75
culture medium was 10% FCS/10 ml glutamine/5 ml Pen-strep (penicillin and 
streptomycin) from Bio*Whittaker in 500 ml DMEM or RMPI from LifeTech. 
Trypsinization required prior washing of the cells in PBS. They were then incubated 5 
min with 2 ml Trypsin (Bio*Whittaker) in a 9 cm diameter plate at 37￿C. Some cell 
lines needed scrapping to detach them (e.g. Kim-2) 
 
For stocks:  
Cells were centrifuged at 1,400 rpm and the supernatant was removed. The 
pellet was resuspended in 90% FCS/10% DMSO and the cells were transferred 
immediately on dry ice in cryotubes. Then the cells were stored overnight at ￿80￿C 
before being transferred into the liquid nitrogen tank for years. 
 
 
2-Transfection 
 
RKO* and 293T** cells were transfected using the PEI method. Briefly, 
13.5￿l of a polyethyleneimine solution (10mM in PBS, high molecular weight PEI 
from Aldrich) were diluted with 150￿l of PBS. In parallel, 5￿l of DNA solution were 
diluted with 150 ￿l of PBS and both solutions were mixed and vortexed. After 10 
minutes of incubation at room temperature, the DNA/PEI mixture was added to the 
cells (1x10
6 cells/10 cm plate) in serum-free medium. 4 hours later, the medium was 
replaced with FCS-containing medium. 
 
*RKO: human colorectal carcinoma cells (Invitrogen). 
**293T: human embryonic kidney cells, transformed with large T antigen 
(Invitrogen). 
 
 
3- Apoptosis quantification by LIVE/DEAD assay 
 
Apoptotic cell death was measured using the LIVE/DEAD 
Viability/Cytotoxicity kit from Molecular Probes according to the supplier·s protocol.  
Cells were washed with PBS and resuspended in 40 µ l of 4 µ M EthD-1/2 µ M Calcein 
for 30 min in the dark at room temperature. In this assay, living cells are distinguished 
by the presence of ubiquitous intracellular esterase activity, determined by the 
enzymatic conversion of the virtually nonfluorescent cell-permeant calcein AM to the 
intensely green fluorescent calcein (ex/em 495 nm/515 nm). Ethidium homodimer-1 
enters cells with damaged membranes and undergoes a 40-fold enhancement of 
fluorescence upon binding to nucleic acids, thereby producing a bright red 
fluorescence in dead cells (ex/em 495 nm/635 nm). EthD-1 is excluded by the intact 
plasma membrane of living cells. For each experiment, at least 200 green and red cells 
were counted using a Nicon fluorescence microscope (TE300). 
 
   76
4- Caspase activity assay. 
 
Cells were washed in PBS, centrifuged at 2,000 rpm, and the pellet was frozen 
immediately in liquid nitrogen then stored at ￿80￿C. The BioVision ￿Mch6 
Fluorometric Protease Assay Kit￿ was used for the following steps. The pellet was 
resuspended in 50 µ l of chilled cell lysis buffer. The mixture was incubated on ice 10 
min then   transfered in a 96 well plate. 50 µ l 2x reaction buffer/10 mM DTT was 
added to the mixture with 5 µ l LEHD-AFC substrate (50 µ M final concentration). The 
mixture was incubate 2 hours at 37￿C and the reaction result was read out at 505 nm.  
 
 
5- KIM-2 cells. 
5.1-Cell culture 
 
Kim-2 cells were cultured and treated as describe in [MacLaren, 2001 #9112; 
Gordon, 2000 #9113; Clarkson, 2000 #9114] to induce differenciation and apoptosis. 
Cells were maintained in ￿maintenance medium￿ and passaged by scrapping 1/5 when 
they reached near confluency. To differentiate them, they were cultured in 
￿maintenance medium￿ up to complete confluency, then the medium was exchanged 
with ￿differentiation medium￿. Cells were kept in this medium for about two weeks, 
changing medium every second day until they formed multiple layer and structures 
similar to tubules (differentiated pattern). To induce apoptosis, differentiated cells 
were incubated overnight in ￿apoptosis medium￿. About 30% of the cells were 
apoptotic. 
 
 
5.2-Buffers and solutions 
 
KIM-2 Maintenance medium: 250ml DMEM (LIFE TECH), 250 ml F-12 nutrient mix 
(LIFE TECH), 50 ml Foetal calf serum (10%) (LIFE TECH), 6 ml L-Glutamine 
(5%)(LIFE TECH), 500 µ l Insulin (5 mg/ml stock solution) (SIGMA), 500 µ l EGF (5 
µ g/ml stock solution) (SIGMA), 250 µ l Linoleic acid (10 mg/ml stock solution) 
(SIGMA). Optional, 500 µ l Gentamicin (50 mg/ml stock solution) (LIFE TECH). 
 
KIM-2 Differentiation medium: 250ml DMEM (LIFE TECH), 250 ml F-12 nutrient 
mix (LIFE TECH), 50 ml Foetal calf serum (10%) (LIFE TECH), 6 ml L-Glutamine 
(LIFE TECH), 500 µ l Insulin (5 mg/ml stock solution) (SIGMA), 500 µ l 
Dexamethosone (40 µ g/ml stock solution) (SIGMA), 500 µ l Prolactin (1 mg/ml stock 
solution) (SIGMA), 250 µ l Linoleic acid (10 mg/ml stock solution) (SIGMA).  
 
KIM-2 Apoptosis medium: 250ml DMEM (LIFE TECH), 250 ml F-12 nutrient mix 
(LIFE TECH), 50 ml Foetal calf serum (10%) (LIFE TECH), 6 ml L-Glutamine (LIFE   77
TECH), 500 µ l Insulin (5 mg/ml stock solution) (SIGMA), 250 µ l Linoleic acid (10 
mg/ml stock solution) (SIGMA).  
 
Collagen coating solution: 5 ml collagen type 1 (SIGMA), 2.8 ml 10% acetic acid 
(filtered), 42.2 ml ddH2O. 
  
 
D-FACS analysis 
1-Propidium Iodide staining of fixed cells 
1.1-Fixation 
 
Cells were centrifuged at 1,400 rpm at 4￿C for 5 minutes, supernatant and 500 
µ l ice cold 70% ethanol was pipetted drop by drop while vortexing. Adherent cells 
had to be trypsinized and washed with PBS. Fixed cells can be conserved at 4￿C for 
several days. 
 
 
1.2-PI staining 
 
The cells were washed with 2 ml 38 mM Na-Citrate pH 7.4 and spin with 
1400 rpm 5 minutes at 4￿C. The supernatant was removed and 500 µ l 38mM Na-
Citrate pH 7.4, 50 mM propidium iodate (1/50 of 2.5 mg/ml stock), 5 mM RNAse 
(1/2000 of 10mg/ml stock solution) were added. The cells were then incubated for 20 
minutes at 37￿C in the dark. The samples were handled immediately. The cell 
suspension was analyzed with a FACScalibur (Becton Dickinson). The ￿Cell Quest 
Pro￿ software was used and PI stained cells were detected in the FL2 fluorescence. 
Cells with hypoploid DNA content (represented in the sub-G1 peak of the cell cycle 
profile) were considered apoptotic. 
 
3-Buffers and solutions 
 
FACS Flow, FACS rinse, Cell WASH were purchased at Becton Dickinson. 
 
 
E-Confocal laser scanning microscopy 
1-Fixation and antibody staining of cells 
 
293T cells were grown in appropriate thin bottom 2.2 cm diameter plates 
(25/22 mm. Serie 3500, WillcoWells B.V.), and transfected as described previously.   78
All subsequent steps were done at room temperature. The supernatant was gently 
removed and cells were washed with 1 ml PBS/1 mM CaCl2/0.5 mM MgCl2. Then 
cells were fixed with 500 µ l 3% Formaldehyde/PBS for 10 min and washed twice 
with 1 ml PBS, 5 min each. Then cells were permeabilized with  500 µ l 0.1% Triton-
100/PBS for 5 min and washed twice 5 min with 3% BSA/PBS. Cells were incubated 
with gentle shaking 1-3 hours with 150 µ l primary antibody 1/100 in 3% BSA/PBS. 
The cells were washed twice with PBS and incubated 1 hour with 150 µ l of the 
species specific secondary antibody 1/1000 in 3% BSA/PBS. As a last step, cells were 
washed twice with PBS, and one drop of Vectashield (mounting medium for 
fluorescence, with DAPI) from LINARIS   was used with 100 µ l PBS to avoid 
dehydratation of the cells. It was possible to keep them up to one week at 4￿C. 
 
 
F- Cancer profiling array with tumours cDNA 
 
To analyze mRNA expression levels in normal and tumour tissue the Cancer 
Profiling Array from Clontech was used (catalog No. #7841-1). This array contains 
many cDNA pairs of tumour and normal tissue, each from the same patient. The 
membrane was hybridzed with [
32P]-labelled cDNA probes of human ubiquitin 
(supplied by Clontech), human c-myc, human ∆ aven, human ∆ roret, human fte-1 and 
mouse  ∆ hmgb1  (which recognises the human hmgb1 transcript) according to the 
supplier·s protocol. Hybridization signals were detected and quantified with a BIO 
RAD phosphoimager (Molecular Imager FX) and the Quantity One software. 
 
 
G-Preparation of protein lysates from tumour samples for Western Blot analysis. 
1-Protein lysate preparation. 
 
All primary human mammary carcinoma samples (kindly provided by Dr. 
Christine Solbach, Frauenklinik, Universit￿tsklinikum, Frankfurt) were collected 
directly after surgery, frozen in liquid nitrogen and stored at -80
0  C. They were 
classified as follows: 
 
Tu.-No. TNM  Grading  ER/PR  Her2/neu 
83  pT3 pN1 M0  3  pos./neg.  neg. 
167  pT4 pN0 M0  3  pos./neg.  neg. 
249  pT2 pN0 M0  2  pos./neg.  neg. 
250  pT2 pN0 M0  3  neg./neg.  neg. 
256  pT1 pN0 M0  2  pos./pos.  neg. 
611 pT3  pN1  3  neg./neg.  nd 
876 pT2  pN0  3  pos./neg.  nd 
1096 pT3  pN1  nd  neg./pos.  nd 
1132 pT3  pN1  3  nd  nd 
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Another seven samples were human breast carcinomas passaged in nude mice 
for several years and tested for human origin. 0.5 cm
3 tumour material was crushed in 
a 12.0/75 mm Greiner tube using a homogenizer (Ultra-Turrax T25, Janke & Kunkel, 
IKA Labortechnik) in 1ml lysis buffer and centrifuged at 4
0C. The supernatant was 
used for quantification of protein concentration and subsequent Western blot analysis 
with 40 ￿g protein per sample.  
 
 
2-Buffers and solutions 
 
Lysis buffer: 30 mM Tris-HCL (pH7.5), 150 mM NaCl, 1% Triton X-100, 10% 
Glycerol, 1 mM PMSF, 1 tablet Complete protease inhibitor cocktail (Roche) per 10 
ml buffer 
 
 
H-Mouse mammary glands mRNA, northern blot analysis. 
 
A mouse mammary gland Northern Blot from RNWAY Laboratories (Catalog 
No. NeverFail
TM m106) was hybridized with 100 ng [
32P]-labelled ∆ hmgb1, β -actin 
and  gapdh mouse cDNA probes following the manufacturer·s instructions. The 
membrane contains mouse mammary gland mRNA preparation from non-pregnant 
and pregnant mice as well as from lactating and involuting animals. 
 
 
I- Common Drugs and companies 
 
Agarose ultra pure (Life Technologies, Gibco BRL) 
Bromophenol blue (Roth) 
Dimethylsulfoxid, DMSO, C2H6SO (Roth) 
ECL western blotting detection reagent (AmershamPharmacia) 
EGTA (Sigma) 
Ethanol 100% (Roth) 
Formaldehyde 37% (Sigma) 
Formamid (Roth) 
Glass beads, 425-600 µ m (Sigma) 
Glycerol (Roth) 
G-418 sulfate (CalBiochem) 
HEPES (Roth) 
Hydrochloric acid 1 M, HCl (Roth) 
Lithium Chloride, LiCl (Roth) 
Lysosym (Roth) 
Methanol (Roth)   80
MOPS, C7H15NO4S (Roth) 
Nonfat dried milk powder (AppliChem) 
Phenol and buffer pH 10.5 for saturated Phenol (Sigma) 
Phosphatase alkalin, AP, (Roche) 
PMSF (Aldrich) 
Potassium acetate, C2H3KO2 (Roth) 
Potassium dihydrogen phosphate, KH2PO4 (Roth) 
2-Propanol, Isopropanol (Roth) 
Proteinase cocktail tablets (Roche) 
Proteinase K (Roche)  
RNase (Roche) 
Rotiphorese Gel 30, polyacrylamid (Roth) 
SDS ultra pure 20% (Roth) 
Sodium acetate, C2H3NaO2•3H2O (Roth) 
Sodium hydroxide, NaOH (Roth) 
TEMED p.a. (Roth) 
Tri reagent (Sigma) 
Trichloromethan/Chlorophorm (Roth) 
Tris, C4H11NO3 (Roth) 
Tris hydrochlorid, C4H11NO3HCl (Roth) 
Tween
R 20 (Roth) 
 
Other more specific reagents and drugs are mentioned in the protocol text with   
companies of purchase. 
 
J- Tools and equipments 
 
Bench tools:  _ Biofuge pico (Heraeus) 
  _Vortex  REAXcontrol  (Heidolph) 
  _Pipetus
R-akku (Hirschmann Laborgeräte) 
    _Electrophoresis power supply- EPS 301  
(Amersham pharmaciabiotech) 
_Hoefer Semiphor, semidry transfer unit 
(Pharmacia Biotech) 
_Hoefer HE33, mini horizontal submarine unit  
(Pharmacia Biotech) 
_GNA 200, for big gels (Pharmacia Biotech) 
_MV120, mini vertical gel system (LTF) 
_Rocking table ￿Rocky￿, to wash membranes  
(Fröbel Labortechnik) 
_Thermomixer compact, for 1.5 ml tubes (Eppendorf) 
_Dri-Block
R DB-2D (Techne) 
 
Centrifuges:  _Biocentrifuge/J2-21 centrifuge with rotor JA-10 and JA-20   
                        (Beckman)    81
  _Ultracentrifuge  TL-100  (Beckman)  
  _SIGMA  2K15  (Laborcentrifugen) 
    _Heraeus Typ. Nr.4400, minifuge GL Heraeus Christ (Heraeus) 
 
TE300, Fluorescent microscope (Nicon) 
FACSCalibur (Becton Dickinson) 
LEICA DMIRBE, Confocal microscope (LEICA) 
iCycler PCR machine (Bio-RAD) 
Branson SONIFIER 250 (G.HEINEMANN) 
1500 TR-CARB
R, liquid scintillation analyser (PACKARD) 
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III-Results. 
A-The screens 
1- The Yeast survival screen 
 
The HC4 strain was derived from wild type S. pombe yeast stably transformed 
with the HA-CED4-pRIP45 vector, containing the adenine selection makers that 
allows growth on medium without adenine. This vector has an nmt-1 inducible 
promoter allowing expression of CED4 when thiamine is removed from the medium. 
When thiamine is present, gene expression is repressed. A stable HC4 yeast strain 
with the HA-CED4-pRIP45 vector integrated in the chromosomal DNA was obtained 
by culturing a CED4 expressing colony in non-selective liquid yeast medium for 2-3 
passages. Then, an aliquot was plated on non-selective agar plates including leucin, 
uracil, adenine, thiamine. Growing colonies were then replica-plated on successively 
selective (containing leucin, uracil, thiamine, and without adenine) and non-selective 
medium (including adenine), the second being important for the survival of the later 
chosen clone colony. During the incubation in non-selective medium, the Ade-
containing plasmid will be lost if it is not stably integrated in the genome. Colonies 
still inducible for CED4 expression and efficient cell killing on agar plates lacking 
adenine were considered stably transformed. It was important to obtain a yeast strain 
that would give the minimal background of colonies surviving CED4 expression, and 
such a strain was chosen and called HC4. 
  
The HC4 S. pombe strain was cultured overnight in 1l of liquid yeast medium 
containing leucin, uracil and thiamine up to O.D600 0.6, and transformed using the 
LiAc method with 320 µ g of a human breast carcinoma library cDNA with the ATG 
containing 5￿-linker and with  64µ g of library cDNA without a linker-encoded start 
codon. The total amount of transformed cDNA was therefore 384 µ g. The efficiency 
of the transformation was determined as 2,5.10
3 colonies/µ g cDNA, resulting in 
9,6.10
5 of clones which were eventually screened. 
After replica-plating twice on uracil and phloxin-containing medium, the surviving 
CED4-expressing colonies were scrapped on uracil media to test their regrowth 
potential. Phloxin is a red dye that penetrates damaged yeast cell membrane walls and 
which allows to determine by its reddish colour if a yeast colony is dying (red) or still 
alive (cream). This ￿regrowth￿ test was important because some yeast colonies are 
feeding themselves from the nutrients provided by surrounding dead yeast cells, and 
can survive regardless of the selective medium based on starvation of essential 
nutrients.  In my screen 473 clones regrew. These 473 clones were pooled in liquid 
medium, incubated for 4 hours and the library cDNA plasmids were extracted 
together with the chromosomal DNA. 1/4 of the amount of DNA was used for a 
second round of selection (transformation of HC4, replica plating twice and regrowth 
test on uracil medium). After this second round of survival selection, 22 clones 
remained.   83
 
Plasmid cDNA were isolated and sequenced. The result is listed below: 
 
B1: Human RoRet / or zinc finger protein 15.. 
B2: Homo sapiens cell death regulator AVEN. 
B3/5: Similar to mus musculus early blastocyst cDNA clone, similar to the 
L36 ribosomal protein. 
B9/10/11/13/18: Expression vector Beta-lactamase and beta-propylmalate 
dehydrogenase genes. 
B12: Human v-fos transformation effector protein (Fte-1)/  
         40S ribosomal protein S3A (human) 
B15: Human tumor necrosis factor/  
         Lysosome-associated membrane glycoprotein 1 precursor . 
B17: PPARγ -cofactor 2 
B19: Peptidyl-prolyl cis-trans isomerase A (human)/ or Cyclophilin A. 
B20: Serum amyloid A (SAA1-2) beta gene. 
B21: Human fuse binding protein. 
B22: Mitochondrial DNA control region sequence. 
 
 
B-Selection of candidate genes for future investigations 
 
The screen came up with potentially interesting anti-apoptotic cDNA 
candidates, but the number of genes excluded the possibility to analyse them all. I 
decided to select only some of them for further investigation. The criteria by which I 
selected them were the maintenance of CED4 expression in HC4 yeast cells 
expressing the library plasmids (to avoid isolation of transcriptional down regulators 
of CED4 expression), the interest of published information about the particular clones 
and their potential to inhibit apoptosis in a mammalian system.  
 
1-CED-4 expression 
 
I cultured the clones in  selective medium (devoid of thiamine to induce CED4 
expression) for 48 hours and extracted protein lysate. These protein extracts were 
used in a Western Blot to test the presence or absence of the killer-protein CED4 (see 
Fig. 15) 
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 Fig. 15 : The isolated 23 HC4 clones transformed with the tumour library (B1-B23) 
were grown in medium plus thiamine to O.D600 0.5, then washed twice with water, 
diluted to O.D. 0.03 and cultured in medium without thiamine overnight to induce 
Ced-4 expression. Protein extracts were prepared and Western Blot was performed 
with an anti-CED4 antibody obtained from Dr. Horwitz (Howard Hughes Medical 
Institute, Department of Biology, Massachusetts Institute of Technology, Cambridge 
02139, USA). The expected size of the protein is 65 kD. CED4 expression had to be 
confirmed to exclude transcriptional downregulation by the protecting library 
plasmid. I was not interested to isolate and analyse transcriptional regulators 
downregulating the CED4 gene expression.  
 
All clones I had obtained in the survival screen were still expressing detectable 
amounts of CED4 except B3 (where the protein concentration was too low to  allow 
interpretation, and B19. 
 
 
2-Literature analysis of the clones encoding for a protein 
 
The sequencing results were blasted in HUSAR (from the webDKFZ site) and 
NIH blast (from the webPubMed site). I determined the clones length, the contained 
coding or non-coding sequence in the clones and the published roles of each protein 
encoded by my cDNAs.   85
 
 
Tab.2 : Details about the cDNA clones found in the CED4 yeast suvival screen. The 
name and the gene fragments are coupled with the published data and informations. 
 
From the literature and the CED4 expression test, I decided to carry on with 
the analysis of the following genes: 
 
Human RoRet/zinc finger protein 15.  
(accession number: U90547) 
Homo sapiens cell death regulator AVEN. 
(accession number: AF283508) 
 
Human v-fos transformation effector protein (Fte-1)/  
         40S ribosomal protein S3a (human) 
(accession number: M84711) 
 
PPARγ -cofactor 2 
(similar to the mus musculus PGC2 with accession number: AF220501) 
 
Serum amyloid A (SAA1-2) beta gene. 
(accession number: M23698)   86
 
Human fuse binding protein. 
(accession number: U05040) 
 
 
3-Anti-apoptotic potential of the candidate clones in mammalian cells 
 
We obtained several full length gene constructs from the laboratories that have 
either identified these proteins or are further studying them: the full length human 
aven cDNA in the CMV expression vector pSG5 (aven-pSG5) from Dr. Marie 
Harwick (Johns Hopkins University, Baltimore, US), the full length human fte-1/s3a 
cDNA in the MSV expression vector pMEXneo (fte-1-pMEXneo) from Dr. Helmut 
Zarbl (Fred Hutchinson cancer research centre, Seattle, WA, USA), the full length 
human SAA1.1β  cDNA in the cloning vector pBR322 (SAA1-1β -pBR322) from Dr. 
Barbara Kluve-Beckerman (Dep. Path. And lab. Medicine, Indianapolis, US) and the 
human FBP cDNA in the CMV expression vector pcDNAI/amp from Dr. David L. 
Levens (NCI, DCS, Bethesda, MD, USA). ∆ roret,  ∆ aven,  PGC2,  ∆ SAA1.1β  and 
∆ FBP were cloned in the pcDNA3.1+ mammalian expression vector (Invitrogen). 
Then two functional tests were performed: analysis of the protecting potential of the 
clones against Bak-GFP induced apoptosis in 293T cells (human embryonic kidney 
cells, transformed with large T antigen) and against FasL/α Flag/cycloheximide-
induced apoptosis in RKO cells (human colorectal carcinoma cells). 
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Fig.16: Two different model systems to study apoptosis inhibition by the cDNA 
clones isolated in the yeast survival screen. 
(A) 293T cells were transfected with 0.5 µ g bak-gfp plus 1.5 µ g pcDNA3.1+ and 
treated (or not) with   M zVAD-fmk. The next day (16 h later) dying cells (round 
bright green cells) were distinguished from living cells (spread living cells with no 
GFP in the nucleus) using a fluorescent microscope. (B) RKO cells were transfected 
with 1 µ g pcDNA3.1+ and the next day treated with 10 ng/ml FasL, 1 mg/ml anti-
FLAG antibody and 0.1 µ g/ml cycloheximide with or without zVAD-fmk. The next 
day (16 h later) cells were collected and the percentage of apoptotic cells was 
determined by FACS analysis of propidium iodide stained fixed cells and by the 
LIVE/DEAD assay from Molecular Probes.  
 
These model systems were used to test the protection efficiency of the isolated clones 
in mammalian cells and to allow us to select the most potent apoptosis inhibitors. 
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Fig.17: 293T cells were transfected with 0.5 µ g  bak-gfp plus 1.5 µ g  ∆ rotet-
pcDNA3.1+, 1.5 µ g aven-pGS5, 1.5 µ g ∆ aven-pcDNA3.1+, 1.5 µ g fte-1-pMEXneo, 
1.5 µ g pgc2-pcDNA3.1+ or fbp-pcDNA3. The next day (16 h later) dying cells (round 
bright green cells) were distinguished from living cells (spread living cells with no 
GFP in the nucleus) by fluorescent microscopy. (A) Picture of Bak-GFP expression in 
the 293T cells. (B) Graphic presentation of green fluorescent dead cells. The 
experiment was repeated twice with similar results.   
 
Unfortunately, the experiment with ∆ SAA1 was unsuccesfull (the cell morphology 
not permitting any real distinction between dead and living cells)  and no conclusion 
about the protective capacity of ∆ SAA1 could be obtained by this particular assay. 
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Fig.18: RKO cells were transfected with either 1 µ g pcDNA3.1+, 1 µ g aven-pGS5, 1 
µ g  ∆ aven-pcDNA3.1+, 1 µ g  fte-1-pMEXneo, 1 µ g  fbp-pcDNA3, 1 µ g  ∆ fbp-
pcDNA3.1+, 1 µ g  ∆ saa1-pcDNA3.1+, 1 µ g  ∆ pgc2-pcDNA3.1+ or 1 µ g  ∆ roret-
pcDNA3.1+. The next day, cells were treated with 10 ng/ml FasL, 1 mg/ml anti-
FLAG antibody and 0.1 µ g/ml cycloheximide with or without zVAD-fmk. The next 
day (16 h later) cells were collected and the percentage of apoptotic cells was 
determined by FACS analysis of propidium iodide stained fixed cells (blue bars) and 
by the LIVE/DEAD assay from Molecular Probes (brown bars).  
 
The readout of these various experiments was that most clones (full length or 
∆  deletion mutants as identified in the screen) were efficiently inhibiting apoptosis 
induced  by Bak and FasL, some of them as efficient as the general chemical caspase-
inhibitor zVAD. While experimental results with FasL-induced apoptosis gave 
variable protection potential depending of the experiment (Fig.18 represents one 
example), the outcome with Bak-induced apoptosis was constant (as shown later by 
the arrow bars of the Bak protection  and caspase activity assays).  
 
3-Computational analysis of Aven, Fte-1 and RoRet. 
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Computational analysis was done with HUSAR (from webDKFZ site) and 
NIH-blast (from webPubMed site). The results are represented below as the schematic 
representations of the proteins (with NIH-blast program) with their predicted domains 
and additional informations published about the particular protein. 
 
3.1-Aven:  
  1                                          362                               
 
Fig.19: Graphic representation of Aven obtained with NIH-blast. The protein 
comprise 362 amino-acids. The program could define no homology to any known 
domain. 
 
BC010488. Homo sapiens, cell death regulator Aven, 
             
     CDS             1..1089 
                     codon_start=1 
                     product=cell death regulator aven 
 
                     protein_id=AAH10488.1 
translation=MQAERGARGGRGRRPGRGRPGGDRHSERPGAAAAVARGGGGGG
GGDGGGRRGRGRGRGFRGARGGRGGGGAPRGSRREPGGWGAGASAPVEDD
SDAETYGEENDEQGNYSKRKIVSNWDRYQDIEKEVNNESGESQRGTDFSVLL
SSAGDSFSQFRFAEEKEWDSEASCPKQNSAFYVDSELLVRALQELPLCLRLNV
AAELVQGTVPLEVPQVKPKRTDDGKGLGMQLKGPLGPGGRGPIFELKSVAA
GCPVLLGKDNPSPGPSRDSQKPTSPLQSAGDHLEEELDLLLNLDAPIKEGDNIL
PDQTSQDLKSKEDGEVVQEEEVCAKPSVTEEKNMEPEQPSTSKNVTEEELED
WLDSMIS 
 
nucleotide sequence, coding region=1 atgcaggcgg agcgaggagc tcggggaggc 
cgtgggcggc ggccaggccg cggccggcct ggcggagatc gccacagcga gcggcccgga gccgcagcgg 
cggtagccag aggcggcggc ggaggcggcg gcggggacgg aggcggacgc cggggccgtg gccgtggccg 
gggcttccgc ggcgctcgcg gaggccgagg aggaggaggc gccccgcgag gcagccgccg ggagccggga 
ggctggggcg caggggccag cgcgccggtt gaagatgaca gcgatgcaga gacctatgga gaagagaatg 
atgaacaggg aaattattct aaaagaaaga ttgtctctaa ctgggatcga tatcaagata ttgaaaaaga 
ggtcaataat gaaagtggag agtcacagag gggaacagat ttcagtgtcc tccttagctc tgcaggggac 
tcattctcac agttccggtt tgctgaggag aaagaatggg atagtgaagc ttcttgtcca aaacagaatt cagcatttta 
tgtggatagt gagttattgg ttcgagccct tcaagagctg cctctctgcc tccgactcaa cgttgctgcc 
gaactggtcc agggtacagt tcctttagag gttcctcagg tgaaaccaaa gagaactgat gatggcaagg 
gattagggat gcagttaaag gggcccttgg ggcctggagg aagggggccc atctttgagc tgaaatctgt 
ggctgctggc tgccctgtgt tgctgggcaa agacaaccca agcccgggtc cttcaaggga ttctcagaaa 
cccacttccc cactgcagtc agcaggagac catttggaag aagaactaga tctgttgctt aatttagatg 
cacctataaa agagggagat aacatcttac cagatcagac gtctcaggac ctgaaatcca aggaagatgg 
ggaggtggtc caagaggaag aagtttgtgc aaaaccatct gtgactgaag aaaaaaacat ggaacctgag 
caaccaagta cctccaaaaa tgttaccgag gaagagctgg aagactggtt ggacagcatg atttcctaa 1081   93
 
 
3.2-Fte-1/S3a:      
 
 
 
Fig.20: Graphic representation of Fte-1/S3a obtained with NIH-blast. The protein 
comprise 264 amino-acids. The blue regions represent so called law complexity 
regions. The program could define a domain with homology to the Ribosomal_S3ae 
domain and homology to the Ribosomal protein S1a (RPS1A). 
 
M84711. Human v-fos transformation effector protein (Fte-1),  
  AUTHORS   Kho,C.J. and Zarbl,H. 
  TITLE     Fte-1 encodes a gene that is highly conserved during evolution 
  JOURNAL   Unpublished (1992) 
 
     gene            1..795 
                     gene=Fte-1 
     CDS             1..795 
                     codon_start=1 
                     product=v-fos transformation effector protein 
                     protein_id=AAA58487.1          
           
translation=MAVGKNKRLTKGGKKGAKKKVVDPFSKKDWYDVKAPAMFNIR
NIGKTLVTRTQGTKIASDGLKGRVFEVSLADLQNDEVAFRKFKLITEDVQGK
NCLTNFHGMDLTRDKMCSMVKKWQTMIEAHVDVKTTDGYLLRLFCVGFTK
KRNNQIRKTSYAQHQQVRQIRKKMMEIMTREVQTNDLKEVVNKLIPDSIGKD
IEKACQSIYPLHDVFVRKVKMLKKPKFELGKLMELHGEGSSSGKATGDETGA
KVERADGYEPPVQESV 
 
nucleotide sequence, coding region=1 atggcggttg gcaagaacaa gcgccttacg aaaggcggca 
aaaagggagc caagaagaaa gtggttgatc cattttctaa gaaagattgg tatgatgtga aagcacctgc 
tatgttcaat ataagaaata ttggaaagac gctcgtcacc aggacccaag gaaccaaaat tgcatctgat 
ggtctcaagg gtcgtgtgtt tgaagtgagt cttgctgatt tgcagaatga tgaagttgca tttagaaaat tcaagctgat 
tactgaagat gttcagggta aaaactgcct gactaacttc catggcatgg atcttacccg tgacaaaatg 
tgttccatgg tcaaaaaatg gcagacaatg attgaagctc acgttgatgt caagactacc gatggttact tgcttcgtct 
gttctgtgtt ggttttacta aaaaacgcaa caatcagata cggaagacct cttatgctca 
gcaccaacaggtccgccaaa tccggaagaa gatgatggaa atcatgaccc gagaggtgca gacaaatgac 
ttgaaagaag tggtcaataa attgattcca gacagcattg gaaaagacat agaaaaggct tgccaatcta tttatcctct 
ccatgatgtc ttcgttagaa aagtaaaaat gctgaagaag cccaagtttg aattgggaaa gctcatggag 
cttcatggtg aaggcagtag ttctggaaaa gccactgggg acgagacagg tgctaaagtt gaacgagctg 
atggatatga accaccagtc caagaatctg tttaa  781   94
 
3.3-RoRet:   
 
 
 
Fig.21: Graphic representation of RoRet obtained with NIH-blast. The protein 
comprise 362 amino-acids. The program could define several domains with homology 
to known protein domains (SPRY, PRY, BBOX, RING and zf-C3HC4 which are 
explained in the discussion). 
 
U90547 Human Ro/SSA ribonucleoprotein homolog (RoRet) 
Chromosomal Locus       HSU90547       REGION: 22..1419 
AUTHORS   Ruddy,D.A., Kronmal,G.S., Lee,V.K., Mintier,G.A., Quintana,L., 
            Domingo,R. Jr., Meyer,N.C., Irrinki,A., McClelland,E.E., Fullan,A., 
            Mapa,F.A., Moore,T., Thomas,W., Loeb,D.B., Harmon,C., 
            Tsuchihashi,Z., Wolff,R.K., Schatzman,R.C. and Feder,J.N. 
  TITLE     A 1.1-Mb transcript map of the hereditary hemochromatosis locus 
  JOURNAL   Genome Res. 7 (5), 441-456 (1997) 
   PUBMED   9149941 
                     chromosome=6 
                     map=6p21.3 
     gene            1..1398 
                     gene=RoRet 
     CDS             1..1398 
                     product=Ro/SSA ribonucleoprotein homolog 
                     protein_id=AAB53425.1 
                     
translation=MASTTSTKKMMEEATCSICLSLMTNPVSINCGHSYCHLCITDFFKN
PSQKQLRQETFCCPQCRAPFHMDSLRPNKQLGSLIEALKETDQEMSCEEHGE
QFHLFCEDEGQLICWRCERAPQHKGHTTALVEDVCQGYKEKLQKAVTKLKQ
LEDRCTEQKLSTAMRITKWKEKVQIQRQKIRSDFKNLQCFLHEEEKSYLWRL
EKEEQQTLSRLRDYEAGLGLKSNELKSHILELEEKCQGSAQKLLQNVNDTLS
RSWAVKLETSEAVSLELHTMCNVSKLYFDVKKMLRSHQVSVTLDPDTAHHE
LILSEDRRQVTRGYTQENQDTSSRRFTAFPCVLGCEGFTSGRRYFEVDVGEGT
GWDLGVCMENVQRGTGMKQEPQSGFWTLRLCKKKGYVALTSPPTSLHLHE
QPLLVGIFLDYEAGVVSFYNGNTGCHIFTFPKASFSDTLRPYFQVYQYSPLFLP
PPGD 
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nucleotide sequence, coding region=1 atggcctcaa ccaccagcac caagaagatg atggaggaag 
ccacctgctc catctgcctg agcctgatga cgaacccagt aagcatcaac tgtggacaca gctactgcca 
cttgtgtata acagacttct ttaaaaaccc aagccaaaag caactgaggc aggagacatt ctgctgtccc 
cagtgtcggg ctccatttca tatggatagc ctccgaccca acaagcagct gggaagcctc attgaagccc 
tcaaagagac ggatcaagaa atgtcatgtg aggaacacgg agagcagttc cacctgttct gcgaagacga 
ggggcagctc atctgctggc gctgtgagcg ggcaccacag cacaaagggc acaccacagc tcttgttgaa 
gacgtatgcc agggctacaa ggaaaagctc cagaaagctg tgacaaaact gaagcaactt gaagacagat 
gtacggagca gaagctgtcc acagcaatgc gaataactaa atggaaagag aaggtacaga ttcagagaca 
aaaaatccgg tctgacttta agaatctcca gtgtttccta catgaggaag agaagtctta tctctggagg 
ctggagaaag aagaacaaca gactctgagt agactgaggg actatgaggc tggtctgggg ctgaagagca 
atgaactcaa gagccacatc ctggaactgg aggaaaaatg tcagggctca gcccagaaat tgctgcagaa 
tgtgaatgac actttgagca ggagttgggc tgtgaagctg gaaacatcag aggctgtctc cttggaactt 
catactatgt gcaatgtttc caagctttac ttcgatgtga agaaaatgtt aaggagtcat caagttagtg tgactctgga 
tccagataca gctcatcacg aactaattct ctctgaggat cggagacaag tgactcgtgg atacacccag 
gagaatcagg acacatcttc caggagattt actgccttcc cctgtgtctt gggttgtgaa ggcttcacct 
caggaagacg ttactttgaa gtggatgttg gcgaaggaac cggatgggat ttaggagttt gtatggaaaa 
tgtgcagagg ggcactggca tgaagcaaga gcctcagtct ggattctgga ccctcaggct gtgcaaaaag 
aaaggctatg tagcacttac ttctccccca acttcccttc atctgcatga gcagcccctg cttgtgggaa tttttctgga 
ctatgaggcc ggagttgtat ccttttataa cgggaatact ggctgccaca tctttacttt cccgaaggct tccttctctg 
atactctccg gccctatttc caggtttatc aatattctcc tttgtttctg cctcccccag gtgactaa  1381 
 
 
Since I only isolated  the 548 last nucleotides of RoRet cDNA, we obtained two full 
length cDNAs from ResGen (Invitrogen corporation): one cDNA from the Celera 
library (RoRet-pCMV.SPORT6) and one cDNA from the Genestorm library (RoRet-
pcDNA3.1/GS).  
 
C-Results in S. pombe 
1-The protection potential against Bak- and CED4- induced yeast cell death. 
 
To test the specificity of the protection I assessed the inhibitory potential of 
the clones B1(RoRet), B2(Aven) and B12(Fte-1) against CED4- and Bak- induced 
yeast cell death. DSI is an S. pombe strain which expresses Bak under control of the 
nmt-1 promoter (as the strain HC4 expresses CED4 under control of the same 
promoter). I transformed DSI and HC4 with either the empty expression vector pArt1 
as a control, ∆ roret-pArt1 (B1), ∆ aven-pArt1 (B2) or fte-1-pArt1 (B12). When 
colonies appeared,  yeasts were replica-plated twice on selective medium without 
thiamine to induce Bak and CED4 expression (Fig. 22).  
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Fig. 22:  (Left of each picture) DSI yeast cells were transformed with 1 µ g pArt1, 
∆ roret-pArt1 (B1), ∆ aven-pArt1 (B2) or fte-1-pArt1 (B12) and plated on agar plates 
containing uracil and thiamine. (left plate in each picture) When the colonies had 
appeared, they were replica-plated in absence of thiamine to allow induction of Bak 
expression (right plate in each picture). 
 
The yeast cells died very efficiently on all plates, and none of the clones was 
able to confer protection against Bak-induced killing in S. pombe.  
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Fig.23:  Left: HC4 yeast were transformed with 1 µ g  pArt1,  ∆ roret-pArt1 (B1), 
∆ aven-pArt1 (B2) or fte-1-pArt1 (B12) and plated on uracil and thiamine containing 
agar plates. The yeast colonies were growing in the absence of CED4 expression.  
Right: when colonies appeared, they were replica-plated twice on agar plates lacking 
thiamine to allow induction of CED4 expression. Dead yeast cells appear dark red 
after uptake of phloxin. 
 
HC4 transformed with empty pArt1 vector became phloxin-red and died, 
whereas HC4 transformed with ∆ roret,  ∆ aven or fte-1 continued to grow which 
proves protection by these cDNAs against CED4-induced cell death in S. pombe. 
 
 
2-CED4 induces cell death rather than growth arrest in S. pombe and Aven, 
RoRet and Fte-1 confer protection against CED4 yeast killing 
 
To distinguish whether CED4 induces cell death or growth arrest in S. pombe , 
I set up the following experiment: HC4 transformed with pArt1, ∆ roret-pArt1, ∆ aven-
pArt1 or fte-1-pArt1 were cultured in liquid culture medium containing uracil and 
thiamine up to O.D.600 0.5. The they were then incubated in selective medium 
inducing CED4 expression for 16h, 24h, 40h, 48h and 64h. When the yeast cultures 
reached an O.D600 of 0.8 they were again diluted to 0.2. At each time point mentioned, 
an aliquot of the same number of yeast cells (calculated using the O.D600) was plated 
on agar plates containing uracil and thiamine to repress again expression of CED4 and 
to test if the yeast cells were able to regrow.  We reasoned that if colonies appeared, 
the yeasts would have only been blocked in growth. Otherwise the yeast cells would 
have been killed by CED4 expression. 
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Fig. 24: HC4 containing ∆ roret,  ∆ aven and fte-1 were starved of thiamine for 
different  lengths of time. 200 yeast cells each were plated on thiamine-containing 
agar plates to repress again CED4 expression. After 2 days colony number were 
counted and presented as percentage of rescued yeast colonies.  
 
Fig. 26  shows that CED4 not only induces growth arrest but rather kills S. 
pombe yeast cells, and that ∆ RoRet,  ∆ Aven and Fte-1 can protect against CED4 
killing.  
 
 
3-Yeast protection assay in liquid medium 
 
To further investigate the protection efficiency of the clones in S. pombe, I 
measured growth curves of HC4 transfomed with pArt1, ∆ roret-pArt1, ∆ aven-pArt1 
or fte-1-pArt1. Transformed yeasts were cultured in liquid culture medium  containing 
uracil and thiamine up to O.D.600 0.5. They were then washed twice with water before 
diluting them in medium containing uracil at O.D600 0.05 and incubating them in 
selective medium without thiamine for 20h, 40h, 60h and 80h. When yeasts reached 
an O.D600 of 0.8 they were again diluted to 0.05 to prevent growth arrest because of  
too low yeast cell concentrations. 
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  Fig.25: The transformed HC4 yeast strains containing the protecting library 
plasmids were cultured for 24h in yeast medium plus thiamine, which represses 
CED4 transcription. The cells were  then washed with H2O twice and diluted to 
aproximatively 0.05 O.D. 600, in medium with (+T, -CED4) or without thiamine (-T, 
+CED4). Cell expansion was quantified by measuring the O.D. 600. 
 
The results showed that ∆ roret was the most efficient cDNA to protect yeast 
cells against CED4 induced cell death. ∆ Aven and Fte-1 were also protecting CED4-
expressing yeast cells. 
 
D-Functional assays 
1- Apoptosis assays quantified by FACS analysis 
 
It was now important to quantify the protection effect of Aven, RoRet and Fte-
1 in mammalian systems (293T and RKO cells) and their efficiency in vivo against 
different apoptotic stimuli (are they general apoptosis inhibitors or do they inhibit 
only specific killing stimuli). Therefore I cloned roret, ∆ roret and ∆ aven in 
mammalian expression vectors: Flag-roret-pCR33,  roret-pEGFP,  ∆ roret-
pcDNA3.1+, Flag- ∆ roret-pCR33, ∆ roret-pEGFP, ∆ aven-pcDNA3.1+, ∆ aven-pEGFP 
and fte-1-pEGFP. Further constructs were obtained either from other laboratories or 
they were purchased commercially: aven-pSG5,  roret-pcDNA3.1/GS and fte-1-
pMEXneo (for further details about these constructs, see Material and methods, 
Plasmids maps and cloning strategies).  
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Because I had screened for inhibitors downstream of apoptosome formation, I 
first looked at the apoptosis-inhibiting potential of Aven, RoRet and Fte-1 against 
caspase-9-induced apoptosis [Rodriguez, 1999 #6714]. I co-transfected RKO cells 
with the constitutively active apaf-1 M368L kindly provide by Dr. Gabriel Nœnez 
(University of Michigan Medical School, Ann Arbor, MI, USA), caspase-9  and 
either pcDNA3.1+, ∆ roret-pcDNA3.1+,  roret-pcDNA3.1/GS,  ∆ aven-pcDNA3.1+, 
aven-pSG5, fte-1-pMEXneo or bcl-xL-pcDNA3.1. Apaf-1 M368L is an Apaf-1 mutant 
that can bind and activate Caspase-9 without Cytochrome c induced conformational 
change [Hu, 1999 #3617]. I analysed by FACS the influence of Aven, RoRet and Fte-
1 on apoptotic cell death. 
 
 
 
 
 
Fig.26: 1x10
6 RKO cells were transfected by Fugene with pcDNA3.1+, or apaf-1 
M368L/caspase-9  with either pcDNA3.1+, or ∆ roret-pcDNA3.1+,  roret-
pcDNA3.1/GS (RoRetg), ∆ aven-pcDNA3.1+, aven-pSG5, fte-1-pMEXneo or bcl-xL-
pcDNA3.1. The next day, cells were fixed, stained with PI and analysed by FACS. 
The experiment was done three times in triplicates. One of the three similar results is 
shown above and the error bars indicate the variation between the three samples of the 
triplicate  in one experiment. 
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RoRet, Aven, Fte-1 and their deletion mutants were efficient in inhibiting 
DNA fragmentation and cell death in a reproducible manner. The low percentage of 
dead cells was certainly due to the poor transfection efficiency in RKO cells. 
 
Fig. 27: 1x10
6 RKO cells were transfected with 1 µ g pcDNA3.1+, 1 µ g  ∆ roret-
pcDNA3.1+, 1 µ g roret-pcDNA3.1/GS, 1 µ g ∆ aven-pcDNA3.1+, 1 µ g aven-pGS5, 1 
µ g fte-1-pMEXneo or xiap-pEBB. XIAP-pEBB was kindly provided by Dr. Colin S 
Duckett (University of Michigan Medical School, Ann Arbor, MI, USA) and contains 
an EF-1α  promoter. 16 hours later, cells were treated with 10 ng/ml FasL, 1 mg/ml 
anti-FLAG antibody and 0.1 µ g/ml cycloheximide with or without zVAD-fmk. 8 
hours later cells were collected and the percentage of apoptotic cells was determine by 
FACS analysis of propidium iodide stained fixed cells. The experiment was done 
three times in triplicates. One of the three similar results is shown above and the error 
bars indicate the variation between the three samples of the triplicate  in one 
experiment. 
 
  The protection efficiency observed was barely visible when measured by 
FACS, but the control was not very convincing either, suggesting that technical 
problems like the transfection efficiency, may obscure the obtained results. 
 
I then tested whether RoRet, Aven, Fte-1 and the ∆ -deletion mutants protect 
against UV-induced apoptosis.   102
 
Fig. 28: 1x10
6 RKO cells were transfected with 1 µ g pcDNA3.1+, 1 µ g  ∆ roret-
pcDNA3.1+, 1 µ g  roret-pcDNA3.1/GS (RoRetg), 1 µ g  ∆ aven-pcDNA3.1+, 1 µ g 
aven-pGS5, 1 µ g fte-1-pMEXneo or xiap-pEBB. 16 hours later, cells were treated 
with 20 sec UV light. The next day (16 h later) cells were collected and the 
percentage of apoptotic cells was determined by FACS analysis of propidium iodide-
stained fixed cells. The experiment was done three times in triplicates. One of the 
three similar results is shown above and the error bars indicate the variation between 
the three samples of the triplicate  in one experiment. 
 
As for the CD95 killing the protection efficiency against UV-induced 
apoptosis was not very convincing. Only about 10-15% protection was observed. The 
low transfection efficiency of RKO cells (20-30%) at best (with the XIAP control) 
was a serious problem and therefore I decided to change model. 
 
 
2- Apoptosis quantified by the LIVE/DEAD assays 
 
In the first experiment I tested the specific protection efficiency of RoRet, 
Aven and Fte-1 against Apaf-1 M368L/Caspase-9 induced apoptosis. Again I used the 
mutated form of Apaf-1 (Apaf-1 M368L) that does not need Cytochrome c release to 
bind Caspase-9 and to trigger its cleavage and activation. 
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Fig. 29: 1x10
6 293Tcells were transfected  with 0,3 µ g apaf-1M368L (Ap)+ 0,3 µ g 
caspase-9 (C9)+ 1,2 µ g  protector plasmid DNA by PEI. The following day cells were 
stained, and red dead cells and green living cells were both counted in a fluorescence 
microscope using UV-light. The figure represents one of three similar experiments 
done in triplicates. For each sample 200 cells were counted. The error bars represent 
the variation between the three sample of a triplicate. 
 
In this assay RoRet, Aven and Fte-1 inhibit Apaf-1/caspase-9 -induced 
apoptosis in human 293T cells as they do in RKO cells (see Fig. 26) 
 
The pro-apoptotic Bcl-2 family member Bak is known to trigger mitochondrial 
induction and to induce apoptosis. I was interested to test whether RoRet, Aven and 
Fte-1 inhibit Bak-induced apoptosis in mammalian cells, as they protect against yeast 
killing by Bak. 
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Fig.30: 1x10
6 293T cells were transfected  with 0,5 µ g bak-gfp + 1,5 µ g  protector 
plasmid DNA (roret, aven, fte-1) by the PEI method. The next day cells were stained 
and red dead cells versus green living cells in UV light were counted using a 
fluorescent microscope. The figure represents one of three similar experiments done 
in triplicates. For each sample 200 cells were counted. The error bars represent the 
variation between the three sample of a triplicate. 
 
 
RoRet, Aven, Fte-1 and their deletion mutants could efficiently inhibit Bak-
induced apoptosis. 
 
 
E- Analysis of the molecular pathways by which RoRet, Aven and Fte-1 may inhibit 
apoptosis 
 
One way to analyse at which level of the apoptotic programme a certain 
protein is inhibiting cell death is to look for caspase cleavage and activation. 
1- Analysis of Caspase-9 and –3 cleavage by Western Blot 
 
In a set of different experiments I looked at Caspase-9 and ￿3 cleavage. I 
transfected 293T cells with either pcDNA3.1+, or apaf-1 M368L/caspase-9 with   105
pcDNA3.1+, ∆ roret-pcDNA3.1+, ∆ aven-pcDNA3.1+, aven-pSG5 or fte-1-pMEXneo. 
The next day I lysed the cells and looked in Western Blot for procaspase-9 cleavage. 
The results of the three Western Blots shown below lack data about RoRet full length, 
because at this time the full length cDNA was not available. 
 
 
Fig. 31: 1x10
6 293Tcells were transfected  with 0,3 µ g  apaf-1M368L+ 0,3 µ g 
caspase-9 + 1,2 µ g  protector plasmid DNA (aven,  fte-1 and ∆ roret) by the PEI 
method. The following day cells were lysed and procaspase-9 cleavage was analysed 
by Western Blot with an anti-Caspase-9 antibody (1/1000) from Pharmingen, and 
anti-rabbit secondary antibody (1/2000) from Amersham. 
 
I observed that pro-Caspase-9 was disappearing when cells over- express 
Apaf-1 M368L and Caspase-9. The levels of procaspase-9 were maintained like in 
healthy cells when the protecting proteins (Aven, Fte-1 and ∆ RoRet) were 
overexpressed together with Apaf-1 M368L and Caspase-9, even though a faint band 
at the correct size of the large subunit of Caspase-9 (p39) was still visible, suggesting 
that the inhibition was not complete. It is unclear why this p39 band was not visible in 
the cells transfected with apaf-1 M368L/caspase-9 only cells. A possibility would be 
that the cells are completely dead and that the proteins are already partly degraded. 
 
I then looked at endogenous Caspase-3 cleavage by Western Blot. In this 
experiment I used RKO cells because they are sensitive to FasL-induce apoptosis and 
have a detectable amount of endogenous Caspase-3. Therefore, they need to be   106
transfected only with the protector gene, while in the previous experiment it was 
important to reach a high transfection efficiency which is possible in 293T cells but 
not in RKO cells.  
 
 
 
Fig. 32: 1x10
6 RKO cells were transfected with 1 µ g pcDNA3.1+, 1 µ g  ∆ roret-
pcDNA3.1+,  1 µ g ∆ aven-pcDNA3.1+, 1 µ g aven-pGS5, or1 µ g fte-1-pMEXneo. The 
next day, cells were treated with 10 ng/ml FasL, 1 mg/ml anti-FLAG antibody and 0.1 
µ g/ml cycloheximide with or without zVAD-fmk. 16 h later the cells were collected 
and lysed. Cell lysates were analysed for Caspase-3 cleavage by Western Blot using 
anti-Caspase-3 antibody (1/1000) from Santa Cruz (and anti-rabbit antibody (1/2000) 
from Amersham). 
 
In this experiment the disappearance of the pro-Caspase-3 band was taken as a 
measure for pro-Caspase-3 cleavage. As can be seen in Fig. 32, ∆ RoRet and ∆ Aven 
could inhibit in part procaspase-3 cleavage, whereas Aven and Fte-1 were ineffective 
to do so when killed by FasL-induced apoptosis.  
 
2- Inhibition of Caspase-9 and – 3 activity by Aven, RoRet and Fte-1 
 
Caspases are enzymes whose activity can be inhibited either by preventing 
their cleavage and subsequent activation, or by inhibiting the activity of the already   107
active enzyme. The difficulty to assess a real difference in the amount of cleaved 
Caspase-9 or ￿3 lead to the hypothesis that the inhibition may take place after the 
cleavage, and would affect enzyme activity. Therefore, I looked for caspase activity 
inhibition in 293T cells. I transfected 293T cells with pEGFP-N1, or bak-gfp with 
pcDNA3.1+,  ∆ roret-pcDNA3.1+,  roret-pcDNA3.1/GS,  ∆ aven-pcDNA3.1+,  aven-
pSG5 or fte-1-pMEXneo. The next day I lysed the cells and measured Caspase-9 and -
3 activity using fluorescent peptides as specific substrates. 
 
 
 
Fig. 33: 1x10
6 293T cells were transfected  with 0,5 µ g bak-gfp + 1,5 µ g  protector 
plasmid DNA by the PEI method. The following day cells were pelleted and lysed to 
perform Caspase-9 (A) and Caspase￿3 (B) activity assays. The error bars represent 
the variability between three independent experiments.  
 
I observed that ∆ RoRet, RoRet, ∆ Aven, Aven and Fte-1 inhibited Caspase-9 
activity. Caspase-3 activity could only be efficiently blocked by ∆ RoRet, RoRet and 
∆ Aven, while Aven and Fte-1 gave different results in different experiments 
permitting no definitive conclusion. Moreover, I observed that only RoRet was 
inhibiting caspase-9 and ￿3 activity in RKO cells treated with FasL (data not shown).   108
∆ Aven and Aven were sometimes inhibiting UV-induced Caspase-3 activty, but the 
variability of the outcome in these experiment did not permit a conclusive analysis of 
these data. 
Taken together, the protection assays, the Western Blots analysis and the 
caspase activity results suggest that while RoRet seems to inhibit apoptosis induced 
by a wider range of stimuli (Bak, Apaf-1/Caspase-9, FasL and sometimes UV). Aven 
inhibits only Bak- and Apaf-1/Caspase-9-induced apoptosis at the level of Caspase-9 
activity. Moreover ∆ Aven is always more potent in inhibiting apoptosis than the full 
length Aven, while ∆ RoRet and RoRet seem to be equally capable to inhibit 
apoptosis. Strangely, despite inhibition of apoptosis and Caspase-9 activity, no 
inhibition of Caspase-3 activity could be seen with Aven full length (not explainable). 
Fte-1 can also inhibit apoptosis at the level of Caspase-9 activation, induced 
by Bak or Apaf-1 M368L/Caspase-9 expression. 
 
 
F- Cellular localization of RoRet, Aven and Fte-1, and analysis of their possible 
interaction with Apaf-1. 
 
The next interesting question was to determine how RoRet, Aven and Fte-1 
can inhibit apoptosis mechanistically. The clones were isolated during a survival 
screen using CED4 as the ￿killer protein￿. CED4 is homologous to the activated form 
of Apaf-1, therefore one possibility is that the protecting proteins might interact with 
Apaf-1, thereby blocking apoptosome activation.  
 
 
1- Apaf-1 interaction studies of RoRet, Aven and Fte-1 in a Two-hybrid system. 
 
One method to study direct interaction between two proteins is to use the Two-
Hybrid assay. This method is based on the fusion of one protein to the DNA binding 
domain of a transcription factor and of the fusion o the other protein to the 
transactivation domain of the same transcription factor, in this case deletion mutants 
of Apaf-1 on one side and ∆ roret,  ∆ aven and fte-1 on the other side. If the two 
proteins bind to each other, the transcription factor is reconstituted and transcription 
of specific reporter genes can take place. Here I cloned ∆ roret, ∆ aven and fte-1 in 
pGADT7 yeast expression vector fusing the proteins to the activation domain of the 
Gal4. Separately I obtained different deletion mutants of Apaf-1 fused to the DNA 
binding domain of the Gal4. These constructs had been cloned into the pAS2-1 yeast 
expression vector (kindly provided by Dr. Seamus Martin, National University of 
Ireland, Maynooth, Co. Kildar, Irland).  These Apaf-1-deletion mutants contained-in 
different combinations-(shown below in Fig. , A) the important domains of Apaf-1: 
the CARD domain that binds to Caspase-9, the CED4 homology domain NB-ARC, 
the linker stretch between the CED4 homolog domain and the WD40 repeat domain, 
and finally the WD40 repeat domain. I then co-transformed by the LiAc method AH-
109 S. cerevisiae with my protecting prey constructs together with the different Apaf-  109
1 mutants, and tested protein-protein interaction by growth on DOBA, -His, -Trp, -
Leu  selective medium. In addition, I performed a β -galactosidase assay. Histidine 
and β -galactosidase served as reporter genes activated by the potentially reconstituted 
Gal4 transcription factor. A positive interaction can be translated by growth on ￿His 
medium and detection of β -galactosidase activity. 
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Fig. 34: (A) The yeast two-hybrid system was used to look for binding of  ∆ Aven and 
∆ RoRet to Apaf-1 and to map the region of the putative Apaf-1 binding site.  ∆ aven, 
∆ roret and fte-1 were co-transfected with several Apaf-1 deletion mutants into the 
yeast strain AH109. Protein interactions were assayed by growth on yeast medium 
lacking histidin and  by β -galacotisidase activity. The table summarizes the different 
Apaf-1-deletion mutant constructs. (B) The picture show Fte-1 interaction with two 
deletion mutants (AC and ACL).  
 
From these results in yeast I conclude that only Fte-1 shows direct binding to 
Apaf-1 in the region between the CED4 like domain and the WD40 repeat domain. 
Nevertheless, Fte-1 showed no binding with the deletion mutant containing the linker 
together with the WD40 repeat region, suggesting that this domain which may 
prohibit binding of Fte-1 to the linker by steric hinderance. ∆ RoRet showed no 
binding to Apaf-1 in the yeast two-hybrid assay. ∆ Aven shows weak binding to the 
CED4-like domain of Apaf-1, yeast cells grew slowly and the β -galacotisidase 
activity assay was positive in one out of two experiments, the filter turning blue after 
a long time (more than 10 hours). It is altogether possible that ∆ Aven binds to Apaf-1, 
but this binding in yeast cells is very weak (+/-), suggesting that some post-
translational modifications take place in mammal cells that are necessary for this 
interaction and which are missing in yeast. 
 
 
2- Analysis of the potential interaction of RoRet, Aven and Fte-1 with Apaf-1 
using the GST-pull down method 
 
One possibility is that Aven and RoRet are not directly binding to Apaf-1, but 
require an intermediate protein which would explain the negative results obtained in 
the yeast-two-hybrid system. This can be tested using a GST-pull down assay by 
incubating GST-fusion proteins with adequate cell lysate (with activated Apaf-1). 
Therefore, I cloned ∆ roret, ∆ aven and fte−1  into the pGEX-AHK vector, fusing them 
to the GST coding sequence. I then expressed the GST-fusion proteins in BL21 
bacteria (mini-GST expression). Upon IPTG treatment, these bacteria can be induced 
to express the GST-fusion proteins, which are later used for the pull down. 
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Fig.35: (A) ∆ roret-pGEX-AHK,  ∆ aven-pGEX-AHK and fte-1-pGEX-AHK were 
transformed into the BL21 bacterial strain by electroporation. Four to six colonies of 
each construct were chosen for protein expression. GST-fusion proteins were then 
purified using GST coupled agarose beads, and an aliquot of the purified proteins was 
loaded on a polyacrylamid/SDS gel to verify protein expression levels. (B) GST-
fusion proteins were used for a pull down experiment with 293T cells lysate. After 
several washing steps, beads were loaded on a  polyacrylamid/SDS gel to perform a 
Western Blot analysis and to look for binding of endogenous Apaf-1 to ∆ RoRet, 
∆ Aven et Fte-1 (anti-Apaf-1 from Pharmingen) presence. 
 
GST-fusion proteins expression was sufficient for ∆ RoRet-GST and ∆ Aven-
GST (Fig. 35, A), but Fte-1-GST could only be poorly expressed and gave high 
amounts of smaller proteins that may be explained by protein degradation or cleavage.  
In figure (Fig. 35, B) I show a representative blot for the GST pull down with   
∆ RoRet-GST, ∆ Aven-GST and  Fte-1-GST.  ∆ Aven and Fte-1 may bind to Apaf-1, 
while the background band obtained with ∆ RoRet is quite fainter and the negative 
control shows a high background band, as a result of Apaf-1 binding to GST alone.  
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3- Co-immunoprecipitation of RoRet, Aven and Fte-1 with Apaf-1. 
 
The next step was to try a mammalian co-immunoprecipitation system. I 
decided to clone roret,  aven and fte-1 in the pEGFP-N1 vector (see material and 
methods) fusing them to the Green Fluorescent Protein (GFP) at their C-terminal end. 
I tried to co-immunoprecipitate the GFP-fused proteins with Apaf-1 by either using an 
anti-GFP antibody or the other way round by using an anti-Apaf-1 antibody. 
 
 
Fig. 36: 293Tcells were transfected  with 3 µ g apaf-1 plus 9 µ g  ∆ aven-pEGFP-N1 by 
the PEI method, 24 hours later cells were lysed and ∆ Aven-GFP was co-
immunoprecipitated with anti-Apaf-1 antibody from Santa Cruz. The GFP antibody 
used in the blot was purchased from Roche. 
 
As shown in Fig. 36, I could co-immunoprecipitate ∆ Aven-GFP  together with 
Apaf-1 with an anti-Apaf-1 antibody, but I could not co-immunoprecipitate either 
∆ RoRet-GFP, RoRet-GFP or Fte-1-GFP with Apaf-1 (data not shown). Another 
experiment when I tried to co-immunoprecipitate FLAG-∆ RoRet and FLAG-RoRet  
with Apaf-1 (with anti-FLAG antibody or with anti-Apaf-1 antibody) was not 
successful either, but led to the hypothesis that RoRet may be cleaved in the cell (data 
not shown). It is still possible that RoRet may interact with Apaf-1, but the conditions 
under which this interaction would be detectable still have to be determined. The 
results from the yeast Two-Hybrid assay suggest that Fte-1 and Apaf-1 are interacting 
directly. 
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4- Cellular localization of RoRet, Aven, Fte-1 and their deletion mutants, and co-
localization studies with Apaf-1 and Caspase-9 by confocal microscopy  
4.1-Co-localization of RoRet, Aven, Fte-1 with Apaf-1 or Caspase-9 
 
 I decided to look for co-localization of RoRet, Aven and Fte-1 with Apaf-1 
and with Caspase-9 using confocal laser scanning microscopy, as well as define the 
cellular localization of RoRet, Aven, Fte-1 using the GFP-tagged versions of them. 
All the subsequent analysis were done using the sequential mode of channel detection. 
As a control I stained the cells with the secondary antibody only and in this case a 
very weak background could be detected that was easily distinguishable from the 
much stronger specific signals. 
 
 
Fig. 37: 1x10
6  293T cells (grown on thin-bottom plates) were transfected with   
∆ Aven-GFP by the PEI method. The following day, cells were fixed with 
formaledhyde and stained with anti-Apaf-1 (Pharmingen) and anti-rabbit-546 
(Molecular Probes) (A) or with anti-Caspase-9 (Pharmingen) and anti-rabbit-546 
(Molecular Probes) (B). I then looked for co-localization by confocal laser scanning 
microscopy. The two images obtained were combined (merged) and co-localization 
was detected by the change of colour (here yellow). 
 
∆ Aven is located in the cytoplasm in a spotted fashion, suggesting some 
aggregates or organelle location (see Fig. 37). No ∆ Aven was detected in the nucleus. 
Apaf-1 showed also a cytoplasmic profile, again spotted rather than diffused. Apaf-1   114
concentration increased around the nucleus and in a compact area near the nucleus. 
Caspase-9 was found in the cytoplasm and in some cells in the nucleus. It is important 
to point out that Apaf-1 and Caspase-9 detected in these experiments are the 
endogenous proteins. The merged pictures for ∆ Aven and Apaf-1 showed yellow 
spots suggesting that ∆ Aven and Apaf-1 are partly co-localizing, whereas the merging 
picture for ∆ Aven and Caspase-9 show a clear co-localization of both proteins. 
  
 
 
Fig. 38: 1x10
6  293T cells (grown on thin-bottom plates) were transfected with  fte-1-
gfp by the PEI method. The following day, cells were fixed with formaledhyde and 
stained with anti-Apaf-1 (Pharmingen) and anti-rabbit-546 (Molecular Probes) (A) or 
with with anti-Caspase-9 (Pharmingen) and anti-rabbit-546 (Molecular Probes) (B). I 
then looked for co-localization of Fte-1 with Apaf-1 and Caspase-9 using confocal 
laser scanning microscopy. The two images obtained were combined (merged) and 
co-localization was detected by the change of colour towards yellow. 
 
 
Fte-1-GFP can be detected in a well-defined compartment that looks like the 
endoplasmic reticulum or the Golgi (see Fig. 38). The specific staining of these 
compartments in future experiments will tell which organelle these structures really 
represent. In this experiment, yellow areas indicating co-localization could be 
detected at the compartment described above in the merged picture for Fte-1 and 
Apaf-1 (see Fig, 38, A), whereas no clear co-localization could be detected for fte-1 
and Caspase-9 (see Fig. 38, B). Martinez-A et al., described Apaf-1 localizing at the   115
Golgi but not the ER in cells expressing Bcl-2, whereas in cells without Bcl-2 (from 
knockout mice) Apaf-1 was diffused in the cytoplasm (Ruiz-Vela, Albar et al. 2001).  
 
Fig. 39: 1x10
6  293T cells (grown on thin-bottom plates) were transfected with   
∆ roret-gfp by the PEI method. The following day, cells were fixed and stained like in 
the previous experiment (see e.g. Fig. 37) I then looked for co-localization by using 
confocal laser scanning microscopy.  
 
∆ RoRet-GFP shows a diffuse cytoplasmatic and a clear nuclear localization. 
Nevertheless, the merged picture is ambiguous and no conclusion about  ∆ RoRet 
localization with either Apaf-1 or Caspase-9 can be drown.  
 
 
4.2- Are Aven, RoRet and Fte-1 localized in the apoptosome ? 
 
I investigated whether Aven, RoRet and Fte-1 co-localize simultaneously with 
Apaf-1 and Caspase-9 in the apoptosome complex which is formed after Cytochrome 
c release during the apoptotic process. For this purpose I used the sequential scanning 
mode (that measure the different fluorescence channels sequentially) in confocal laser 
scanning microscopy. I stained 293T cells co-transfected with the gfp-fusion 
constructs,  caspase-9 and apaf-1 M368L with antibodies suitable for 
immunohistochemistry.  
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Fig. 40: (A) 293T cells were stained for endogenous Apaf-1 with an anti-Apaf-1 
antibody from Santa Cruz and anti-goat-564 antibody from Molecular Probes. (B) 
293T cells were stained for endogenous Caspase-9 with anti-Caspase-9 antibody from 
Pharmingen and anti-rabbit-633 antibody from Molecular Probes. 
 
The experiment shown in Fig. 40 proves the specificity of the anti-Apaf-1 and 
anti-Caspase-9 antibodies used. Moreover, the localization of both Apaf-1 (cytosolic) 
and Caspase-9 (cytosolic and nuclear) were in accordance with the published 
observations of other groups (Ritter, Marti et al. 2000; Ruiz-Vela, Albar et al. 2001). 
The colour code in the following experiments is as follows: green for the GFP fusion 
proteins (∆ RoRet-GFP,  ∆ Aven-GFP and Fte-1-GFP), red for Apaf-1, blue for 
Caspase-9, yellow for co-localization of the GFP fusion proteins with Apaf-1, light-
blue for co-localization of the GFP fused proteins with Caspase-9, lila for co-
localization of Apaf-1 with Caspase-9 and white for simultaneous co-localization of 
the GFP fusion protein with Apaf-1 and Caspase-9.  
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Fig. 41: 1x10
6 293T cells, grown on thin-bottom culture plates, were transfected with  
Apaf-1M368L plus caspase-9 plus ∆ Aven-gfp by the PEI method. The following day, 
cells were fixed with formaldehyde and stained with anti-Caspase-9 antibody 
(Pharmingen) plus anti-rabbit-633 antibody (Molecular Probes), or anti-Apaf-1 
antibody (Santa Cruz) plus anti-goat-564 antibody (Molecular Probes). We then 
looked for co-localization (merged picture) by using confocal laser scanning 
microscopy (sequential scanning mode).  
 
Co-localization of Apaf-1 with Caspase-9 was detectable (lila colour) only in 
those cells with Apaf-1 and Caspase-9 overexpression. In such cells that also 
expressed ∆ Aven-GFP, white streaks were detectable in the cytoplasm suggesting co-
localization of all three proteins (see Fig. 41).  
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Fig. 42: 1x10
6 293T cells, grown on thin-bottom culture plates, were transfected with  
Apaf-1M368L+ caspase-9 + fte-1-gfp by the PEI method. Subsequently, cells were 
fixed and stained as before with anti-Caspase-9 antibody (Pharmingen) plus anti-
rabbit-633 antibody (Molecular Probes), or anti-Apaf-1 antibody (Santa Cruz) plus 
anti-goat-564 antibody (Molecular Probes), and analysed for co-localization (merged 
picture) by using confocal laser scanning microscopy (sequential scanning mode).  
 
 
In the experiment shown in Fig. 42 the result was less clear. In some cells 
white areas (Fte-1-GFP, Apaf-1 and Caspase-9 co-localization)could be detected, in 
others (not shown) only yellow areas (co-localization of Fte-1-GFP with Apaf-1) was 
observed. Moreover, the white areas co-exist with green ones within some cells, 
suggesting that only a specific pool of Fte-1-GFP co-localizes with Apaf-1 and/ or 
with Caspase-9. Numerous lila areas confirm the expected Apaf-1 and Caspase-9 co-
localization. 
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Fig. 43: 1x10
6 293T cells, grown on thin-bottom culture plates, were transfected with  
Apaf-1M368L+ caspase-9 + ∆ roret-gfp by the PEI method. Subsequently, cells were 
fixed and stained as before with anti-Caspase-9 antibody (Pharmingen) plus anti-
rabbit-633 antibody (Molecular Probes), or anti-Apaf-1 antibody (Santa Cruz) plus 
anti-goat-564 antibody (Molecular Probes). They were analysed for co-localization 
(merged picture) using confocal laser scanning microscopy (sequential scanning 
mode). 
 
∆ RoRet-GFP seems to co-localize with caspase-9 (light blue areas) but not 
with Apaf-1 (yellow areas were rarely detected only in dying cells). No white areas 
could be detected (see Fig. 45). 
 
Full length RoRet-GFP  showed a largely punctuated pattern that looks similar 
to some vesicular structure (see Fig. 43). Further characterization of theses organelles 
should tell what they exactly are. RoRet-GFP could also be detected in the nucleus of 
a few cells. The dramatically different localization pattern of ∆ RoRet-GFP and 
RoRet-GFP (data not shown), suggesting the presence of a cytoplasmic localization 
signal in the amino-acid sequence of RoRet that must be deleted in the ∆ RoRet 
mutant. 
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A. 
 
 
 
 
 
 
 
 
 
 
 
 B.  
 
 
Fig. 44: (A) 1x10
6 293T cells, grown on thin-bottom culture plates, were transfected 
with  Apaf-1M368L+ caspase-9 + roret-gfp by the PEI method. Subsequently, cells   121
were fixed and stained as before with anti-Caspase-9 antibody (Pharmingen) plus 
anti-rabbit-633 antibody (Molecular Probes), or anti-Apaf-1 antibody (Santa Cruz) 
plus anti-goat-564 antibody (Molecular Probes), and analysed for co-localization 
(merged picture) using confocal laser scanning microscopy (sequential scanning 
mode). (B) The same experiment as shown in A presented with a larger 
magnification.  
 
As for ∆ RoRet-GFP, light blue areas show co-localization of RoRet-GFP with 
Caspase-9, but no white areas could be detected, which would indicate simultaneous 
co-localization of RoRet-GFP with Caspase-9 and Apaf-1 (see Fig. 44). Lila areas 
show again that Apaf-1 and Caspase-9 co-localize. It is also to note that some 
remaining green spots in the merged picture show that only a certain pool of RoRet-
GFP co-localizes with Caspase-9. 
 
G-Possible involvement of Aven, Fte-1 and RoRet in mammary gland development 
and/or tumourigenesis 
1-Mammary gland development 
 
Aven, RoRet and Fte-1 were indentified in a breast tumour cDNA library, 
which may indicate that these genes are  involved in mammary gland development. I 
first looked for Aven expression during mouse mammary gland development. For this 
purpose, I used a mRNA Northern Blot from Clontech with RNA samples prepared 
from female mouse mammary glands during different developmental stages. 
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Fig. 45: Different mRNA preparations of mammary glands from non-pregnant (NP), 
pregnant (E7-E17), lactating (1WL, 2WL) and involuting (1dI-5dI) mice were used 
for Northern Blot analysis. The membrane was hybridized sequentially with cDNA 
probes for mouse ∆ aven, β -actin and gapdh. aven RNA expression was normalized to 
β -actin (grey bars) or gapdh (black bars) RNA levels. Hybridization signals were 
quantified with a BIO RAD phosphoimager. 
 
Down regulation of aven mRNA was clearly visible during lactation and 
during the time of involution, when the glands undergo apoptosis. aven expression 
levels show a tendency to increase again during the late days of involution (day 5). 
The same experiment is planned for Fte-1 and RoRet. 
 
2- Kim-2 cells as an in vitro model for differentiation and apoptosis induction in 
the mammary gland 
 
I used the published model system of KIM-2 cells to mimic differentiation and 
apoptosis induction in mammary gland (Gordon, Binas et al. 2000). I cultured Kim-2 
cells in differentiating medium for two weeks and then drove them into apoptosis by 
removing the lactogenic hormones. Then I studied Aven expression during these 
different steps (undifferentiated, differentiated and apoptotic) by Western Blot.  
 
Fig. 46: Kim-2 cells were grown in normal medium, differentiated for two weeks in 
differentiation medium and driven into apoptosis by removal of cytokines as 
published [Gordon, 2000 #9113]. At each step of differentiation, cell lysates were 
prepared, and Aven expression was studied in western blot.  
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I found that Aven slightly decreases in differentiating cells, and significantly 
decreases in apoptotic cells. A lower band that seems to be specific appears only in 
undifferentiated cells. As it is described that only about 30% of the cells undergo 
apoptosis, it is also possible that the remaining Aven comes from the non-apoptotic 
cells 
 
 
2-Aven, Fte-1 and RoRet expression in tumours 
2.1- The cancer profiling arrays 
 
Aven, Fte-1 and RoRet were isolated during a survival screen using a breast 
cancer cDNA library. The idea was that in such a library some anti-apoptotic genes 
important for tumourigenesis and survival of the tumours would be overexpressed 
(gain-of-function). As  number of anti-apoptotic proteins have been correlated with 
tumourigenesis, I tested the possible implication of my clones in this context. For this 
I analysed the expression levels of my clones in tumour versus the normal tissue.  
To analyse mRNA expression levels in normal and tumour tissue I used the 
Cancer Profiling Array from Clontech. This array contains many cDNA pairs of 
tumour and normal tissue of a single patient. The membrane was hybridzed with 
32[P]-labelled cDNA probes of human ubiquitin (supplied by Clontech), human 
∆ aven, human c-myc, human ∆ roret  and human fte-1 according to the supplier·s 
protocol.  
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Fig.47: A Cancer Profiling Array from Clontech was hybridized with a 
32[P]-labelled 
∆ aven probe. cDNA synthesized from different tumour RNAs was spotted pairwise 
on the array together with cDNA derived from corresponding normal tissue of the 
same patient. In total, 42 tumours of the uterus, 35 colon cancers, 27 stomach cancers, 
14 tumours of the ovary, 1 cervix carcinomas, 21 lung carcinomas, 20 renal 
carcinomas, 18 adenocarcinomas of the rectum, 2 tumours of the small intestine, 6 
thyroid gland carcinomas, 4 prostate carcinomas and 1 pancreas carcinoma were 
screened for potential  upregulation. 
 
The same membrane was stripped and re-hybridized up to three times with a 
different cDNA probe. Radioactive intensity was then quantified each time with a 
BIO RAD phosphoimager and I calculated for each sample the ratio between the 
signal strength for the intensity for the tumour and the normal tissue. The results are 
pictured below as EXEL graphs. 
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Fig. 48: A Cancer Profiling Array from Clontech was hybridized with a 
32[P]-labelled 
∆ aven, c-myc, ∆ roret, fte-1 and ubiquitin probe. cDNA synthesized from different 
tumour RNAs was spotted pairwise on the array together with cDNA derived from 
corresponding normal tissue of the same patient. Hybridization signals were 
quantified with a BIO RAD phosphoimager. Represented in the figure are the ratios 
between the signal strength of tumour and normal tissue. Values greater than one 
indicate  aven tumour overexpression. For additional controls the array was re-
hybridized with probes for the bona fide oncogene c-myc and ubiquitin as house 
keeping gene. 
 
I observed upregulation of aven in tumours of the uterus, colon and kidney. 
fte-1 mRNA levels were upregulated in colon, lung and kidney cancers and roret 
mRNA in uterus, stomac and kidney cancers. These data have to be confirmed at the 
protein level in tumour samples by Western Blotting.  c-myc is as expected   126
upregulated for example in colon cancer (Russo, Arzani et al. 2003), but it was a 
surprise to observe some regulation in the  ubiquitin levels as well (e.g. upregulation 
in kidney tumours). These results are of course only indicative which tumour entities 
might be worth of further analysis on the protein level. For this reason I started to 
collect samples of normal tissue/tumour pairs of breast, colon and kidney. 
 
 
2.2- Western Blots analysis of tumour lysates 
 
 
 
 
 
Fig. 49: Aven protein expression in human mammary carcinomas. 40 ￿g of protein 
lysates from normal breast tissue (p7a, p9a, p11a, N1, N2, N3) from breast reductions, 
primary breast tumours (83, 167, 249, 250, 256, 611, 876, 1096, 1132) and breast 
tumours passaged in nude mice (T13, T27, T48, T83, T130, T136, T236) were 
analysed in a Western blot experiment with an anti-Aven B antibody kindly provided 
by Dr. Marie Harwick (Johns Hopkins University, Baltimore, USA). As a loading 
control, the membrane was rehybridized with an anti-HSP27 antibody. For more 
detail about the sample provenance see Material and methods, Protein lysates from 
tumour samples. 
 
  An upregulation of Aven could be detected in the breast tumours passaged in 
nude mice. No real difference could be seen in the Aven expression level of normal 
tissue and primary mammary carcinoma. Hsp 27 was used as a loading control, but 
showed variations in its expression. Actin and tubulin (data not shown) also showed 
variations in their expression level. 
 
 
 
IV-Identification of HMGB1 in a yeast survival screen as an apoptosis-inhibiting 
protein. 
1-A yeast survival screen with Bak as the “killer” protein led to isolation of 
HMGB1 
 
 
We wanted to employ functional yeast survival screens to identify new anti-
apoptotic mammalian genes out of tumour-derived libraries as described in the 
previous part of my work. To test the system, we originally used an inducible Bak   127
expression system in S. pombe to screen a cDNA library prepared from exponentially 
growing NIH3T3 mouse fibroblasts. Altogether 5x10
4 transformed yeast clones were 
tested for Bak-resistance in a non-saturated library screen. One of the S. pombe 
colonies surviving Bak expression after library transformation contained a truncated 
deletion mutant of the mouse Hmgb1 gene lacking the C-terminal 33 amino acids. 
This ∆ Hmgb-1 deletion mutant does not represent a naturally occuring mRNA variant 
but was rather generated in the cloning process when the oligo-dT primer annealed 
within the Hmgb1 coding sequence during reverse transcription of the RNA. 
∆ HMGB1 still contains the two HMG-boxes identified in the full length HMGB-1 
while the highly acidic C-terminal tail is deleted. I cloned mouse ∆ hmgb-1 and mouse 
full length Hmgb1 in a constitutive S. pombe expression vector and further analyzed 
∆ HMGB1-conferred protection in Bak expressing yeasts. When Bak expression is 
induced in the S. pombe yeast strain DSI growing on agar plates, the yeast cells die 
within 48 hours. Co-expression of either ∆ HMGB1 or full length HMGB1 protects 
the yeast colonies from Bak-induced cell death (Fig.50 , A). 
 
Fig. 50: Functional S. pombe yeast survival screen with inducible bak expression. A: 
Principle of the screen: The S. pombe yeast strain DSI was transformed with an NIH 
3T3 mouse fibroblast-derived cDNA library and plated on thiamine-containing agar 
plates to allow growth of the colonies (bak off). Replica-plating onto thiamine-free 
agar plates induced bak and library cDNA expression. Only those yeast colonies 
which were protected against Bak-induced cell death survived. Untransformed or 
pArt1 empty vector-transformed DSI yeast colonies, when replica-plated onto 
thiamine-free agar plates, died upon induction of bak. B: A Hmgb-1 deletion mutant   128
lacking the C-terminal 33 amino acids (∆ Hmgb1) was identified in the screen and - 
like full length Hmgb1 - protects DSI yeast cells against Bak-induced cell death. 
 
I also measured growth curves of the different yeast strains in liquid culture. S. 
pombe cells cease growth upon Bak expression (DSI,  -T) (Fig. 50, B). When co-
expressing ∆ HMGB1 or full length HMGB1 the Bak transformed yeasts continued to 
grow exponentially, as they do when the Bak-antagonist Bcl-xL is co-expressed. I then 
performed Western- and Northern blot analysis to confirm expression of HMGB-1 
and Bak in the yeast strains we had used for the experiments (Fig. 50, C and D). I 
could detect full length HMGB1 protein in the transformed yeasts but the anti-
HMGB1 antibody did not recognize ∆ HMGB1 due to the C-terminal deletion. 
Induction of bak transcription in the DSI S. pombe strain leads to the production of 
small amounts of bak mRNA and protein sufficient to kill the DSI strain. In DSI cells 
co-transformed with ∆ Hmgb1  a much higher amount of Bak RNA and protein is 
detectable and - in the presence of ∆ HMGB1 - tolerated by the yeast cells. 
Interestingly, I was unable to detect Bak expression in DSI yeast colonies co-
transformed with full length Hmgb1.  
These results show that full length HMGB1 and ∆ HMGB1 protect S. pombe 
cells against Bak-induced yeast killing. While we cannot rule out that the protective 
effect of full length HMGB1 involves transcriptional downregulation of the Bak yeast 
expression construct, the largely increased amount of Bak in ∆ hmgb-1 co-transformed 
yeast cells indicates protection by ∆ HMGB1 against the Bak protein by another 
mechanism. Moreover, yeast transformed with HMGB1 and bak-gfp are still green 
(data not shown) suggesting that the mechanism of protection does not involved 
transcriptional downregulation of bak mRNA. 
 
 
2-HMGB1 protects mammalian cells against Bak-induced apoptosis 
 
Next I wanted to investigate whether HMGB1 is able to suppress cell death 
upon Bak overexpression not only in yeast but also in mammalian cells. For this 
experiment I used the human colon carcinoma cell line RKO. Transient transfection 
of RKO cells with Bak alone induced apoptosis which was blocked by co-transfection 
of either ∆ Hmgb1 or full length Hmgb1. The percentage of dead cells was measured 
with the LIVE/DEAD assay in fluorescent microscopy (Fig. 51, A) and by PI staining 
in FACS (Fig. 51, B).   129
Fig. 51: HMGB1 and ∆ HMGB1 inhibit Bak-induced apoptosis in RKO cells. A: RKO 
cells were seeded in 6-well plates at 1x10
6 cells/well. The next day 0.5 ￿g gfp-bak 
cDNA together with 1.5 ￿g of either empty vector pcDNA3.1, Hmgb1, ∆ Hmgb1 or 
bcl-xL cDNA were transfected using FUGENE (Roche). 16 hours later cells were 
collected (including floating cells) and the percentage of dead cells was determined 
using the LIVE/DEAD Viability/Cytotoxicity kit from Molecular Probes. Co-
transfection of both Hmgb1 and ∆ Hmgb1 reduced the level of apoptosis to the same 
extent as did transfection of the bona fide inhibitor of Bak-killing, bcl-xL. B: 
Quantification of a similar experiment as shown in A by a different method. Dead 
cells were counted by FACS analysis after ethanol fixation and propidium iodide 
staining. Apoptotic cells appear in the hypoploid sub-G1 peak. Results shown in A are 
from 3 independent experiments, and results shown in B represent one of three 
experiments with similar results. 
 
HMGB1 was as effective in inhibiting Bak killing as was Bcl-xL in control co-
transfections (see Fig. 51). The experiment was repeated with a different method to 
detect apoptotic cell death and the results were confirmed. Interestingly, endogenous 
HMGB1 is expressed at a relatively high level in RKO cells (data not shown), yet   130
further elevation of the HMGB1 level rescued RKO cells from apoptosis induced by 
bak transfection. 
These data indicate that the protection conferred by HMGB1 in yeast against 
Bak-induced cell death is a general phenomenon observable also in mammalian cells. 
The overall low numbers of apoptotic cells  in the experiment shown in Fig. 51, B are 
probably due to the poor transfection efficiency obtained in RKO cells. 
 
 
3-Correlation between HMGB1 expression and tumourigenesis 
 
Mutational activation of anti-apoptotic proteins is one possible mechanism 
through which transformed cells evade apoptosis and propagate to form tumours. 
Since HMGB1 protects against Bak-induced cell death in mammalian cells I analyzed 
HMGB1 protein levels in normal breast and in primary breast carcinoma material by 
performing Western blot experiments (Fig.52). I examined six different samples 
derived from normal breast tissue and they showed hardly any detectable HMGB1 
protein (first six lanes). In comparison, of nine primary breast carcinomas tested, all 
expressed HMGB1, six of them in high amounts. I also examined seven human breast 
carcinomas which were passaged for a long time in nude mice. Such passaging of 
tumour cells in mice is regarded as an artificial model for tumour metastasis, i.e. 
genes important for metastasis become upregulated.  
 
 
 
 
 
 
 
 
Fig. 52: HMGB1 protein overexpression in human mammary carcinomas. 40 ￿g of 
protein lysates from normal breast tissue (p7a, p9a, p11a, N1, N2, N3), primary breast 
tumours (83, 167, 249, 250, 256, 611, 876, 1096, 1132) and breast tumours passaged 
in nude mice (T13, T27, T48, T83, T130, T136, T236) were analyzed in a Western 
blot experiment with an anti-HMGB1 antibody (PharmMingen). As a loading control, 
the membrane was rehybridized with an anti-HSP27 antibody (Santa Cruz). 
 
All seven passaged breast tumours expressed high HMGB1 protein levels. 
 
These expression data suggest that the HMGB1 protein is indeed upregulated 
in human breast carcinomas and that it is expressed constantly at a high level in a 
tumour transplantation model. 
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Since HMGB1 protein levels were elevated in breast carcinomas compared to 
normal breast tissue, I examined other tumour entities for HMGB1 mRNA 
upregulation. For this purpose I hybridized a human cancer array with a 
32[P]- labelled 
Hmgb1 cDNA probe (Fig. 53). Onto this cancer array equal amounts of cDNAs 
prepared from human tumour and corresponding normal tissue of the same patient 
were spotted in a pairwise fashion. The array represented a large collection of 
different tumours that were screened for HMGB1 upregulation (for detail on the 
tumour types, see The cancer profiling array). To quantifiy expression levels, 
hybridization intensities were measured with a phosphoimaging system and to 
indicate up- or downregulation of a particular gene in a certain tumour the ratio 
between the arbitrary intensity values of a tumour and of the corresponding normal 
tissue were obtained. A ratio of greater than one would represent a tumour with an 
upregulated mRNA level compared to normal tissue while values smaller than one 
indicate mRNA downregulation in a certain tumour. 
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Fig. 53: Elevated HMGB1 mRNA levels in tumours of the uterus, colon and stomach. 
A Cancer Profiling Array from Clontech was hybridized with a 
32[P]-labelled 
∆ Hmgb1 probe. cDNA synthesized from different tumour RNAs was spotted pairwise 
on the array together with cDNA derived from corresponding normal tissue of the 
same patient. Hybridization signals were quantified with a BIO RAD phosphoimager. 
Represented in the figure are the ratios between the signal strength of tumour and 
normal tissue. Values greater than one indicate HMGB1 tumour overexpression. For 
additional controls the array was re-hybridized with probes for the bona fide oncogene 
c-myc and for ubiquitin. A: Mean values of the signal strength ratio for each tumour 
entity. Uterus-, colon- and stomach-derived carcinomas show HMGB1 
overexpression. B: Expression ratios for each individual tumour. In some of the 
tumours HMGB1 mRNA is expressed up to six times higher than in the corresponding 
normal tissue. 
 
 
Fig. 53 summarizes the results for HMGB1, c-myc and ubiquitin in tumours of 
uterus, colon and stomach. For each gene, the mean ratio between several 
tumour/normal tissue pairs is represented for every tumour entity. c-myc as a bona 
fide oncogene is upregulated in tumours of the stomach and, even more prominently, 
in colon cancers. c-myc levels in tumours of the uterus appear normal. Ubiquitin 
expression in uterus and colon cancers seems to be unchanged. HMGB1 mRNA on 
the other hand is upregulated in tumours of the uterus, colon and stomach. In further 
tissues represented on the tumour array but not shown in Fig. 53 I could not detect 
significant mean upregulation of HMGB1  in the corresponding tumours although 
several individual tumours showed an obvious increase in the amount of HMGB1 
mRNA. While Fig. 53, A shows the mean ratio for each gene and tumour entity, Fig. 
53, B displays the ratio of HMGB1 mRNA expression levels between tumour and 
normal tissue for every single cancer represented on the array. Within individual 
tumours HMGB1 mRNA is upregulated up to sixfold compared to the corresponding 
normal tissue. 
 
In summary, these data imply that, in addition to HMGB-1 protein 
overexpression in breast carcinomas, HMGB1 mRNA is upregulated in tumours 
derived from uterus, colon and stomach. 
 
  Dr. Kirsten V￿lp from Dr. Martin Z￿rnig laboratory (Georg-Speyer-Haus, 
Frankfurt) and Dr. Stephan Joos from Dr. Peter Lichter (DKFZ, Heidelberg) 
performed complementary experiments to this work. Their working results combined 
with mine allowed acceptance of the manuscript “HMGB1 inhibits cell death in 
yeast and mammalian cells and is abundantly expressed in human breast 
carcinoma” in FASEB Journal (in press). See Index. 
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V-Discussion 
A-The survival screen and the selection of the isolated cDNA clones 
 
Most of human diseases and disorders are related to the apoptotic pathway 
dysfunction. The aim of this work was to identify new anti-apoptotic proteins and 
understand their mechanistic function in order to provide new targets for therapies. I 
performed a yeast survival screen to look for ￿anti-apoptotic proteins inhibiting 
downstream of Cytochrome c release (Jurgensmeier, Krajewski et al. 1997; Xu and 
Reed 1998). For the screen I used as a ￿killer￿ gene, CED4, the C. elegans homologue 
of Apaf-1 that is inducing cell death in S. pombe (James, Gschmeissner et al. 1997). 
After two rounds of selection I isolated 22 cDNA that did confer protection against 
CED4 induced yeast cell death and verified that CED4 was still expressed in these 
clones under selective conditions (Fig.15), thus preventing the isolation of false 
positive clones mutated in their genome-integrated nmt-1-CED4. They were all 
sequenced and analysed by biocomputing whereas their name, the part of the protein 
encoded and the published data records. Particularly interesting were:  the human 
RoRet / or zinc finger protein 15, the homo sapiens cell death regulator AVEN, the 
human thymosin beta 4, the  human v-fos transformation effector protein (Fte-1)/or  
40S ribosomal protein S3a, the human tumor necrosis factor/ or Lysosome-associated 
membrane glycoprotein 1 precursor ,  the  PPARγ -cofactor 2 (PGC2), the Serum 
amyloid A (SAA1-2) beta gene and the human fuse binding protein (FBP). Most of 
the cDNA clones were truncated, encoding only for a more or less extensive C-
terminal part. This was due to the fact that very often the reverse polimerase 
transcribes only partly from 3￿ end to 5￿end of the mRNA. Moreover some of the 
cDNAs were not in frame due to a base pair insertion disturbing the reading frame. 
Nevertheless some reports state that the yeast transcription machinery some times 
slips on the chromatine, permitting the transcription of a coding transcript. This 
frame-shift was later corrected by PCR. 
Because none of the identified clones were typical antiapoptotic proteins, even 
though later some would be published as displaying antiapoptotic activity like Fte-1 
and PPARγ , I made extensive literature research to determine all the known data 
about each found protein (Tab.2). I decided to discard the Thymosin beta 4, because it 
encoded for the antisense DNA strand (-/+ strand ) of the gene. Even though it would 
have been interesting to know how the antisense Thymosin beta 4 may have 
antiapoptotic activity, I decided to look for real potential antiapoptotic proteins. The 
same reason made me discard the human tumor necrosis factor/ or Lysosome-
associated membrane glycoprotein 1 precursor, because the cDNA isolated encoded 
for a sequence in the 3￿-untranslated, and the mitochondrial DNA control region. 3￿-
untranslated regions by controlling the specific decay of a mRNA have been found 
regulating cell fate (Bevilacqua, Ceriani et al. 2003; Stoecklin, Lu et al. 2003), but it 
was not the purpose of my work. I was interested in antiapoptotic proteins. From the 
literature and the CED4 expression test, I decided that the interesting clones to 
analyse would be: the RoRet, zinc finger protein 15, the homo sapiens cell death 
regulator AVEN, the v-fos transformation effector protein (Fte-1/ S3a), the PPARγ -  134
cofactor 2  (PGC2), the Serum amyloid A (SAA1-2) beta gene and the fuse binding 
protein (FBP).  
 
Indeed, Aven (Fig. 19) was just published to be antiapoptotic (Chau, Cheng et 
al. 2000) and act by binding to Apaf-1 and Bcl-XL. The article was stating that its 
activity was derived from it￿s bringing Bcl-XL and Apaf-1 together. But in my 
screening system only CED4 (or activated Apaf-1) was expressed with the C-terminal 
region of Aven. This was suggesting that Aven could by itself inhibit activated-Apaf-
1-induced apoptosis and that the deleted protein contained the inhibitory activity of  
Aven. The deletion mutant encoded by the cDNA isolated in my screen is 
corresponding to the 183 last amino-acids of Aven where the putative Apaf-1 binding 
domain was define by Harwick and Al.  
Fte-1/S3a (Fig. 20) was by then only described as encoding for a mammalian 
homologue for a yeast gene involved in protein import into mitochondria (Kho and 
Zarbl 1992) and as overexpressed in some tumour types(Kho, Wang et al. 1996). It 
was later published to have antiapoptotic (Song, Sakamoto et al. 2002) activity, even 
though the data produced in this paper were not very convincing concerning the 
mechanism proposed (that it may bind PARP and inhibit its DNAse activity).  
PGC2 is a PPARγ  cofactor found up to now only in fat tissue, and which 
function is still unknown. It was lately published that the PPARγ  receptor could play a 
role in modulating apoptosis(Padilla, Kaur et al. 2000; Goetze, Eilers et al. 2002), and 
the mechanism was shown to involve FLIP for the antiapoptotic activity (Okada, Yan 
et al. 2002).  
The serum amyloid 1 beta gene is involved in rheumatoid arthritis and 
amyloidosis (Moriguchi, Terai et al. 2001). FBP (fuse binding protein) was identified 
during another screen for antiapoptotic proteins using a different method, mentioned 
in the publication, but not further investigated in its mechanism (Brockstedt, Rickers 
et al. 1998).  
And finally RoRet (Fig. 21), was just a predicted protein, but its numerous and 
complex domains (a ring domain, a SPRY domain and a B-Box) suggested some very 
interesting functions like E3-ubiquitine ligase potential, DNA binding potential, and 
other undefined functions for the SPRY and B-Box domains. It was identified during 
the sequencing of the 1.1-Mb Transcript Map of the Hereditary Hemochromatosis 
Locus, and was named RoRet for its homology to the 52-kD Ro/SSA lupus and 
Sjogren￿s syndrome auto-antigen and the RET finger protein (Ruddy, Kronmal et al. 
1997). The cDNA isolated during my screen corresponds to the PRY-SPRYdomain.  
 
To increase the stringency of the selection, I then decided to test these clones 
in a mammalian system, against Bax induced apoptosis in 293T cells and FasL 
induced apoptosis in RKO cells. I cloned the deletion part of each gene 
(corresponding to the cDNA isolated during the survival screen) in pcDNA3.1+, a 
mammalian expressing vector, and obtained most full length genes in mammalian 
expressing vectors from various groups. The only missing clone was RoRet, which 
was later purchased from Invitrogen Corporation, ResGen. The readout of these 
various experiments was that most clones full length or deletion mutants were   135
efficient in inhibiting apoptosis induced by Bak and FasL with an efficiency of  30% 
to 50% reduction of the dead cells (Fig.16-18).  
For practical reasons I decided to reduce the number to three candidate clones. 
Based on the literature and the computational analyses, I finally decided to follow 
Aven as a new promissing anti-apoptotic molecule in collaboration with Dr. M. 
Harwick (Johns Hopkins University, Baltimore, US) who first isolated and 
characterized the gene. I also chose Fte-1, because ribosomal proteins have revealed 
along the years to be implicated in more mechanisms than just protein translation, and 
RoRet because even though nothing else than its gene sequence is published, it 
contains very interesting domains. Two cDNA encoding for the full length gene were 
purchased by ResGen: RoRetg from the genestorm cDNA library contained the 
predicted DNA sequence, but RoRetc from the celera cDNA library contained a TTA 
stop codon in frame after 762 bp and should have led to the expression of a shorter 
protein. Intriguingly, cloning of this cDNA in the pEGFP-N1 vector that fused GFP to 
the C-terminal end of RoRetc, resulted in a protein migrating at the same hight as 
RoRetg protein fused to GFP. The cellular localization looked the same as well. We 
are not able to explain this result. One possibility would be that the translation 
machinery is somehow  slipping over the stop codon without recognizing it.  
 
 
B-Analysis of RoRet, Aven and Fte-1 protection in yeast S. pombe and mammalian 
cells against apoptosis induction by different stimuli . 
1-RoRet, Aven and Fte-1 protect mammalian cells against cells death induced by 
Bak and Apaf-1 M368L/Caspase-9 overexpression, but protect S.pombe only 
against CED4 induced cell death. 
 
The different killing assays in S. pombe and in 293T and RKO cells had two 
goals. First I wanted to determine the protection efficacy against apoptosis induction 
by different stimuli, and second, I wanted to define if there is some similarity in the 
apoptotic pathway taking place in S. pombe and in mammalian cells. Indeed, some 
lately published work report of a yeast caspase existence (Madeo, Herker et al. 
2002), and yeast cell death similar to apoptosis has long been observed without 
identification of the yeast homologues to the proteins able to induce these cell deaths 
(Bak, Bax, CED4￿) (Jurgensmeier, Krajewski et al. 1997), (James, Gschmeissner 
et al. 1997). 
The first experiments in yeast showed that ∆ RoRet, ∆ Aven and Fte-1 can 
protect S. pombe against CED4 but not Bak induced cell death (Fig. 22-25). The 
rescuing experiment of HC4 cells confirmed that CED-4 not only induces growth 
arrest but rather kills S. pombe yeast cells actively, and that ∆ RoRet, ∆ Aven and Fte-
1 can protect against CED4 killing (Fig. 24). The low percentage of yeast cells 
reappearing when cultured only in non selective medium suggests that the nmt-1 
promoter may be leaky, allowing a certain amount of CED4 to be expressed in non 
selective medium as well. The growth curve (Fig. 25) showed the effect of ∆ RoRet, 
∆ Aven and Fte-1 expression in S. pombe cells on their growth when CED4 is   136
induced (Fig. 23). The results showed that ∆ RoRet was the most efficient to protect 
yeast cells against CED4 induced cell death. ∆ Aven and Fte-1 were also efficient in 
their protection. And interestingly, the HC4 yeast cells transformed with the 
protective cDNAs were growing faster than the HC4 yeast cells growing in non 
selective medium, suggesting again that the nmt-1 promoter may be leaky and allow 
a certain amount of CED4 to be expressed in non selective medium. This would 
explain the apparent slow growth of these HC4 S. pombe yeast cells in non selective 
medium. In S. pombe, CED4 induces cell death by translocating from the cytoplasm 
to the nucleus and inducing chromatin condensation. When co-expressed with CED9 
its anti-apoptotic partner, it relocates at the endoplasmic reticulum and outer 
mitochondrial membrane (James, Gschmeissner et al. 1997). This suggests several 
possibilities of inhibitory mechanisms for RoRet, Aven and Fte-1. They could either 
block CED4 translocation to the nucleus, or block its binding to the chromatin, or 
sequester CED4 to some other compartment (mitochondria, ER, Golgi￿). 
Nevertheless, all those mechanisms suggest direct or indirect binding to CED4. 
  The experiments aiming at testing the protective effect of  Aven, Fte-1 
and RoRet were first performed in RKO cells, which are suitable for FACS analysis. 
The propidium iodide staining and FACS cell cycle analysis  is a convenient way to 
quantify apoptotic cell death. I co-transfected RKO cells with apaf-1 M368L and 
caspase-9  and pcDNA3.1+, ∆ roret-pcDNA3.1+,  roret-pcDNA3.1/GS,  ∆ aven-
pcDNA3.1+, aven-pSG5, fte-1-pMEXneo or bcl-xL-pcDNA3.1. Apaf-1 M368L is an 
Apaf-1 mutant which doesn￿t need Cytochrome c release to activate Caspase-9, it can 
self-associated and bind procaspase-9 independently of the conformational change 
induced by Cytochrome c, but still requiring dATP/ATP [Hu, 1999 #3617]. Even 
though the induction of apoptosis was not strikingly high, certainly due to the 
transfection efficiency always quite low in RKO cells (20% to 30%), it was 
nevertheless obvious that RoRet, Aven, Fte-1 and their deletion mutants were 
efficient in inhibiting DNA fragmentation and cell death in a reproducible manner 
(Fig. 26). 
 
Because RKO cells are probably type II cells, which means that their apoptotic 
onset needs mitochondrial activation and can be blocked by Bcl-2 overexpression 
(data obtained in our laboratory), I tested the protection efficiency of RoRet, Aven 
and Fte-1 against FasL induced apoptosis (Fig. 27). The protection effect was never 
exceeding 10% inhibition of cell death. But the transfection efficiency in RKO cells is 
ranging between 20% to 30% (determined by the number of cells expressing GFP 
when transfected with the pEGFP-N1) so in the end a 10% protection could still be 
significant if related to the amount of cells effectively overexpressing RoRet, Aven 
and Fte-1. FACS or MACS-sorting could have probably solved this problem, but our 
FACSCalibur (Becton Dickinson) didn￿t possessed this mode.  
I also tested  RoRet, Aven and Fte-1 protection efficiency against UV-induced 
apoptosis (Fig. 28). UV is known to induce p53 which in turn induces Bak targeting 
to the mitochondria[Degenhardt, 2002 #2212][Pohl, 1999 #6427] and Bax 
transcription (Kugu, Ratts et al. 1998). But again the protection efficiency was not 
very striking. It is possible that RoRet, Aven and Fte-1 protect only at the level of 
Caspase-9 activation, and that FasL and UV are inducing more than only one   137
apoptotic pathway. It was also obvious that the transfection efficiency was a problem, 
so I decided to change the system with cells easier to transfect like the 293T human 
embryonic kidney cells. But when tested in FACS, I observed that 293T cells do not 
fragment their DNA when induced into apoptosis by UV, Bak or Apaf-1 
M368L/Caspase-9 overexpression. Thus I also had to change the readout system. As it 
is published in many papers and not necessary to prove anymore, Bak and Apaf-
1/Caspase-9 overexpression induce apoptosis in mammalian cells. I decided to choose 
a system where I would only have to distinguish between dead and living cells. I 
found such a system provided by Molecular Probes: the LIVE/DEAD assay.  
I co-transfected again RoRet, Aven, Fte-1 and their deletion mutants with 
Apaf-1 M368L and Caspase-9, in 293T cells (Fig. 29). This time I could reach 70% to 
80% transfection efficiency, and apoptosis induction ranged between 40% and 60%. 
In this case an inhibition from 50% apoptosis to 20%-30% could be judged as 
significant. In this assay RoRet, Aven and Fte-1 inhibit Apaf-1/caspase-9 -induced 
apoptosis in efficiently in 293T cells. Furthermore, as Bak is known to trigger the 
mitochondrial pathway for apoptosis, I tested RoRet, Aven and Fte-1 potential to 
inhibit Bak induced apoptosis. The co-transfection experiment of Bak-GFP with 
RoRet, Aven, Fte-1 and their deletion mutants showed that RoRet, Aven, Fte-1 and 
their deletion mutants could efficiently inhibit Bak induced apoptosis, or with other 
words, mitochondrial activation induced apoptosis (Fig. 30). Taken together, these 
results point to the hypothesis that RoRet, Aven and Fte-1 inhibit apoptosis at the 
level of the apoptosome formation and Caspase-9 activation. 
 
Because the results in S. pombe showed no inhibition of RoRet, Aven or Fte-1 
Bak-induced cell death (Fig. 22), but inhibition of CED4 induced cell death (Fig. 23), 
I concluded that the pathways inducing cell death by CED4 or Bak expression were 
different and separated in yeast S. pombe, whereas in mammalian cells Bak activates 
the mitochondria and leads to activation of Apaf-1 downstream of Cytochrome c 
release. This hypothesis of separate death pathways induced in yeast would account 
for the different morphological features described for Bak, Bax  or CED4 induced cell 
death. Bax causes growth arrest of yeast cells accompanied by cytochrome c release 
from mitochondria to cytosol, but in this case Cytochrome c is not necessary to induce 
cell death, it seems to be only a side effect of Bax killing (Manon, Chaudhuri et al. 
1997), this cell death can be blocked by Bcl-2 coexpression. Bak is able to induce 
yeast cell lethality that can be antagonized by the mammalian anti-apoptotic protein 
Bcl-xL. In this case cell death is accompanied by morphological feature resembling 
apoptosis like loss of nuclear membrane integrity, vacuolisation and chromatin 
condensation and fragmentation (Ink, Zornig et al. 1997). And CED-4 could induce 
active Cell Death in S. pombe, that was accompanied by the translocation of CED-4 
from the ER and mitochondria to the nucleus (James, Gschmeissner et al. 1997). All 
these feature belong to the described morphological changes occurring during 
mammalian cells apoptosis, but none of the cell death inducers (Bak, Bax or CED4) 
was able to result in all these morphological changes at once. This suggest that yeast 
is still a simple organism, and the complicated pathway cross-talks occurring in 
mammalian cells do not exist into yeast.   138
 
Fig. : Schematic representation of the obtained results about the protection capacity of 
RoRet, Aven and Fte-1. 
 
2-RoRet, Aven and Fte-1 protect differently against apoptosis in mammalian 
cells.  
 
 RoRet, Aven and Fte-1 are inhibiting downstream of apoptosome formation 
as shown in the previous chapter. There are nevertheless, several possible inhibiting 
roles they can exert. They can block Caspase-9 cleavage, or only inhibit its activity. 
They could also act downstream of Caspase-9 activation by inhibiting Caspase-3 
cleavage or activity. To test theses different hypothesis, I co-transfected 293T cells 
with Apaf-1 M368L, Caspase-9 and RoRet, Aven, Fte-1 and their deletion mutants. I 
then looked by Western Blot for procaspase-9 cleavage. The data did not include 
results about RoRet full length, because at this time I  had not obtained yet the full 
length cDNA. I could observe that procaspase-9 was disappearing when cells were 
overexpressing Apaf-1 M368L and Caspase-9 (Fig. 31). The levels of Procaspase-9 
were maintained when the protecting proteins were over expressed together with 
Apaf-1 M368L and Caspase-9, even though a faint band at the correct size of 
Caspase-9 (p39) was still visible, suggesting that the inhibition was not complete. 
This would confirmed the protection data showing only 30% to 50% apoptosis 
inhibition. I then tried to look at Caspase-3 cleavage (Fig. 32). The result was not 
conclusive, due again perhaps to the low transfection efficiency of RKO cells. 
Nevertheless,  ∆ RoRet and ∆ Aven could inhibit in part procaspase-3 cleavage, 
whereas Aven and Fte-1 were quite ineffective. Again, FasL induced apoptosis in   139
RKO cells may also act through activation of other caspases. Unfortunately no clear 
data could be obtained with 293T cells. 
The next step in the unravelling of the molecular pathway was to test caspase 
activity inhibition. The rather strong specificity of RoRet, Aven and Fte-1 protection 
in mind, I looked for inhibition of caspases activity (Fig. 33) focussing on Caspase-9 
and-3 only by mitochondrial activation induced apoptosis in 293T cells. In theses 
experiments , it was obvious that ∆ RoRet, RoRet, ∆ Aven, Aven and Fte-1 could 
inhibit Caspase-9 activity. When Caspase-3 activity could only be efficiently blocked 
by  ∆ RoRet, RoRet and ∆ Aven, while Aven and Fte-1 give different results in 
different experiments permitting no definitive conclusion. Similar results, if 
somewhat less striking (again due to the transfection efficienty limits) were observed 
in RKO cells (data not shown).  
The western blots data and the caspases activity data taken together, I can  
conclude that ∆ RoRet, RoRet and ∆ Aven are efficient inhibitors of Caspase-9 and 
Caspase-3 activity. In contrast, Aven full length and Fte-1 can only partly inhibit 
Caspase-9 activity. It is interesting to note again that the deleted forms are as if not 
more efficient than the full length protein, one possible explanation would be that the 
active inhibitory part of the protein must be activated through conformational changes 
or cleavage, whereas the deletion mutant already exhibit this inhibitory function 
without further activation necessary. I could conclude from this that the inhibition 
activity of both RoRet and Aven was situated in the deletion part isolated in the 
survival screen. The unpublished data from Dr. Marie Harwick about Aven confirm 
the last assumption for Aven. The deletion mutants of Aven without the domain 
define by my work had no inhibitory activity when they tested them for Caspase-9 
activation. 
 
  A protein can inhibit the activity of another by binding directly or indirectly to 
it and blocking its activation or its catalytic activity. Because I isolated RoRet, Aven 
and Fte-1 in a screen against CED4 (activated Apaf1 homologue) induced cell death, I 
wanted to see if they could bind to Apaf-1. I had thus tested this hypothesis by ￿Yeast 
two-hybrid￿ for the possibility of direct binding. I also looked at potential interaction 
by ￿GST-pull down￿ of Apaf-1 from 293T cell lysate with RoRet, Aven and Fte-1  or 
￿Co-immuniprecipitation￿ of Apaf-1 from 293T cell lysate with RoRet, Aven and Fte-
1. The last two methods were interesting if the binding of Apaf-1 to one of the clones 
was indirect, or would require some post-translational modification and activation, 
that would be provided by the cell lysate components.  
 
 
The results of the Yeast two-hybrid (Fig. 34) showed that only Fte-1 could 
binding to Apaf-1 in the region between the CED4 like domain and the WD40 repeat 
domain, from amino-acid 412 to amino-acid 601. Moreover, it is interesting to notice 
that Fte-1 do not bind to this region of Apaf-1 if the WD40 repeat region in present, 
suggesting that normally this region is masked, and when Apaf-1 is activated by 
binding to Cytochrome c it undergo a conformational change that would expose this 
domain to where Fte-1 can bind. ∆ RoRet and ∆ Aven showed no binding, in the two-
hybrid, meaning that if there is interaction, it is not direct interaction, or it needs post-  140
translational modification that do not occur in S. cerevisiae. The results from the 
GST-pull down (Fig. 35) couldn￿t be analysed because Apaf-1 M368L did bind to the 
GST protein alone, if some what less strongly, still well enough to disturb the 
outcome of the experiment.  
I also tried co-immunoprecipitation of my clones tagged to GFP, using either 
anti-GFP antibody, or anti-Apaf-1 antibody. I could co-immunoprecipitate ∆ Aven  
together with Apaf-1 (Fig. 36), but I couldn￿t co-immunoprecipitate either ∆ RoRet, 
RoRet or Fte-1 with Apaf-1. The result was quite puzzling for Fte-1 because the 
former data suggested that Apaf-1 and Fte-1 do interact. Maybe the interaction occurs 
under specific conditions not yet determined. It is also possible that the presence of 
the GFP protein (28 kD) at the C-terminal end of the protein disturb the interaction. 
Therefore I planned the repetition of these co-immunoprecipitation  with FLAG-
tagged proteins. Further studies will also try to detect theses proteins within the 
apoptosome in collaboration with Sebastian Wesselborg by gel size chromatography 
and Western Blot analysis. 
 
In further studies, I used confocal scanning microscopy to determine the 
cellular localization of RoRet, Aven, Fte-1 and their deletion mutants in order to 
verify if interaction can happen in vivo and to confirm co-localization. And following 
the previous experiments, it seemed relevant to try to look if ∆ Aven and Fte-1 may 
co-localize with Apaf-1. It was also interesting to study the cellular localization of 
RoRet, which until now was completely unknown. Moreover, because it wasn￿t clear 
from the previous experiments, whether  there is interaction with Apaf-1, and if this 
interaction is direct or indirect, I decided to look also for co-localization with 
Caspase-9. Caspase-9 and Apaf-1 bind to one another during the apoptosome 
formation (Li, Nijhawan et al. 1997; Srinivasula, Ahmad et al. 1998; Rodriguez and 
Lazebnik 1999), and RoRet and Aven could bind to Apaf-1 through Caspase-9. And 
as the issue of their maybe protection at the apoptosome level was still open, it was 
interesting to investigate if Aven, RoRet and Fte-1 could co-localize simultaneously 
with Apaf-1 and Caspase-9 in the apoptosome complex. For this purpose I have used 
the sequential scanning mode in confocal laser scanning microscopy. I have 
specifiquely stained 293T cells co-transfected with the GFP fusion constructs, 
Caspase-9 and Apaf-1 M368L. The specific Apaf-1 mutant was used in order to 
trigger Caspase-9/Apaf-1 complex formation without any other stimuli than protein 
over-expression (Hu, Benedict et al. 1999). The first thing that I could say is that co-
localization of Apaf-1 with Caspase-9 was detectable only in theses cells showing 
Apaf-1 over-expression. This was logical if we assume that only the mutant form of 
Apaf-1 can bind and activate Caspase-9 without further stimuli as protein over-
expression.  
 
∆ Aven-GFP showed a localization pattern similar to the one published for 
Aven (Chau, Cheng et al. 2000) (Fig. 41). ∆ Aven is located in the cytoplasm in a 
spotted fashion, suggesting some aggregates or organelles location. No ∆ Aven was 
detected in the nucleus. Apaf-1 showed also a cytoplasmic profile, and again spotted 
and not diffuse. Apaf-1 concentrations increase around the nucleus and in a compact 
area near the nucleus (Fig. 37-44). Former reported data observed that Apaf-1   141
localizes at the Golgi in cells expressing Bcl-2 and in the cytoplasme in cells lacking 
Bcl-2 (Ruiz-Vela, Albar et al. 2001). Caspase-9 was found in the cytoplasm and 
sometimes the nucleus (Fig. 37-44). Theses results are also confirming published the 
data about its cellular localization (Hausmann, O’Reilly et al. 2000; Shikama, U et al. 
2001). The overlay pictures of ∆ Aven and Apaf-1 showed that ∆ Aven and Apaf-1 are 
partly co-localizing, whereas the overlay picture of ∆ Aven and Caspase-9 show a 
clear co-localization of these two proteins (Fig. 37). Moreover, in cells over 
expressing Apaf-1 M368L the overlay picture of  ∆ Aven, Apaf-1 and Caspase-9 
suggests the presence of all three proteins in a complex (Fig. 41). It would be 
interesting to look for co-immunoprecipitation of Aven with Caspase-9, and check if 
it￿s interacting with pro-caspase-9 or the cleaved activated form.  
Fte-1-GFP could be detected in a well define compartment that looks like the 
endoplasmic reticulum or the Golgi (Fig. 38), specific staining of these compartments 
are planned and should confirm this guess. In this experiment, the overlay  of Fte-1 
and Apaf-1 could detect co-localization at the compartment described above, whereas 
the overlay  of Fte-1 and Caspase-9 could detect co-localization areas surrounding this 
compartment. I could say that Fte-1 and Apaf-1 partly co-localize, but the result with 
Caspase-9 was not clear (Fig. 38). In the experiment with Fte-1-GFP, Apaf-1 M368L 
and Caspase-9 showed that in some cells co-localization of all three proteins could be 
detected, whereas in others only areas where Fte-1-GFP  co-localizes with Apaf-1 
M368L but not Caspase-9 could be seen (Fig. 42). Moreover, theses co-localization of 
all three proteins areas co-exist with still free Fte-1-GFP, suggesting that only a 
specific pool of Fte-1-GFP co-localizes with Apaf-1 and/ or with Caspase-9. The 
exact conditions in which this co-localization would take place are not yet 
determined. One hypothesis is that Fte-1 would be the unknown protein that encores 
Apaf-1 to the Golgi in those cells expressing Bcl-2(Ruiz-Vela, Albar et al. 2001).  
∆ RoRet-GFP shows a diffuse cytoplasmatic and nuclear cellular localization 
(Fig. 39). The merged picture of  ∆ RoRet-GFP and Apaf-1 or Caspase-9 was not clear 
enough to really suggest a co-localization with either Apaf-1, either Caspase-9 (Fig. 
39). But in the experiment where I tried to look for all three protein colocalization, 
∆ RoRet-GFP seem to co-localize with caspase-9 but not really with Apaf-1 M368L 
(Fig. 43). No co-localization of all three proteins could be detected, suggesting a more 
probable interaction with Caspase-9 that with Apaf-1. It is altogether possible that 
∆ RoRet-GFP protect the cell against apoptosis by binding to Caspase-9 and 
preventing its recruitment to Apaf-1. Such a hypothesis will be investigated in the 
future by co-immunoprecipitation attempts of ∆ RoRet-GFP with Caspase-9. Full 
length RoRet was also cloned in pEGFP-N1 and the fusion GFP construct was used 
for detection in confocal laser scanning microscopy (Fig. 44) . The cellular 
localization of the full length protein showed a largely punctuated pattern that looks 
similar to some kind of vesicles suggesting that the deletion mutant protein lack some 
targeting signal in its sequence. Further characterization of theses organelles should 
tell us what they are exactly. RoRet-GFP could also sometimes (not shown because 
not significantly frequent) be detected into the nucleus. And, like for ∆ RoRet, I saw 
co-localization of RoRet with Caspase-9, but not with Apaf-1 together with Caspase-
9, even though Apaf-1 and Caspase-9 obviously co-localized. It suggests that two 
different pools of Caspase-9 interact with either RoRet either Apaf-1. This could join   142
the hypothesis emitted for ∆ RoRet, that RoRet would bind Caspase-9 and preventing 
it from being recruited at the apoptosome. 
 
 
C-Analysis of the In vivo relevance of these inhibitors of apoptosis: their possible 
implication in tissue homeostasis, regulation or tumourigenesis.  
 
It was important to investigate the physiological relevance of these proteins 
function. It was not possible to look for RoRet protein because of the absence of 
antibodies (we are in the process of raising and purifying them). Nevertheless, it was 
still possible to analyse expression levels of this gene at the mRNA level. On the other 
side, Aven and Fte-1 could be investigated on both protein and mRNA levels. The 
functional and physiological aspects were investigated  by studiing the expression of 
Aven in a highly regulated tissue: the mammary gland, and secondly by investigating 
the different expression levels of Aven, Fte-1 and RoRet in tumour tissues versus 
healthy tissues.  
To look for Aven regulation in morphologically changing tissue, the choice of 
the mammary glands tissue was relevant. Indeed, during pregnancy the mammary 
glands are the siege of multiple changes: epithelial mammary cells differentiate and 
form branching tubules and small alveoli. Then during lactation the differentiation 
continues and the alveoli produce milk proteins. After birth, these alveoli undergo 
apoptosis, the mammary tissue undergo involution and returns to its state before   
pregnancy. For this purpose I analysed the expression of aven on a Northern Blot 
(from Clontech) where equal amounts of mRNA from the different  differentiated 
stages of the mammary gland were spotted (Fig. 45). I could observe downregulation 
of Aven during lactation and during involution. What was more surprising was that if 
we consider the lactation state as highly differentiated for the mammary gland cells, 
then there is the question, why don￿t we observe down regulation already during the 
pregnancy when the cells are differentiating? It is possible that during the pregnancy 
the cells need a higher proliferation potential and not so much differentiating capacity. 
It may imply that Aven is important during proliferation and would be downregulated 
during differentiation. It is also possible that Aven is downregulated during lactation 
to prepare the cells for apoptosis during involution. It was nevertheless reassuring to 
observe the lowest expression levels of Aven (which is anti-apoptotic) during 
involution time which witnesses high apoptosis within the mammary gland cells. RT-
PCR studies (data not shown) showed a tendency of down regulation already during 
pregnancy, and already an up-regulation to normal levels during day 5 of involution. 
I tried to go one step further by using the published model of KIM-2 cells. 
This mouse mammary epithelial cell line can be induce to differentiate and after 
differentiation further induced into apoptosis (Gordon, Binas et al. 2000). I studied 
Aven expression at the different differentiated stages of this cell line: undifferentiated, 
differentiated and apoptotic by Western Blot (Fig. 46). I found that Aven slightly 
decreases in differentiating cells, and significantly decreases in apoptotic cells. As it is 
described that only about 30% of the cells undergo apoptosis, it is also possible that 
the remaining Aven comes from the non-apoptotic cells. This question will be   143
answered in further studies involving aven anti-sense RNA and siRNA. Nevertheless, 
the results are consistent with the described anti-apoptotic activity of Aven that will 
suppose downregulation or rapid degradation of the protein to allow apoptosis. 
Furthermore, the decrease in the protein level during the differentiated stage suggest 
again that Aven may also be important during proliferation. 
 
To investigate the possible role of Aven, RoRet or Fte-1 in cancergenesis I 
analyse mRNA expression levels in normal and tumour tissue. For this I used the 
Cancer Profiling Array from Clontech. This array contains many cDNA pairs of 
tumour and normal tissue, each from a single patient (Fig. 47). This array was intend 
to screen a large panel of tumour types an allow us to determine in what possible 
tumour type our apoptosis inhibitors could play a role. It was interesting to observe a 
tendency to up regulation of aven in uterus, colon and especially in kidney tumours. 
fte-1 showed a tendency to be up regulated in colon cancers and roret in uterus 
cancers. Moreover, the specific tumours where c-myc was up-regulated, like colon 
and rectum, showed that the array screen should be accurate. Indeed some published 
data already state that c-myc play an important role in colon cancer-genesis (Funato, 
Kozawa et al. 2001; Wilson, Velcich et al. 2002). The ubiquitin  was mend as a 
negative control, and  not surprisingly was only found slightly up-regulated in kidney 
cancer. Zarbl and Al. have already studied the role of Fte-1 in transformed mouse 
fibroblasts, they observed that Fte-1 is not sufficient to induce cell transformation, but 
the suppression of Fte-1 could suppress the transformed phenotype (Kho, Wang et al. 
1996) (Fig. 48). This would suggest that Fte-1 is necessary if not enough for cell 
transformation. But of course these data have to be confirmed at the protein level in 
tumour samples by western blotting. And for this reason I have started to collect 
samples of normal tissue/tumour pairs of breast, colon and kidney. Further 
investigations are also pursue in collaboration with Dr. Stephan Joos (DKFZ, 
Heidelberg, Germany), that will allow the testing of tumour tissue arrays with the 
anti-aven and the anti-Fte-1 antibody. 
 
 
D-HMGB1inhibits cell death in yeast and mammalian cells and is overexpressed in 
certain human tumours. 
 
HMGB1 was identified during a different screen where we set up an inducible 
Bak expression system in S. pombe. When we transformed Bak expressing S. pombe 
yeast cells with a cDNA library synthesized from mouse NIH 3T3 fibroblasts, we 
found the chromosomal protein HMGB1 as a protector against Bak-induced yeast cell 
death. The deletion mutant ∆ HMGB1, which we isolated in the screen and which 
lacks the C-terminal 33 amino acids, is even more potent in inhibiting Bak-killing in 
yeast than the full length protein (Fig. 50). Since we only tested 5x10
4 transformed 
yeast colonies for Bak-resistance, screening of the NIH 3T3 library was by far not 
complete. This probably explains why we did not isolate well-known inhibitors of 
Bak cytotoxicity like Bcl-xL.   144
If protected against Bak-killing by overexpression of ∆ HMGB1,  S. pombe 
cells grow exponentially while expressing a large amount of Bak (which is much 
higher than the amount of Bak necessary to kill untransformed yeast cells). These data 
rule out the possibility that ∆ HMGB1 downregulates Bak-transcription from the nmt-
1 promoter used to express Bak in the yeast. 
 
I could show that both ∆ HMGB1 and full length HMGB1 are able to suppress 
Bak-induced apoptosis in mammalian cells (Fig.51). HMGB1 is an abundant nuclear 
protein with roughly 1x10
6 molecules per nucleus (Bianchi and Beltrame 1998). Yet 
despite its abundance the protein may be limiting within cells: transient 
overexpression of HMGB1 enhances the transcriptional activity of factors such as P53 
and steroid hormone receptors. Similarly, an increase of HMGB1 protein levels in 
mammalian cells by transfection leads to inhibition of Bak-killing. Since we have 
identified HMGB1 in a yeast screen for anti-apoptotic genes and because we have 
shown HMGB1·s anti-apoptotic capacity in mammalian cells, we investigated 
whether the protein is overexpressed in human tumours. Our analysis revealed 
profound HMGB1 protein expression in human primary breast carcinomas (Fig.52). 
We also observed strong HMGB1 expression in human breast carcinomas 
transplanted into nude mice. In contrast, we could not detect significant amounts of 
HMGB1 protein in normal breast tissue arguing that the protein is overexpressed in 
mammary carcinomas. We also detected overexpression of HMGB1 RNA in human 
tumours of the uterus, colon and stomach (Fig.53). 
Elevated  HMGB1  mRNA levels have already been reported in human 
gastrointestinal adenocarcinomas compared to corresponding non-cancerous mucosa. 
The authors had suggested a correlation between HMGB1 mRNA expression and 
differentiation /staging of the carcinomas. Furthermore, a strong intertumoural 
variation of HMGB1 mRNA expression within 13 breast cancer samples was 
published by Flohr et al. (Flohr, Rogalla et al. 2001). The authors argue that this 
variation may contribute to the different response of estrogen receptor-positive breast 
tumours to endocrine therapy. This argument is based on the observation that HMGB-
1 increases binding of the estrogen receptor to its DNA target 
sequence(Boonyaratanakornkit, Melvin et al. 1998). HMGB1 binds with high affinity 
to DNA damaged by cisplatin, and it is speculated that HMGB1 contributes to 
cisplatin cytotoxicity by shielding damaged DNA from repair (Pasheva, Ugrinova et 
al. 2002). Paradoxically, HMGB1 overexpression has also been correlated with 
cisplatin-resistance in cell lines (Imamura, Izumi et al. 2001) which could be 
explained by our data demonstrating anti-apoptotic properties for HMGB1. Both 
HMGB1 and HMGB-2 contain two similar, but distinct "HMG boxes" (A and B), and 
a long acidic C-terminal tail, which is deleted in the ∆ HMGB1 protein identified in 
our yeast screen (reviewed in (Travers 2000)). The HMG box consists of 
approximately 80 amino acids and has a characteristic, twisted, L-shaped fold formed 
by three α -helical segments (Read, Cary et al. 1993). It binds to DNA through the 
minor groove and induces site-specific DNA deformations. HMGB proteins recognize 
and bind to altered DNA confirmations, such as stem-loop, four-way-junction, kinked 
or underwound DNA ((Travers 2000)and references herein). Although they possess 
little or no sequence preference, HMGB1 interacts with proteins like P53 or steroid   145
hormone receptors and increases the apparent DNA binding affinity of these 
transcription factors (Jayaraman, Moorthy et al. 1998). Lack of the protein in Hmgb1 
knockout mice did not disrupt cell growth but rather caused lethal hypoglycaemia in 
the newborn mice, possibly due to impaired transcriptional glucocorticoid receptor 
activity (Calogero, Grassi et al. 1999). Such a role for HMGB1 as a regulator of 
transcription may influence the apoptotic behaviour of a cell. It has for example been 
shown that HMGB1 inhibits both P73α /β - and P53-dependent transactivation from 
the  bax gene promoter in p53-deficient SAOS-2 cells (Stros, Ozaki et al. 2002). 
Although this does not explain HMGB1·s ability to suppress cell death upon Bak 
overexpression, it is certainly possible that HMGB1 transcriptionally regulates a 
downstream component of the Bak- triggered apoptosis pathway. 
 
 
VII-Summary and outlooks 
 
The aim of this work was to identify new anti-apoptotic proteins and to 
understand their mechanistic function in order to provide new potential targets for 
molecular therapies. I performed a yeast survival screen to identify anti-apoptotic 
proteins inhibiting apoptosis downstream of Cytochrome c release (Jurgensmeier, 
Krajewski et al. 1997; Xu and Reed 1998). For the screen I used as a ￿killer￿ protein, 
CED4, the C. elegans homologue of Apaf-1, to induce cell death in S. pombe (James, 
Gschmeissner et al. 1997). Six proteins were isolated that inhibit CED4-induced yeast 
cell death. Overexpression of these proteins also prevents induction of apoptosis by 
Caspase-9 activation through the apoptosome formation. Those six molecules were 
RoRet (Ruddy, Kronmal et al. 1997), Aven (Chau, Cheng et al. 2000), Fte-1/S3a 
(Kho, Wang et al. 1996), PGC2 (Padilla, Kaur et al. 2000; Goetze, Eilers et al. 2002), 
SAA1-2β  (Moriguchi, Terai et al. 2001) and FBP (Brockstedt, Rickers et al. 1998) of 
which I selected RoRet, Aven and Fte-1/S3a for further analysis. 
RoRet is a new anti-apoptotic molecule that can inhibit the mitochondrial 
pathway via its PRY-SPRY domain. Its intracellular localization seems to  vary 
depending of the cells. It can be either nuclear or localize in organelles which nature 
remains to be determined. The PRY-SPRY domain when expressed alone is located in 
the cytoplasm and into the nucleus.  Whether it binds to Caspase-9 and prevents its 
recruitment to the apoptosome still has to be proven, but I did not obtain evidence that 
RoRet binds to Apaf-1. I also does not co-localize with the activated Apaf-1/Caspase-
9 complex. The future production and analysis of knockout mice should help to better 
understand the in vivo functions of RoRet.  
Aven was published to act as an anti-apoptotic protein and suggested to 
function via the recruitment of Bcl-XL to Apaf-1. I could show that its C-terminal 
domain can bind to Apaf-1 and has a strong anti-apoptotic activity by itself. 
Moreover, I could show that Aven co-localizes with the activated Apaf-1/Caspase-9 
complex suggesting that it is a component of the apoptosome. I could also show that 
the expression of Aven is regulated in mammary glands during the pregnancy cycle. 
Here again the production of knockout mice should help to unravel the complex 
activity of this protein.   146
Fte-1/S3a has been already implicated in increased transformation capacity of 
v-Fos in fibroblasts (Kho and Zarbl 1992; Kho, Wang et al. 1996). I could confirm in 
my work that it has anti-apoptotic activity and can protect against Bak- and Apaf-1-
induced apoptosis. I could also show that it binds directly to activated Apaf-1 at the 
linker domain between the WD40 repeats and the CED4-like domain, suggesting that 
it may protect by sequestering the activated Apaf-1 to some organelles whose nature 
remains to be determined (Golgi, ER or even mitochondria). Moreover, expression 
studies on mRNA and protein level showed upregulation of Fte-1/S3a in colon, lung 
and kidney carcinoma. A larger panel of colon tumour samples is currently tested for 
expression, and should allow us to validate these data. 
Hmgb1 (Flohr, Rogalla et al. 2001; Pasheva, Ugrinova et al. 2002; Stros, 
Ozaki et al. 2002) was identified during a survival screen performed with a NIH 3T3 
mouse fibroblast cDNA library in a Bak-expressing yeast S. pombe strain. HMGB1 
displays a broader anti-apoptotic activity, it can protect against Bak-, but also UV-, 
FasL- and TRAIL-induced apoptosis. I detected significant over expression of 
HMGB1 in breast and colon cancer, and elevated HMGB1 mRNA amounts in uterus, 
colon and stomach tumours. The mechanism by which HMGB1 may protect remains 
nevertheless unclear, but doesn￿t involve binding of HMGB1 for example to Bak or 
downregulation of bak transcription (Brezniceanu et al; 2003). 
Finally, theses results show as a proof of principle that the survival screen in S. 
pombe was successful in identifying new and already known anti-apoptotic proteins 
that act downstream of Cytochrome c release during apoptosis and which might act as 
death-inhibiting oncogenes.  
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shortened title: The anti-apoptotic HMGB1 is overexpressed in breast carcinoma 
Abstract 
 
Apoptosis is a fundamental biological process used to eliminate unwanted cells in a 
multicellular organism. An increasing number of regulatory proteins have been 
identified which either promote or inhibit apoptosis. For tumours to arise apoptosis 
must be blocked in the transformed cells, for example by mutational overexpression 
of anti-apoptotic proteins which represent attractive target proteins for molecular 
therapy strategies. 
In a functional yeast survival screen designed to select new anti-apoptotic mammalian 
genes we have identified the chromosomal High-Mobility Group Box-1 protein 
(HMGB-1) as an inhibitor of yeast cell death induced by the pro-apoptotic Bcl-2 
family member Bak. The C-terminal 33 amino acids of HMGB-1 are dispensable for 
this inhibitory function. HMGB-1 is also able to protect mammalian cells against 
different death stimuli including UV radiation, CD95-, TRAIL-, Casp-8- and Bax-
induced apoptosis. We found high HMGB-1 protein levels in human primary breast 
carcinoma.  hmgb1 RNA levels are changing during different stages of mouse 
mammary gland development and are particularly low during lactation and involution. 
These data suggest that HMGB-1 may participate in the regulation of mammary gland   163
apoptosis and that its high expression level promotes tumour growth because of its 
anti-apoptotic properties. 
 
 
Introduction 
 
Apoptosis is a genetically determined process leading to cell death in mammalian 
cells [Strasser, 2000 #70; Zornig, 2001 #69]. As the predominant form of 
physiological cell death it is crucial for the removal of excess, hazardous or damaged 
somatic cells during development and in the adult organism. The apoptotic process 
includes mechanisms that organize both packaging and disposal of cell corpses, 
thereby preventing inflammation of the surrounding tissue [Conradt, 2002 #68]. 
Apoptosis is characterized by significant morphological features like cell shrinkage, 
nuclear condensation and fragmentation of the whole cell. Biochemically, activation 
of apoptosis-specific proteases - the caspases - is observed [Shi, 2002 #67]. Caspases 
are common effectors of classical metazoan apoptosis. Upon activation they cut a 
range of substrate proteins whose cleavage either mediates or attends the apoptotic 
process. 
Deregulation of apoptosis is involved in many pathological conditions. While 
too much apoptosis is implicated for example in neurodegenerative diseases 
and AIDS, the inhibition of apoptosis is a functional prerequisit for 
tumourigenesis and certain autoimmune diseases [Thatte, 1997 #65; Thompson, 
1995 #66]. Acquired resistance towards apoptosis is a hallmark of most and 
perhaps all types of cancer and enhanced cell survival is needed for several 
steps during tumourigenesis [Hanahan, 2000 #64]. This includes suppression of 
apoptosis in transformed cells harbouring activated oncogenes like c-myc, in 
hypoxic tumour cells and in metastasizing cancer cells which - once deprived 
of cell-cell contact and of their normal environment - are prone to anoikis 
(apoptosis upon detachment [Frisch, 2001 #63]). In addition, inhibition of 
further apoptotic pathways and stimuli is associated with the resistance of 
tumours against radiation- and chemotherapy [Damiano, 2002 #62]. 
Decreased apoptotic sensitivity in tumour cells is either due to loss-of-function 
of pro-apoptotic proteins or to increased activity of anti-apoptotic molecules 
(gain-of-function;  [Hanahan, 2000 #64]). Therefore, anti-apoptotic genes 
overexpressed in tumours are attractive targets for anti-tumour gene therapy 
approaches (e.g. bcl-2 [Gutierrez-Puente, 2002 #60; Nicholson, 2000 #61]) and the 
identification of additional and novel anti-apoptotic genes activated in tumour 
cells has become an important issue. 
We and others have shown that yeast can undergo cell death accompanied by cellular 
markers of apoptosis and that both S. pombe and S. cerevisiae cells are killed upon 
overexpression of certain mammalian proteins such as the pro-apoptotic Bcl-2 family 
member Bak [Ink, 1997 #57; Jurgensmeier, 1997 #58; Sato, 1994 #59]. Co-expression 
of anti-apoptotic Bcl-2 family members like Bcl-xL inhibits the effective and rapid 
killing activity of Bak in S. pombe [Hanada, 1995 #56; Ink, 1997 #57]. Therefore, 
screening of mammalian cDNA libraries co-transformed into yeast cells which   164
express a mammalian killer gene is a powerful system avoiding many of the 
background problems experienced with similar screens for death-inhibiting genes in 
mammalian cells. Such a survival screen has already been performed successfully in 
the yeast S. cerevisiae [Greenhalf, 1999 #52; Kampranis, 2000 #51; Matsuyama, 1998 
#55; Shaham, 1998 #53; Xu, 1998 #54]. 
We have established a functional survival assay in the yeast S. pombe with the aim to 
identify anti-apoptotic mammalian genes in tumour-derived cDNA libraries. As a first 
step we screened an NIH 3T3 mouse fibroblast-derived library and found the 
mammalian chromosomal High Mobility Group box-1 protein (HMGB-1) as an 
inhibitor of Bak-induced cell death in S. pombe and in mammalian cells. Furthermore, 
we could show that overexpression of HMGB1 inhibits UV- CD95-, TRAIL-, Casp-8- 
and Bax-mediated apoptosis. 
HMGB-1 has been implicated in a variety of biologically important processes 
including transcription, DNA repair, V(D)J recombination [Bianchi, 2000 #7; Kwon, 
1998 #8], differentiation, development and extracellular signalling ([Mitsouras, 2002 
#49; Muller, 2001 #50] and references herein). As a nuclear protein, HMGB-1 binds 
to the minor groove of DNA and facilitates the assembly of site-specific DNA binding 
proteins like P53 at their cognate binding sites within chromatin [Thomas, 2001 #48]. 
In certain cells, HMGB-1 can be observed at the cell surface where it has been 
reported to contribute to cellular migration and tumour invasion [Taguchi, 2000 #47]. 
In addition, the molecule is secreted by activated monocytes and macrophages [Wang, 
1999 #46] and released by necrotic, but not apoptotic cells [Scaffidi, 2002 #45]. 
Under such conditions, HMGB-1 acts as a cytokine and mediates inflammation. 
We observed profound HMGB-1 protein expression in primary human breast 
carcinomas compared to normal breast tissue. hmgb1 mRNA levels are regulated 
during mouse mammary gland development and are particular low during lactation 
and apoptotic involution. Our results show that a functional yeast survival screen in S. 
pombe is well suited to identify anti-apoptotic mammalian genes and that HMGB-1 
might act as an oncoprotein supporting tumourigenesis by inhibiting apoptosis. 
Materials and methods 
 
Yeast strains, cell lines and DNA constructs 
 
All S. pombe strains used were derived from the wild-type strains 972h- and 975h+. 
Media and growth conditions were as described previously [Moreno, 1991 #44]. The 
yeast strain DSI contains stably integrated human bak [Ink, 1997 #57] and grows in 
EMM minimal medium (Bio 101) supplemented with leucine (Bio 101, 250 mg/l), 
uracil (Bio 101, 250 mg/l) and thiamine (Sigma, 5￿g/ml, to repress nmt-1 promotor-
driven  bak expression). To induce Bak expression cells were washed three times 
before culturing in liquid medium lacking thiamine. For induction of Bak expression 
in yeast growing on agar plates, colonies were replica-plated at least twice onto 
thiamine-free agar plates.   165
The RKO cell line (ATCC number CRL-2577) is a poorly differentiated colon 
carcinoma cell line containing wildtype p53. 293T cells are human embryonic kidney 
cells immortilized by large T antigen. NRK1 is a normal rat kidney cell line. 
The coding sequences of mouse hmgb-1, mouse ∆ hmgb-1 and human bcl-xL were 
cloned into the S. pombe constitutive expression vector pArt1 (Dr. Paul Nurse, ICRF, 
London, UK). For localisation studies, the human bak coding sequence was cloned in 
frame into the yeast vector pREP42/EGFP N (Dr. Paul Nurse) to express an N-
terminally GFP-tagged fusion protein with a uracil marker. Mouse hmgb-1 and 
∆ hmgb-1 cDNAs were cloned into pREP41/EGFP N (Dr. Paul Nurse, N-terminal 
GFP, with leucine marker). For mammalian expression, bcl-xL was cloned into 
pcDNA3.1+ (Invitrogen) and hmgb-1 and ∆ hmgb-1 into the retroviral vectors pBabe 
hygro and pBabe puro, respectively (Dr. Hartmut Land, University of Rochester 
Medical Center, Rochester, USA). 
To express a Bak-GFP fusion protein in mammalian cells, the bak cDNA was cloned 
in frame into a modified pEGFP-C1-vector from Clontech. This vector contains an EF 
(elongation factor) rather than the usual CMV promoter. Casp-8 (aa 1-478) was cloned 
as a GFP fusion protein into pEGFP-N1 (Clontech; kind gift from M. Lenardo, NIH 
Bethesda, USA). pIC-Bax was a  gift from J. Martinou, Departement de Biologie 
Cellulaire, Sciences III, Geneva, Switzerland. 
 
Yeast transformation 
 
150 ml of yeast culture in EMM medium (Bio 101) plus appropriate supplements 
(leucine, uracil, adenine (all Bio 101), thiamine (Sigma)) were grown to a density of 
1x10
7 cells/ml (O.D.600 = 0.5). Yeast cells were washed twice with water 
(centrifugation at 1,000 g) and resuspended in 1.5 ml fresh 1xTE/1xLiAc (0.1 M) 
yielding competent cells. 100 ng plasmid DNA (yeast expression construct with 
appropriate selection marker) were mixed with 0.1 mg denaturated herring sperm 
DNA (Bio 101) and 100 ￿l competent yeast cell suspension. 600 ￿l 40% PEG 8000 
(Sigma)/LiAc (0.1 M) were added and the mixture was vortexed for 10 seconds. The 
cells were incubated at 30
0C for 30 minutes with mild shaking, then after adding 70 ￿l 
DMSO the suspension was heat shocked for 15 minutes at 42
0C. Afterwards, yeast 
cells were chilled for 2 minutes on ice, washed, resuspended in 100 ￿l TE and plated 
on EMMA agar plates (Bio 101) containing appropriate supplements. 
 
 
Yeast survival screen and yeast plasmid recovery 
 
S. pombe yeast cells were transformed by electroporation according to standard 
protocols [Moreno, 1991 #44]. Briefly, a 400 ml yeast culture of DSI cells in rich 
yeast extract medium (bak  repressed) was grown to a density of 1x10
7 cells/ml 
(O.D.600 = 0.5). Cells were washed once in ice-cold water (centrifugation 5 minutes at 
1,000 g), once in ice-cold 1 M sorbitol (Sigma) and resuspended in 2 ml ice-cold 1 M 
sorbitol. 40 ￿l aliquots of the cell suspension were added to chilled Eppendorf tubes 
each containing 100 ng plasmid library DNA, and incubated on ice for 5 minutes. For 
the screen, 5 ￿g of a REP/cDNA library prepared from exponentially growing mouse 
NIH 3T3 fibroblasts (provided by Dr. Chris Norbury, ICRF, University of Oxford,   166
UK) were used. To generate this library, the cDNAs had been cloned into a REP3Xho 
(pMBS36Leu) S. pombe expression vector which contains a thiamine repressible nmt-
1 promotor and a leucine marker. Cells were electroporated with a BioRad 
electroporator (2.25 kV, 200 ￿, 25 ￿F), resuspended in 0.9 ml of ice-cold 1 M 
sorbitol and plated onto EMMA agar plates containing uracil and thiamine to allow 
growth of the colonies (bak off). Replica-plating onto thiamine-free agar plates 
induced simultaneous bak and library cDNA expression (bak on). In total, 5x10
4 yeast 
colonies were screened for Bak-resistance. DSI yeasts were re-transformed with 
library plasmids isolated from surviving colonies to confirm that the protection 
against Bak-killing was due to the plasmid-encoded library cDNA. 
For plasmid recovery from S. pombe, yeasts were grown in 50 ml selective EMM 
medium containing uracil to an O.D.600 of 0.5. The cells were resuspended in TE 
buffer and transferred to a 1.5 ml Eppendorf tube. To 1 volume TE/yeast, 1 volume 
phenol/chlorophorm and 1 volume glass beads (425-600 micron, Sigma) were added. 
The tube was vortexed for 5 minutes and centrifuged at 13,000 g for 2 min. The upper 
aqueous phase was transferred to a fresh Eppendorf tube and plasmid DNA was 
precipitated by adding 2 volumes of 100% ethanol, vortexing and centrifugation for 
30 minutes at 13,000 rpm. The DNA pellet was washed with 70% ethanol, 
resuspended in 100 ￿l water plus 5 ￿g RNase A (Roche), transformed into competent 
DH5α  bacteria and plated onto ampicillin containing LB agar plates. Plasmid DNA 
was prepared from growing bacterial colonies by miniprep isolation according to 
standard procedure. 
 
 
Yeast growth curves 
 
Yeast strains were grown in liquid EMM medium containing the appropriate 
supplements (uracil, thiamine (bak off)) to an O.D.600 of 0.5. The cultures were 
washed twice in water to remove traces of thiamine and then diluted to O.D.600 of 0.03 
(lower cell concentrations led to growth arrest) in EMM medium containing uracil 
and no thiamine (bak on). The O.D.600 was then measured every 8 hours and the 
cultures were diluted to keep them in exponential growth (O.D.600 max. 0.8). Such 
dilutions were taken into account when plotting the O.D./cell number kinetic versus 
time. 
 
 
Western and Northern blot analysis 
 
Yeast cell lysates were prepared by vortexing yeast cells for 5 min. in lysis buffer (TE 
buffer/1 mM PMSF, 1 tablet Complete-Mini protease inhibitor cocktail (Roche) per 
10 ml buffer) and glass beads (1 volume beads per 1 volume yeast suspension). The 
mixture was centrifuged at 13,000 g and 4
0C. The supernatant was used for 
quantification of protein concentration and Western blot analysis. 5 ￿g yeast proteins 
were loaded on a 12.5% SDS polyacrylamide gel. After transfer by semi-dry blotting 
onto a PVDF membrane (Immobilon-P, Millipore), the membrane was blocked in 5% 
nonfat milk powder and 0.05% Tween 20 in PBS. The rabbit anti-Bak antibody was 
purchased from Calbiochem, rabbit anti-HMGB-1 from PharMingen and goat anti-
Hsp27 from Santa Cruz (all used at 1:1000).   167
Yeast RNA was obtained by vortexing yeast cells in Trizol reagent (Life 
Technologies) with glass beads (1 volume beads per 1 volume yeast cell suspension) 
according to the manufacturer·s protocol. 15 ￿g of total RNA were loaded on a 
formaldehyde-containing agarose gel. After migration, RNA was transfered onto a 
Hybond N
+ membrane (Amersham) and hybridized with 100 ng of a 
32[P]-labelled full 
length human bak cDNA probe according to standard protocols. A mouse mammary 
gland Northern Blot from RNWAY Laboratories was hybridized with ∆ hmgb1, β -actin 
and gapdh cDNA probes following the manufacturer·s instructions. The membrane 
contains mouse mammary gland mRNA from non-pregnant and pregnant mice as well 
as from lactating and involuting animals. 
 
 
Localisation experiments in S. pombe using confocal microscopy 
 
For confocal microscopy, a Leica TCS SL laser scanning microscope was used. To 
stain yeast mitochondria, cells were resuspended at 1x10
6 cells/ml in 10 mM HEPES 
buffer (pH 7.4) containing 5% glucose. DiOC6(3) (Molecular Probes) was added to a 
final concentration of 175 nM, before cells were incubated at room temperature for 15 
minutes and analyzed by confocal microscopy. 
 
 
Transfection of mammalian cells 
 
RKO, 293T and NRK1 cells were transfected using the PEI method. Briefly, 13.5￿l of 
a polyethyleneimine solution (10mM in PBS, high molecular weight PEI from 
Aldrich) were diluted with 150￿l of PBS. In parallel, 5￿l of DNA solution were 
diluted with 150 ￿l of PBS and both solutions were mixed and vortexed. After 10 
minutes incubation at room temperature, the DNA/PEI mixture was added to the cells 
(1x10
6 cell/10cm plate) in serum-free medium. 4 hours later, the medium was 
replaced with FCS-containing medium. 
 
 
Quantification of apoptosis 
 
For Death Receptor-induced apoptosis, 10 ng/ml recombinant CD95L (crosslinked 
with 1 ￿g/ml anti-Flag antibody M2 from Sigma) or 10 ng/ml KILLER TRAIL (both 
from  Alexis) were used in combination with 1 ￿g/ml cycloheximide (Sigma). 
Alternatively, apoptotic cell death was triggered by UV radiation (10 s) or 
transfection with bak-gfp, bax or casp-8-gfp. Apoptotic cell death was measured using 
the LIVE/DEAD Viability/Cytotoxicity kit from Molecular Probes according to the 
supplier·s protocol. In this assay, living cells are distinguished by the presence of 
ubiquitous intracellular esterase activity, determined by the enzymatic conversion of 
the virtually nonfluorescent cell-permeant calcein AM to the intensely green 
fluorescent calcein (ex/em 495 nm/515 nm). Ethidium homodimer-1 enters cells with 
damaged membranes and undergoes a 40-fold enhancement of fluorescence upon 
binding to nucleic acids, thereby producing a bright red fluorescence in dead cells 
(ex/em 495 nm/635 nm). EthD-1 is excluded by the intact plasma membrane of living   168
cells. For each experiment, at least 200 green and red cells were counted using a 
Nicon fluorescence microscope (TE300). 
 
 
Tumour material 
 
All primary human mammary carcinoma samples were collected directly after 
surgery, frozen in liquid nitrogen and stored at -80
0  C. They were classified as 
follows: 
 
Tu.-No. TNM  Grading  ER/PR  Her2/neu 
83  pT3 pN1 M0  3  pos./neg.  neg. 
167  pT4 pN0 M0  3  pos./neg.  neg. 
249  pT2 pN0 M0  2  pos./neg.  neg. 
250  pT2 pN0 M0  3  neg./neg.  neg. 
256  pT1 pN0 M0  2  pos./pos.  neg. 
611 pT3  pN1  3  neg./neg.  nd 
876 pT2  pN0  3  pos./neg.  nd 
1096 pT3  pN1  nd  neg./pos.  nd 
1132 pT3  pN1  3  nd  nd 
 
Another seven samples were human breast carcinomas passaged in nude mice for 
several years and tested for human origin. 0.5 cm
3 tumour material was crushed using 
a homogenizer (Ultra-Turrax T25, Janke & Kunkel, IKA Labortechnik) in 1ml lysis 
buffer (30 mM Tris-HCL (pH7.5), 150 mM NaCl, 1% Triton X-100, 10% Glycerol, 1 
mM PMSF, 1 tablet Complete protease inhibitor cocktail (Roche) per 10 ml buffer) 
and centrifuged at 4
0C. The supernatant was used for quantification of protein 
concentration and subsequent Western blot analysis with 40 ￿g protein per sample 
and a rabbit anti-HMGB-1 antibody (1:1000, BD PharMingen Biosciences). 
 
 
Breast tissue microarray 
 
Expression of HMGB1 in human breast carcinoma was studied using a tissue 
microarray (CB2c, BioCat) containing 50 breast tumour biopsies and 10 biopsies of 
normal breast tissue. HMGB1 levels were determined using a rabbit antibody (BD 
PharMingen Biosciences) which was detected using biotinylated anti-rabbit IgG in the 
first and fluorescein avidin DCS (Vector laboratories) in a second step. For 
quantification purposes, 16-bit grayscale images were aquired from each biopsy of the 
microarray and intensity values (I Biopsie) were calculated according to: 
 
() local Biopsie mean
local Biopsie
Biopsie BG I
SD BG Pixel
I − ×
+ >
= , % 100
1 %
 
 (BG; background intensity, SD; standard deviation; I mean, Biospsie; mean pixel intensity 
of a single biopsie on the microarray).   169
Results 
 
High mobility group-1 protein (HMGB-1) protects against Bak-induced cell 
death in S. pombe 
 
We employed functional yeast survival screens to identify new anti-apoptotic 
mammalian genes out of tumour-derived libraries. In a first experiment we used an 
inducible Bak expression system in S. pombe to screen a cDNA library prepared from 
exponentially growing NIH3T3 mouse fibroblasts (see Materials and methods). 
Altogether 5x10
4 transformed yeast clones were tested for Bak-resistance in a non-
saturated library screen. One of the S. pombe colonies surviving Bak expression after 
library transformation contained a truncated deletion mutant of the mouse hmgb-1 
gene lacking the C-terminal 33 amino acids. This ∆ hmgb-1 deletion mutant does not 
represent a naturally occuring mRNA variant but was rather generated in the cloning 
process when the oligo-dT primer annealed within the hmgb-1 coding sequence 
during reverse transcription of the RNA. ∆ HMGB-1 still contains the two HMG-
boxes identified in the full length HMGB-1 while the highly acidic C-terminal tail is 
deleted. 
We cloned mouse ∆ hmgb-1 and mouse full length hmgb-1 in a constitutive S. pombe 
expression vector and further analyzed ∆ HMGB-1-conferred protection in Bak 
expressing yeasts. When Bak expression is induced in the S. pombe yeast strain DSI 
growing on agar plates, the yeast cells die within 48 hours (see Fig. 1A). Co-
expression of either ∆ HMGB-1 or full length HMGB-1 protects the yeast colonies 
from Bak-induced cell death. 
We also measured growth curves of the different yeast strains in liquid culture (see 
Fig. 1B). S. pombe wildtype cells cease growth and cell division upon Bak expression 
(DSI, -T). When co-expressing ∆ HMGB-1 or full length HMGB-1 the Bak 
transformed yeasts continue to grow exponentially, as they do when the Bak-
antagonist Bcl-xL is co-expressed.  
We then performed Western- and Northern blot analysis to confirm expression of 
HMGB-1 and Bak in the yeast strains we had used for the experiments (see Fig. 1C 
and 1D). We could easily detect full length HMGB-1 protein in the transformed 
yeasts but the anti-HMGB-1 antibody did not recognize ∆ HMGB-1 due to the C-
terminal deletion. Nevertheless, in similar studies with a  ∆ hmgb-1-gfp fusion 
construct Bak killing was inhibited as efficiently as with ∆ HMGB-1 and the positive 
GFP-staining in these cells proved the presence of the ∆ HMGB-1 protector (data not 
shown). 
Induction of Bak transcription in the DSI S. pombe strain leads to the production of 
small amounts of Bak mRNA and protein sufficient to kill the DSI strain (see Fig. 1A 
and 1B). In DSI cells co-transformed with ∆ hmgb a much higher amount of Bak 
RNA and protein is detectable and - in the presence of ∆ HMGB-1 - tolerated by the 
yeast cells (Fig. 1C and 1D). Interestingly, we were unable to detect Bak expression 
in DSI yeast colonies co-transformed with full length hmgb-1.  
These results show that full length HMGB-1 and ∆ HMGB-1 protect S. pombe cells 
against Bak-induced yeast killing. While we cannot rule out that the protective effect 
of full length HMGB-1 involves transcriptional downregulation of the Bak yeast 
expression construct, the largely increased amount of Bak in ∆ hmgb-1 co-transformed   170
yeast cells indicates protection by ∆ HMGB-1 against the Bak protein by another 
mechanism. 
 
HMGB-1 does not interact with Bak in yeast 
 
Having established the protective potential of HMGB-1 against Bak killing in S. 
pombe we set out to analyze the localization of HMGB-1 and Bak in yeast. In 
mammalian cells, Bak is affiliated with the mitochondrial membrane where it is 
believed to be involved in the release of Cytochrome c after an apoptotic stimulus 
[Degenhardt, 2002 #43]. HMGB-1 on the other hand is mostly localized in the 
nucleus of a mammalian cell [Muller, 2001 #50], although in addition to its 
intranuclear function as a regulator of transcription, HMGB-1 can also be secreted by 
certain cells [Wang, 1999 #46]. 
To fascilitate detection of the Bak protein in yeast cells we cloned a gfp-bak fusion 
construct from which expression can be induced in S. pombe. The GFP-Bak fusion 
protein killed the yeast cells as efficiently as the Bak wildtype molecule (data not 
shown). GFP-Bak accumulated in dotlike structures of varying size within the S. 
pombe cytoplasm (see Fig. 2A and 2B). 
The mitochondrial staining of Bak-expressing cells shows the tubular mitochondrial 
network already reported for exponentially growing S. pombe cells [Yaffe, 1996 #42]. 
With the techniques used for intracellular localisation studies, simultaneous detection 
of GFP-Bak and DiOC6(3)-stained yeast mitochondria was not possible. Obviously, 
the GFP-Bak localization looks different from the typical mitochondrial pattern in the 
dying yeast cell. However, we cannot exclude that the GFP-Bak accumulations are 
part of or connect with the S. pombe mitochondrial network. 
In a similar experiment we transformed the Bak expressing S. pombe strain DSI with 
∆ hmgb-1-gfp and full length hmgb-1-gfp fusion constructs. The fusion proteins 
maintained their protective capacity against Bak killing in S. pombe (data not shown). 
Fig. 2E represents a typical example of the exclusively nuclear staining of both 
∆ HMGB-1-GFP and full length HMGB-1-GFP. 
The different localization of cytoplasmic Bak and nuclear HMGB-1/∆ HMGB-1 
suggested that HMGB-1 does not inhibit yeast cell death by simply binding and 
thereby neutralizing Bak. This conclusion was supported by Yeast-Two-Hybrid 
analysis and co-immunoprecipitation experiments with overexpressed Bak and 
HMGB-1/∆ HMGB-1: We could not detect protein interaction between Bak and 
HMGB-1 or ∆ HMGB-1 in such binding assays (data not shown). 
 
HMGB-1 overexpression inhibits apoptosis induced by different stimuli in 
mammalian cells 
 
Next we wanted to investigate whether HMGB-1 is able to suppress cell death upon 
Bak overexpression, not only in yeast but also in mammalian cells. For these 
experiments we used the human embryonic kidney cell line 293T, the human colon 
carcinoma cell line RKO and the rat kidney cell line NRK1. Transient transfection of 
all three cell lines with bak alone induced apoptosis which was blocked profoundly by 
co-transfection of either ∆ hmgb-1 or full length hmgb-1 (see Fig. 3). HMGB-1 was as 
effective in inhibiting Bak killing as was Bcl-xL in control co-transfections (data not   171
shown). Transfection of hmgb1 or ∆ hmgb1 alone did not lead to apoptotic cell death. 
The observed inhibition of Bak killing was not due to transcriptional downregulation 
of Bak since cells co-transfected with the protecting ∆ hmgb1 expressed the 
fluorescent Bak-GFP construct (data not shown). 
We also tested whether HMGB1 expression inhibits apoptosis induced by other death 
stimuli. RKO cells were treated with UV radiation, CD95 Ligand or TRAIL (Fig.3). 
Both HMGB1 and ∆ HMGB1 transfection inhibited apoptosis induced by radiation or 
Death Receptor ligands. In this context, the protection against TRAIL killing was 
remarkably effective. We also transfected 293T cells with a casp-8 expression 
construct and NRK1 cells with the cDNA of another pro-apoptotic member of the 
Bcl-2 gene family, bax. Again, HMGB1 and ∆ HMGB1 inhibited both apoptotic 
insults (Fig.3). 
Interestingly, endogenous HMGB-1 is expressed at a relatively high level in RKO 
cells (data not shown), yet further elevation of the HMGB-1 level rescued RKO cells 
from different apoptotic stimuli. 
These data indicate that the protection conferred by HMGB-1 in yeast against Bak-
induced cell death is a general phenomenon observable also in mammalian cells. 
Furthermore, apoptosis mediated by other stimuli as diverse as UV radiation, Death 
Receptor triggering and Bax and Casp-8 overexpression, is inhibited in different 
mammalian cell lines by co-expression of HMGB1. 
 
 
HMGB-1 protein is highly expressed in human breast carcinomas 
 
Mutational activation of anti-apoptotic proteins is one possible mechanism by which 
transformed cells evade apoptosis and propagate to form tumours. Since HMGB-1 
protects against several apoptotic stimuli in mammalian cells we analyzed HMGB-1 
protein levels in normal breast and in primary breast carcinoma material by 
performing Western blot experiments (see Fig. 4). We examined six different samples 
derived from normal breast tissue and they showed hardly any detectable HMGB-1 
protein (first six lanes). In comparison, of nine primary breast carcinomas tested, all 
expressed HMGB-1, six of them in high amounts. We also examined seven human 
breast carcinomas which were passaged for a long time in nude mice. Such passaging 
of tumour cells in mice is regarded as an artificial model for tumour metastasis, i.e. 
genes important for metastasis become upregulated. All seven passaged breast 
tumours expressed high HMGB-1 protein levels. 
These data suggest that the HMGB-1 protein is indeed highly expressed in human 
breast carcinomas and in a tumour transplantation model. 
To screen a larger pannel of breast carcinoma for HMGB1 expression we analyzed a 
human breast tissue microarray with fixed tissue sections from 10 different normal 
breast samples and 50 different breast carcinoma. The intensity of the HMGB1 
staining was quantified and the results are shown in Fig. 5. On average, three times 
higher HMGB1 protein levels were detected in the tumour samples compared to the 
normal tissue controls which is consistent with the Western Blot results described 
above.   172
hmgb1 mRNA levels are regulated during different stages of mouse mammary 
gland development 
 
The high expression of HMGB1 protein in human breast carcinoma prompted us to 
analyze whether HMGB1 levels change during mammary gland development. For this 
purpose, we used a ∆ hmgb1 cDNA probe to hybridize a Nothern blot with mouse 
mammary gland mRNA preparations from different stages before and during 
pregnancy and from lactating and involuting glands. Quantification of the resulting 
blot is shown in Figure 6. hmgb1 expression levels were normalized in two different 
data sets to the mRNA amounts of either of the two housekeeping genes β -actin or 
gapdh. We observed clear differences in hmgb1 expression during mammary gland 
development. While significant levels of hmgb1 RNA are detected in the glands of 
non-pregnant and pregnant mice, expression of hmgb1 mRNA is low during lactation 
and in the involuting glands which undergo apoptosis. This result indicates that 
HMGB1 may regulate growth and involution of mammary gland tissue, possibly by 
influencing the apoptotic behaviour of the cells. 
Discussion 
 
Programmed cell death (PCD) - in its most prominent form known as apoptosis in 
metazoa - is also used as an altruistic response for the sake of a colony in unicellular 
organisms like bacteria or monocellular eukaryotes (e.g. Trypanosoma cruzi, T. brucei 
rhodesiense,  Tetrahymena thermophila and Dictyostelium discoideum) [Ameisen, 
2002 #39]. Evidence is accumulating that a cell death machinery may also exist in 
yeast. This includes identification of a metacaspase in S. cerevisiae which becomes 
activated during yeast cell death induced by H2O2, acetic acid and ageing [Madeo, 
2002 #38]. 
Yeast has proven itself extremely successful as a model system used to answer many 
biological questions. In the absence of obvious homologues of major apoptotic 
regulators like the Bcl-2 family, yeast has also been used to study interactions 
between heterologously expressed components of apoptotic pathways [Hawkins, 2001 
#37]. Interestingly, several pro-apoptotic mammalian proteins kill yeast cells upon 
overexpression, for example pro-apoptotic members of the Bcl-2 family (Bax and Bak 
[Ink, 1997 #57; Jurgensmeier, 1997 #58; Sato, 1994 #59]) and caspases (-3 and -8 
[Kang, 1999 #36]). We could show some time ago that Bak killing of the fission yeast 
S. pombe is inhibited by co-expression of human Bcl-xL, and that the same critical 
BH3 domain of Bak that is required for induction of apoptosis in mammalian cells is 
also required for inducing death in yeast [Ink, 1997 #57]. These findings, and the fact, 
that typical phenotypic features of apoptosis are observed during yeast cell death [Ink, 
1997 #57; Ligr, 1998 #34; Madeo, 1997 #35], are indicative of an intrinsic cell death 
program in yeast which can be triggered by pro-apoptotic mammalian proteins. 
The molecular mechanisms by which pro-apoptotic Bcl-2 family members induce 
yeast cell death remain unknown. Bax killing in S. cerevisiae requires aspects of 
mitochondrial biochemistry, including the mitochondrial F0F1-ATPase proton pump 
[Gross, 2000 #32; Matsuyama, 1998 #55; Priault, 1999 #33; Shimizu, 2000 #31]. 
Reports concerning the release of Cytochrome c (Cyt c) in Bax overexpressing yeast 
cells appear controversial [Gross, 2000 #32; Manon, 1997 #30; Priault, 1999 #33; 
Shimizu, 2000 #31] and blocking Cyt c release does not inhibit Bax-induced cell 
death in S. cerevisiae [Roucou, 2000 #29]. Our own overexpression studies with a   173
functional Bak-GFP-construct in S. pombe were not suggestive of an exclusive 
mitochondrial localization of Bak-GFP in these cells. Remarkably, Bax and Bak have 
recently been reported to leave the mitochondrial membranes and to coalesce into 
mitochondria-associated clusters during apoptosis in mammalian cells [Nechushtan, 
2001 #71]. 
Several groups have successfully performed survival screens in S. cerevisiae to screen 
heterologous cDNA libraries for suppressors of Bax killing in yeast [Greenhalf, 1999 
#52; Kampranis, 2000 #51; Matsuyama, 1998 #55; Shaham, 1998 #53; Xu, 1998 
#54]. We set up an inducible Bak expression system in S. pombe with the aim to 
screen human tumour-derived cDNA libraries to identify potential anti-apoptotic 
oncogenes. When we transformed Bak expressing S. pombe yeast cells in a first 
experiment with a cDNA library synthesized from mouse NIH 3T3 fibroblasts, we 
found the chromosomal protein HMGB-1 as a protector against Bak-induced yeast 
cell death. The deletion mutant ∆ HMGB-1, which we isolated in the screen and which 
lacks the C-terminal 33 amino acids, is even more potent in inhibiting Bak-killing in 
yeast than the full length protein. Since we only tested 5x10
4 transformed yeast 
colonies for Bak-resistance, screening of the NIH 3T3 library was by far not 
complete. This explains why we did not isolate well-known inhibitors of Bak 
cytotoxicity like Bcl-xL. 
If protected against Bak-killing by overexpression of ∆ HMGB-1, S. pombe cells grow 
exponentially while expressing a large amount of Bak (which is much higher than the 
amount of Bak necessary to kill untransformed yeast cells). These data rule out the 
possibility that ∆ HMGB-1 downregulates Bak-transcription from the nmt-1 promoter 
used to express Bak in the yeast. We can also dismiss a scenario where HMGB-1 
directly binds to Bak thereby neutralizing Bak·s killing activity, similar to the way in 
which Bcl-xL prevents Bak-induced cell death. Our localization studies and our 
negative results in a Yeast-Two-Hybrid-analysis and in co-immunoprecipitation 
experiments to prove direct Bak-HMGB-1-interactions do not support such a binding 
model. 
We could show that both ∆ HMGB-1 and full length HMGB-1 are able to efficiently 
suppress apoptosis induced by several different stimuli in mammalian cells. The 
inhibition of apoptosis includes protection against Bak- and Bax-killing as well as 
prevention of apoptosis induced by overexpression of Casp-8, UV radiation and 
triggering of the Death Receptors CD95 and the TRAIL receptors. HMGB-1 is an 
abundant nuclear protein with roughly 1x10
6 molecules per nucleus [Bianchi, 1998 
#28]. Yet despite its abundance the protein may be limiting within cells: transient 
overexpression of HMGB-1 enhances the transcriptional activity of factors such as 
P53 and steroid hormone receptors. Similarly, an increase of HMGB-1 protein levels 
in mammalian cells by transfection leads to profound inhibition of apoptosis. 
Suppression of apoptosis is a key event at the onset of and during tumourigenesis 
[Hanahan, 2000 #64]. Increased resistance to the many apoptotic stimuli a tumour cell 
is exposed to can be achieved by loss-of-function mutations (resulting in inactivation 
of pro-apoptotic genes) or gain-of-function mutations (resulting in increased activity 
of anti-apoptotic genes). A prototypic example of the latter is represented by the 
t(14;18)-translocation involving bcl-2 which leads to Bcl-2-overexpression in human 
follicular B-cell lymphoma [Vaux, 1988 #27]. Since we have identified HMGB-1 in a 
yeast screen for anti-apoptotic genes and because we have shown HMGB-1·s anti-
apoptotic capacity in mammalian cells, we investigated the expression of the protein 
in human tumours. Our analysis revealed profound HMGB-1 protein levels in human 
primary breast carcinomas. We also observed strong HMGB-1 expression in human   174
breast carcinomas transplanted into nude mice. In contrast, expression of HMGB1 in 
normal breast tissue was low. This suggests that HMGB1 is involved in the 
development of mammary carcinomas. Interestingly, hmgb1 mRNA appears to be 
regulated during mouse mammary gland development. Its expression is lowest during 
lactation and involution, when the mammary ducts undergo apoptosis. This finding 
raises the possibility that HMGB1 participates in the cyclic regulation of mammary 
gland apoptosis. 
Elevated hmgb-1 mRNA levels have already been reported in human gastrointestinal 
adenocarcinomas compared to corresponding non-cancerous mucosa [Xiang, 1997 
#26]. The authors had suggested a correlation between hmgb-1 RNA expression and 
differentiation /staging of the carcinomas. Furthermore, a strong intertumoural 
variation of hmgb-1 mRNA expression within 13 breast cancer samples was published 
by Flohr et al. [Flohr, 2001 #25], which corresponds nicely to our tissue microarray 
results. The authors argue that this variation may contribute to the different response 
of estrogen receptor-positive breast tumours to endocrine therapy. This argument is 
based on the observation that HMGB-1 increases binding of the estrogen receptor to 
its DNA target sequence [Boonyaratanakornkit, 1998 #24]. Comparison of hmgb-1 
mRNA levels in normal breast tissue with expression in breast cancer samples was 
not included in this study. 
Enhanced co-expression of trx (thioredoxin) and hmgb-1 mRNAs has been observed 
in human hepatocellular carcinomas and higher expression of trx correlated with 
decreasing tumour sensitivity to cisplatin [Kawahara, 1996 #23]. The cytotoxic effect 
of cisplatin is believed to result from the formation of covalent adducts with DNA 
(reviewed in [Jamieson, 1999 #22]). HMGB-1 binds with high affinity to DNA 
damaged by cisplatin, and it is speculated that HMGB-1 contributes to cisplatin 
cytotoxicity by shielding damaged DNA from repair [Pasheva, 2002 #20; Pil, 1992 
#21]. Paradoxically, HMGB-1 overexpression has also been correlated with cisplatin-
resistance in cell lines [Imamura, 2001 #19] which could be explained by our data 
demonstrating anti-apoptotic properties for HMGB-1. 
Inhibition of apoptosis by HMGB-1 has to the best of our knowledge not been 
reported so far. Several other interesting aspects of HMGB-1 biology have however 
been investigated. The HMGB-1 protein belongs to the high mobility group (HMG) 
of DNA-binding proteins, which are abundant, heterogeneous, nonhistone 
components of chromatin [Bianchi, 2000 #7; Grosschedl, 1994 #18]. High mobility 
group proteins are subdivided into three distinct families: HMGB (with the proteins 
HMGB-1, -2, -3 (formerly HMG-1, -2, -4)), HMGA (HMGA-1a, b, c, -2 (formerly 
HMG-I(Y), HMGI-C)) and HMGN (formerly HMG-14/17 [Bustin, 2001 #17]). 
Members of the structurally distinct HMGA family are highly expressed during 
embryonic development and in proliferating cells but are rare in adult cells 
[Chiappetta, 1996 #16]. As critical components of enhanceosomes they participate in 
gene regulation and their overexpression has been strongly correlated with 
tumourigenesis ([Fedele, 2002 #15] and references herein). 
Both HMGB-1 and HMGB-2 contain two similar, but distinct "HMG boxes" (A and 
B), and a long acidic C-terminal tail, which is deleted in the ∆ HMGB-1 protein 
identified in our yeast screen (reviewed in [Travers, 2000 #14]). The HMG box 
consists of approximately 80 amino acids and has a characteristic, twisted, L-shaped 
fold formed by three α -helical segments [Read, 1993 #12; Weir, 1993 #13]. It binds 
to DNA through the minor groove and induces site-specific DNA deformations. 
HMGB proteins recognize and bind to altered DNA confirmations, such as stem-loop, 
four-way-junction, kinked or underwound DNA ([Travers, 2000 #14] and references   175
herein). Although they possess little or no sequence preference, HMGB-1 interacts 
with proteins like P53 or steroid hormone receptors and increases the apparent DNA 
binding affinity of these transcription factors [Jayaraman, 1998 #11; Romine, 1998 
#10]. Lack of the protein in hmgb-1 knockout mice did not disrupt cell growth but 
rather caused lethal hypoglycaemia in the newborn mice, possibly due to impaired 
transcriptional glucocorticoid receptor activity [Calogero, 1999 #6]. Such a role for 
HMGB-1 as a regulator of transcription may influence the apoptotic behaviour of a 
cell. It has for example been shown that HMGB-1 inhibits both P73α /β - and P53-
dependent transactivation from the bax gene promoter in p53-deficient SAOS-2 cells 
[Stros, 2002 #9].  
Future studies including transgenic mouse models will investigate whether by 
suppressing cell death HMGB-1 can act as an oncogene which might be considered 
for molecular tumour therapy. Our data show that screening of mammalian cDNA 
libraries in yeast survival assays allows the isolation of new anti-apoptotic tumour-
relevant molecules and we are currently using tumour-derived cDNA libraries to 
identify further cell death-inhibiting oncogenes. 
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Figure  and legends 
 
 
 
Fig. 1: HMBG-1 inhibits Bak-induced cell death in the yeast S. pombe. A: DSI cells 
growing on thiamine-free agar plates with phloxin (5 ￿g/ml, Sigma). Dead yeast cells 
appear dark red, pink colonies are growing. While co-transformation of the empty 
vector pArt1 cannot rescue colony growth, co-expression of pArt1-∆ hmgb-1 (and full 
length pArt1-hmgb-1, data not shown) protects against Bak-killing of the yeast. B: 
DSI yeast growth curves in liquid medium lacking thiamine (bak on). While pArt1 
empty vector-transformed cells cease proliferation and die, Bak-induced cell death is 
inhibited upon HMGB-1 expression leading to exponential colony growth. ∆ hmgb-1-
transformed cells grow twice as fast as full length HMGB-1 expressing yeasts, which 
themselves propagate as quickly as bcl-xL-transformed control cells. The results were 
obtained by 3 independent experiments. C: Western blot analysis showing HMGB-1 
expression in two DSI yeast colonies independently co-transformed with pArt1-
HMGB-1. The parental DSI strain, either in the presence or absence of thiamine, does 
not express HMGB-1. ∆ HMGB-1 lacking the C-terminus is not recognized by the 
antibody. An unspecific band marked with an asterix indicates equal loading of the 
protein gel. DSI cells in thiamine-free medium express a small amount of Bak protein 
and bak RNA (D) sufficient to induce yeast cell death. While we could not detect Bak 
protein or RNA (D) in DSI cells co-transformed with full length HMGB-1, a large 
amount of Bak protein and RNA (D) is present in ∆ HMGB-1-expressing DSI cells. D: 
bak Northern blot experiment with the same DSI yeast strains as analyzed in C.   177
 
 
 
Fig. 2: Localization studies in S. pombe. A: GFP-Bak accumulates in the cytoplasm. 
C: Yeast cells stained with DiOC6(3) - the tubular network of mitochondria is clearly 
visible.  E: Nuclear localization of the ∆ HMGB-1-GFP fusion protein. B, D, F: 
Normal transmission microscopy pictures of the same yeast cells as shown in A, C 
and E. 
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Fig. 3: HMGB-1 and ∆ HMGB-1 inhibit apoptosis induced in mammalian cells by 
different stimuli. RKO, 293T and NRK1 cells were seeded in 10 cm plates at 1x10
6 
cells/plate. The next day, 1.3 ￿g gfp-bak, casp-8 or bax cDNA together with 4.0 ￿g of 
either empty vector pcDNA3.1, hmgb-1 or ∆ hmgb-1 cDNA were introduced using the 
PEI transfection method. 16 hours later, cells were collected (including floating cells) 
and the percentage of dead cells was determined using the LIVE/DEAD 
Viability/Cytotoxicity kit from Molecular Probes. For UV, CD95L and TRAIL 
killing, 5 ￿g of either empty vector DNA, hmgb-1 or ∆ hmgb-1 cDNA were 
transfected. 24 hours after transfection, the cells were treated with either 10 s UV 
radiation, 10 ng/ml recombinant CD95L plus 1 ￿g/ml cycloheximide and 1 ￿g/ml 
anti-Flag antibody, or with 10 ng/ml TRAIL plus 1 ￿g/ml cycloheximide. 16 hours   179
later, apoptosis was quantified using the LIVE/DEAD assay. All apoptotic stimuli 
were significantly inhibited by overexpression of either hmgb-1 or ∆ hmgb-1. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: HMGB-1 protein overexpression in human mammary carcinomas. 40 ￿g of 
protein lysates from normal breast tissue (p7a, p9a, p11a, N1, N2, N3), primary breast 
tumours (83, 167, 249, 250, 256, 611, 876, 1096, 1132) and breast tumours passaged 
in nude mice (T13, T27, T48, T83, T130, T136, T236) were analyzed in a Western 
blot experiment with an anti-HMGB-1 antibody. As a loading control, the membrane 
was rehybridized with an anti-HSP27 antibody. 
 
 
 
Fig.5: Antibody staining of a breast tissue microarray reveals elevated HMGB1 
protein expression in breast carcinoma. The array is composed of tissue sections from 
10 normal breast samples and 50 different breast carcinoma. A: Fluorescent signals   180
from the sections after incubation with rabbit anti-HMGB1 antibody, followed by 
treatment with biotynilated anti-rabbit antibody and fluorescein-conjugated avidin. 
Signal intensities were quantified and averaged for normal and tumour sections and 
are presented as bars on the right side of the figure. Individual signal strengths are 
plotted in B. 
 
 
 
 
 
Fig. 6:  hmgb1 mRNA levels are regulated during mouse mammary gland 
development. Different mRNA preparations of mammary glands from non-pregnant, 
pregnant ((E7-E17), lactating (1WL, 2WL) and involuting (1dI-5dI) mice were used 
for Northern Blot analysis. The membrane was hybridized sequentially with cDNA 
probes for mouse ∆ hmgb1,  β -actin and gapdh.  hmgb1 RNA expression was 
normalized to β -actin (grey bars) or gapdh (black bars) RNA levels. hmgb1 
transcription is downregulated during lactation and involution. 
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